



(11) **EP 0 962 467 A1**

(12) **EUROPEAN PATENT APPLICATION**  
published in accordance with Art. 158(3) EPC

(43) Date of publication:  
**08.12.1999 Bulletin 1999/49**

(21) Application number: **97942194.8**

(22) Date of filing: **24.09.1997**

(51) Int. Cl.<sup>6</sup>: **C07K 16/18**, C07K 16/46,  
C12N 15/13, C12N 15/62,  
C12N 5/16, C12P 21/02,  
C12P 21/08, A61K 39/395  
// (C12P21/02, C12R1:91),  
C12P21:08

(86) International application number:  
**PCT/JP97/03382**

(87) International publication number:  
**WO 98/13388 (02.04.1998 Gazette 1998/13)**

(84) Designated Contracting States:  
**AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC  
NL PT SE**

(30) Priority: **26.09.1996 JP 25519696**  
**24.07.1997 JP 21416897**

(71) Applicant:  
**CHUGAI SEIYAKU KABUSHIKI KAISHA**  
**Tokyo 115 (JP)**

(72) Inventors:  
• **SATO, Kou,**  
**Chugai Seiyaku Kabushiki Kaisha**  
**Gotenba-shi, Shizuoka 412 (JP)**

• **WAKAHARA, Yuji,**  
**Chugai Seiyaku Kabushiki Kaisha**  
**Gotenba-shi, Shizuoka 412 (JP)**  
• **YABUTA, Naohiro,**  
**Chugai Seiyaku Kabushiki Kaisha**  
**Gotenba-shi, Shizuoka 412 (JP)**

(74) Representative:  
**Harding, Charles Thomas**  
**D. Young & Co.**  
**21 New Fetter Lane**  
**London EC4A 1DA (GB)**

(54) **ANTIBODY AGAINST HUMAN PARATHORMONE RELATED PEPTIDES**

(57) Disclosed are an antibody against human parathyroid-hormone-related protein, a DNA coding for the antibody, a recombinant vector containing the DNA, a transformant transformed with the recombinant vector, a method for preparation of the antibody, and uses of the antibody.

**EP 0 962 467 A1**

## Description

## TECHNICAL FIELD

- 5 [0001] The present invention relates to a human/mouse chimeric antibody comprising a variable region (V region) of a mouse monoclonal antibody against a parathyroid hormone related protein and a constant region (C region) of a human antibody, a humanized antibody in which complementarity determining regions of the light chain (L chain) and heavy chain (H chain) V regions of a mouse monoclonal antibody against a parathyroid hormone related protein (PTHrP) are grafted to a human antibody, the L and H chains of said antibody, as well as a polypeptide comprising the
- 10 V region constituting the L or H chain of said antibody.
- [0002] The present invention also relates to a DNA comprising a base sequence coding for the above mentioned antibody, particularly its V region, and a DNA coding for an L or H chain comprising the V region. Further, the present invention relates to a recombinant vector comprising said DNA and a host transformed with said vector.
- 15 [0003] Furthermore, the present invention relates to processes for preparing the chimeric and humanized antibodies against a PTHrP. Still further, the present invention relates to a pharmaceutical composition, and hypercalcemia-suppressing or hypophosphatemia-improving agent comprising the antibody against a PTHrP as an effective ingredient.

## BACKGROUND OF THE INVENTION

- 20 [0004] Hypercalcemia associated with malignant tumor is a serious complicated symptom found in 5 to 20% of the whole patients suffering from malignant tumor and is considered to be a terminal symptom of malignant tumor since it certainly leads to death if it is left as it is. Control of hypercalcemia may greatly affect the prognosis and QOL (quality of life) of a patient; therefore, it will clinically play a significant role.
- [0005] Generally, hypercalcemia in patients suffering from malignant tumor is roughly classified between HHM (humoral hypercalcemia of malignancy) based on tumor-producing humoral bone resorption factors and LOH (local osteolytic hypercalcemia) based on local action of tumor transferred or infiltrated to the bone. In HHM, it is believed that bone resorption or osteoclasts is promoted to increase the flow of calcium and produces hypercalcemia in cooperation with the reduced renal calcium-excreting ability (S. Wada and N. Nagata, Internal Medicine, 69, 644-648).
- 25 [0006] Hypercalcemia is considered to exhibit its symptoms when the concentration of calcium in the serum exceeds 12 mg/dl; as its symptoms, anorexia (inappetence), nausea and emesis (vomiting) are non-specifically observed at the early stage in patients suffering from malignant tumor. When hypercalcemia is worsened, the reduction of water-concentrating ability due to lesion of the renal distal tubules leads to hyperuresis (polyuria) and anorexia and nausea will be accompanied with dehydration due to insufficient uptake of water.
- 30 [0007] As humoral factors causing HHM among the hypercalcemia associated with malignant tumor, Moseley, J.M. et al. found parathyroid hormone related protein (hereinafter referred to as "PTHrP") which are substances like parathyroid hormone (PTH): Proc. Natl. Acad. Sci. USA (1987) 84, 5048-5052.
- [0008] Thereafter, a gene coding for PTHrP was isolated (Suva, L.J. et al., Science (1987) 237, 893) and it was elucidated from its analysis that there are three kinds of human PTHrPs having 139, 141 and 173 amino acids due to alternative splicing of the gene and that various fragments are present in the blood due to restricted degradation of PTHrP
- 40 (1-139) having the whole structure: Baba, H., Clinical Calcium (1995) 5, 229-223. In PTHrP, 8 amino acids of the N-terminal 13 amino acids are identical with those in PTH and it is deduced that the amino acid site at position 14 to position 34 has a steric structure similar to PTH as well; thus, PTHrP and PTH bind to a common PTH/PTHrP receptor at least in the N-terminal region: Jueppner, H. et al., Science (1991) 254, 1024-1026; Abou-Samra, A-B. et al., Proc. Natl. Acad. Sci. USA (1992) 89, 2732-2736.
- 45 [0009] PTHrP is reported to be produced in a variety of tumoral tissues and it has been elucidated that not only in tumors, PTHrP is also produced in various normal tissues of from fetuses to adults, including skin, central nervous system, uterus, placenta, lactating mammary gland, thyroid gland, parathyroid gland, adrenal gland, liver, kidney and urinary bladder: Burtis, W.J., Clin. Chem. (1992) 38, 2171-2183; Stewart, A.F. & Broadus, A.E., J. Clin. Endocrinol. (1991) 71, 1410-1414. Further, PTHrP is considered to play an important role in the metabolic regulation of calcium which is maintained at a higher level in the fetal to newborn period than in the mother.
- 50 [0010] PTH/PTHrP receptors are known to be present mainly in the bone and kidney (C. Shigeno, Clinical Calcium (1995) 5, 355-359) and to activate plural intracellular signal transmission systems by binding of PTHrP to the receptors. One of them is adenylate cyclase and the other is phospholipase C. Activation of adenylate cyclase increases the concentration of intracellular cAMP to activate protein kinase A. Phospholipase C decomposes phosphatidylinositol 4,5-bisphosphonate to produce inositol 1,4,5-triphosphonate and diacylglycerol. G-protein is involved in these signal transmission systems: Coleman, D.T. et al., Biochemical mechanisms of parathyroid hormone action. In: "The parathyroids" (Bilezikian, J.P. et al.), Raven Press, New York (1994) page 239.
- 55 [0011] Through these signal transmission systems, PTHrP causes hypercalcemia, hypophosphatemia, decrease of

renal phosphate-resorbing ability, increase of renal cAMP-excretion and the like which are observed in HHM.

[0012] Thus, it has been elucidated that PTHrP is closely related to hypercalcemia associated with malignant tumor. In the treatment of hypercalcemia associated with malignant tumor, calcitonin, steroid agents, indomethacin, inorganic phosphate salts, bisphosphonates and the like are used, as well as fluid replacement. However, these agents may show reduction of their effects upon consecutive use, some serious side-effects, or slow expression of their pharmacological effects; accordingly, use of agents or drugs which have higher therapeutic effects and less side-effects is highly expected.

[0013] On the other hand, as a new attempt to treat hypercalcemia associated with malignant tumor, Kukreja, S.C. et al, reported that when a neutralizing antiserum against PTHrP was administered to athymic mice in which human lung or larynx cancer cells had been transplanted to generate hypercalcemia, the blood calcium concentration and urinary cAMP level were reduced: J. Clin. Invest. (1988) 82, 1798-1802. Kanji Sato et al, reported that when an antibody against PTHrP (1-34) was administered to nude mice to which a PTHrP-producing human tumor was transplanted, the hypercalcemia was reduced and the viable time period of the mice was greatly prolonged: J. bone & Mine. Res. (1993) 8, 849-860. Further, Japanese Patent Application Laid Open Publication No. 4-228089 discloses mouse/human chimeric antibodies against human PTHrP (1-34).

[0014] Mouse monoclonal antibodies are highly immunogenic (sometimes also referred to as "antigenic") in humans, which limits the medical therapeutic values of the mouse monoclonal antibodies in humans. For instance, a mouse antibody may be metabolized as a foreign matter when administered to a human; therefore, the half-life of the mouse antibody is relatively short in humans and its expected effects are not sufficiently exhibited. Further, human anti-mouse antibodies (HAMA) raised against the administered mouse antibody may cause immune responses which are inconvenient and dangerous to patients, such as serum diseases and other allergic reactions. Accordingly, mouse monoclonal antibodies can not frequently be administered to humans.

[0015] In order to solve these problems, methods for reducing the immunogenicity of non-human derived antibodies, for example, mouse-derived monoclonal antibodies have been developed. One of these methods is to make a chimeric antibody in which the variable region (V region) is derived from a mouse monoclonal antibody and the constant region (C region) is derived from an appropriate human antibody.

[0016] Since the resulting chimeric antibody has the intact variable region of the original mouse antibody, it can be expected that the chimeric antibody may bind to an antigen with the same specificity as the original mouse antibody. Further, such a chimeric antibody has a substantially reduced proportion of an amino acid sequence derived from a non-human animal; therefore, it is anticipated to have a lower immunogenicity as compared with the original mouse antibody. Although the chimeric antibody binds to its antigen equivalently with the original mouse monoclonal antibody while showing a lower immunogenicity, some immune responses to the mouse variable region may still be possibly generated: LoBuglio, A.F. et al., Proc. Natl. Acad. Sci. USA, 86, 4220-4224, 1989.

[0017] A second method for reducing the immunogenicity of mouse antibodies is still more complicated but expected to further greatly reduce the potential immunogenicity of the mouse antibodies. In this method, only the complementarity determining regions (CDRs) of the variable region of a mouse antibody are grafted to a human variable region to create a "reshaped" human variable region. If required, a partial amino acid sequence of a framework region (FR) supporting the CDRs in a variable region of a mouse antibody may be grafted to a human variable region in order to make the structure of CDRs in the reshaped human variable region closer to that of the original mouse antibody.

[0018] Then, these humanized, reshaped human variable regions are combined with human constant regions. In the finally reshaped, humanized antibody, the portions derived from non-human amino acid sequences are only CDRs and a very small part of FR. The CDRs are composed of a hypervariable amino acid sequence and these do not show any species-specific sequences. Therefore, a humanized antibody comprising mouse CDRs will no longer have any stronger immunogenicity than a naturally occurring human antibody containing human CDRs.

[0019] With respect to humanized antibodies, further reference should be made to Riechmann, L. et al., Nature, 332, 323-327, 1988; Verhoeve, M. et al., Science, 239, 1534-1536, 1988; Kettleborough, C.A. et al., Protein Engng., 4, 773-783, 1991; Maeda, H. et al., Human Antibodies and Hybridoma, 2, 124-134, 1991; Gorman, S.D. et al., Proc. Natl. Acad. Sci. USA, 88, 4181-4185, 1991; Tempest, P.R. et al., Bio/Technology, 9, 266-271, 1991; Co, M.S. et al., Proc. Natl. Acad. Sci. USA, 88, 2869-2873, 1991; Carter, P. et al., Proc. Natl. Acad. Sci. USA, 89, 4285-4289, 1992; Co, M.S. et al., J. Immunol., 148, 1149-1154 1992; and Sato, K. et al., Cancer Res., 53, 851-856, 1993.

[0020] Although humanized antibodies are expected to be useful for therapeutic purposes as previously mentioned, no humanized antibody against PTHrP has been known nor suggested in the aforementioned references. Further, there is no standardized means generally applicable to any antibodies in the process for preparing humanized antibodies; various means and methods are necessary to make a humanized antibody exhibiting a sufficient binding, neutralizing activity to a specific antigen: see, for example, Sato, K. et al., Cancer Res., 53, 851-856, 1993.

## DISCLOSURE OF THE INVENTION

**[0021]** It is an object of the present invention to provide a human/mouse chimeric antibody comprising a variable region (V region) of a mouse monoclonal antibody against PTHrP and a constant region (C region) of a human antibody, a humanized antibody in which complementarity determining regions of V regions of the light chain (L chain) and heavy chain (H chain) of a mouse monoclonal antibody against PTHrP are grafted to a human antibody, the L and H chains of said antibody, as well as a polypeptide comprising the V region constituting the L or H chain of said antibody.

**[0022]** It is another object of the present invention to provide a DNA comprising a base sequence coding for the above mentioned antibody, particularly its V region, and a DNA coding for an L or H chain comprising a polypeptide comprising the V region. Still another object of the present invention is to provide a recombinant vector comprising said DNA and a host transformed with said vector. Further, an object of the present invention is to provide processes for preparing the chimeric and humanized antibodies against PTHrP. It is a still another object of the present invention to provide an antibody against PTHrP having a high neutralizing activity, A still further object of the present invention is to provide a pharmaceutical composition, and hypercalcemia-suppressing, hypophosphatemia-improving or alkalosis-improving agent comprising the antibody or humanized antibody against PTHrP as an effective ingredient.

**[0023]** As a result of the energetic study with a view to the above mentioned objects, the present inventors have successfully obtained an antibody in which the immunogenicity of mouse monoclonal antibodies against PTHrP is reduced in humans; thus, the present invention has been accomplished.

**[0024]** The present invention is directed to a chimeric L chain comprising an L chain C region of a human antibody and an L chain V region of a mouse monoclonal antibody against PTHrP. The L chain V region includes one comprising an amino acid sequence as shown in SEQ ID NO:45 and the L chain C region includes a C $\lambda$  region.

**[0025]** The present invention is also directed to a chimeric H chain comprising an H chain C region of a human antibody and an H chain V region of a mouse monoclonal antibody against PTHrP. The H chain V region includes one comprising an amino acid sequence as shown in SEQ ID NO:46 and the C region includes a C $\gamma$ 1 region.

**[0026]** Further, the present invention is directed to a chimeric monoclonal antibody against PTHrP comprising said chimeric L chain and said chimeric H chain.

**[0027]** Still further, the present invention includes a polypeptide comprising an L chain V region of a humanized antibody comprising framework regions 1 to 4 of an L chain V region of a human antibody and complementarity determining regions 1 to 3 of an L chain V region of a mouse monoclonal antibody against PTHrP. The complementarity determining regions 1 to 3 include those comprising amino acid sequences as shown in SEQ ID NOs:59-61, respectively; the framework regions 1 to 3 include those derived from the framework regions 1 to 3 of human antibody HSU03868, respectively, and the framework region 4 includes one derived from the framework region 4 of human antibody S25755; or the framework regions 1 to 3 include those substantially identical with the framework regions 1 to 3 of human antibody HSU03868, respectively, and the framework region 4 includes one substantially identical with the framework region 4 of human antibody S25755.

**[0028]** The term "substantially identical" as used herein means that the framework regions of the human antibody used in a humanized antibody may have a deletion, replacement and/or addition of amino acid(s) required to form the complementarity determining regions of a mouse monoclonal antibody such that the humanized antibody should have an activity equivalent to that of the mouse monoclonal antibody.

**[0029]** Thus, the present invention is concerned with a polypeptide comprising an L chain V region of a humanized antibody wherein in the framework regions the 36th and 49th amino acids in accordance with Kabat's prescription (Kabat, E.A. et al., US Dept. Health and Human Services, US Government Printing Offices, 1991) are tyrosine and aspartic acid, respectively.

**[0030]** The present invention is also directed to a polypeptide comprising an L chain V region of a humanized antibody comprising an amino acid sequence as shown in any of SEQ ID NOs:48-51.

**[0031]** Further, the present invention is directed to a polypeptide comprising an L chain V region of a humanized antibody wherein the 45th and 87th amino acids in accordance with Kabat's prescription in the framework regions are lysine and isoleucine, respectively.

**[0032]** Still further, the present invention is directed to a polypeptide comprising an L chain V region of a humanized antibody comprising an amino acid sequence as shown in any of SEQ ID NOs:52-55.

**[0033]** The present invention is further concerned with a polypeptide comprising an H chain V region of a humanized antibody comprising framework regions 1 to 4 of an H chain V region of a human antibody and complementarity determining regions 1 to 3 of an H chain V region of a mouse monoclonal antibody against a human PTHrP. The complementarity determining regions 1 to 3 include those comprising amino acid sequences as shown in SEQ ID NOs:62-64, respectively, the framework regions 1 to 4 include those derived from framework regions 1 to 4 of a human antibody belonging to human subgroup III (Human Subgroup III (HSG III), Kabat, E.A. et al., US Dept. Health and Human Services, US Government Printing Offices, 1991), more particularly those derived from the framework regions 1 to 4 of human antibody S31679, respectively, or those substantially identical with the framework regions 1 to 4 of human anti-

body S31679, respectively.

**[0034]** Also, the present invention is concerned with a polypeptide comprising an H chain V region of a humanized antibody comprising the amino acid sequence as shown in SEQ ID NO:56.

**[0035]** The present invention is also concerned with an L chain of a humanized antibody against a human PTHrP comprising a polypeptide comprising an L chain V region of said humanized antibody and a polypeptide comprising an L chain C region of a human antibody. The C region includes a C $\lambda$  region, the framework regions 1 to 3 include those substantially identical with the framework regions 1 to 3 of human antibody HSU03868, respectively, the framework region 4 includes one substantially identical with the framework region 4 of human antibody S25755, and the amino acid sequences of the complementarity determining regions 1 to 3 include those represented by SEQ ID NOs:59-61, respectively.

**[0036]** Further, the present invention is also concerned with an H chain of a humanized antibody against a human PTHrP comprising polypeptides comprising an H chain C region and H chain V region of said human antibody. The C region includes a C $\gamma$ 1 region, the framework regions 1 to 4 include those derived from the framework regions 1 to 4 derived from a human antibody belonging to HSGIII, and the complementarity determining regions 1 to 3 include those comprising the amino acid sequences as shown in SEQ ID NOs:62-64, respectively.

**[0037]** Still further, the present invention is also concerned with an anti-PTHrP antibody with a weak antigenicity and a high neutralizing activity. The PTHrP antibody includes a human antibody, a humanized antibody, a chimeric antibody and a primatized antibody, which may be utilized in the treatment of human diseases. The antibody has a low dissociation constant. Further, the antibody of the present invention has a high neutralizing activity due to its low dissociation constant and, therefore, can be utilized for the treatment of human diseases.

**[0038]** The antibody of the present invention has a dissociation constant of  $1.86 \times 10^{-7}$  [M] or less, a dissociation rate constant of  $1.22 \times 10^{-1}$  [1/Sec] or less, and an association rate constant of  $6.55 \times 10^4$  [1/M.Sec] or more. These constants may be measured by Scatchard analysis using RI labeled ligands or Surface plasmon resonance sensor.

**[0039]** The present invention is further directed to a DNA comprising a base sequence coding for an L chain V region or H chain V region of a mouse monoclonal antibody against a human PTHrP. The L chain V region and H chain V region include those comprising the amino acid sequence as shown in SEQ ID NOs:45-46, respectively, the DNA comprising a base sequence coding for the L chain V region includes, for example, one represented by SEQ ID NO:65, and the DNA comprising a base sequence coding for the H chain V region includes one represented by SEQ ID NO:57.

**[0040]** Further, the present invention is also directed to a DNA coding for said chimeric L or H chain. The DNA coding for said L chain includes, for example, one comprising the base sequence as shown in SEQ ID NO:65 and the DNA coding for said H chain includes one comprising the base sequence as shown in SEQ ID NO:57.

**[0041]** Still further, the present invention is also directed to a DNA comprising a base sequence coding for an L chain V region or H chain V region of said humanized antibody. The DNA comprising a base sequence coding for the L chain V region includes one comprising the base sequence as shown in any of SEQ ID NOs:66-74 and the DNA comprising a base sequence coding for the H chain V region includes one represented by SEQ ID NO:58.

**[0042]** The present invention also relates to a DNA for an L chain V region of a humanized antibody comprising a base sequence coding for the amino acid sequence as shown in any of SEQ ID NOs:47-55. Said DNA includes one comprising the base sequence as shown in any of SEQ ID NOs:66-74.

**[0043]** Still further, the present invention relates to a DNA for an H chain V region of a humanized antibody coding for the amino acid sequence as shown in SEQ ID NO:56. Said DNA includes one comprising the base sequence as shown in SEQ ID NO:58.

**[0044]** The present invention further relates to a recombinant vector comprising any of said DNAs.

**[0045]** The present invention still further relates to a transformant transformed with said recombinant vector.

**[0046]** Also, the present invention relates to a process for preparing a chimeric or humanized antibody against a human parathyroid hormone related protein comprising cultivating said transformant and collecting a chimeric or humanized antibody against a human parathyroid hormone related protein from the resulting culture.

**[0047]** Still further, the present invention also relates to a pharmaceutical composition, or hypercalcemia-suppressing or hypophosphatemia-improving agent comprising said antibody as an effective ingredient. The calcemia is caused by malignant tumor and the hypophosphatemia is often observed in patients suffering from hypercalcemia associated with malignant tumor. Thus, the antibody of the present invention can be used in the treatment of the malignant tumor or in the improvement of hypercalcemia or hypophosphatemia symptoms. The malignant tumor may include, but not limited to, at least one selected from the group consisting of pancreas, lung, pharynx, larynx, tongue, gingiva, esophagus, stomach, biliary duct, breast, kidney, urinary bladder, uterus and prostate cancers, and malignant lymphoma. The hypercalcemia-suppressing agent of the present invention can be applicable to any malignant tumor which may cause hypercalcemia.

**[0048]** The present invention will be described in detail hereinbelow.

# 1. Production of mouse monoclonal antibodies against human PTHrP

**[0049]** Mouse monoclonal antibodies against PTHrP may be prepared by preparing hybridomas through cell fusion between myeloma cells and antibody-producing cells derived from animals immunized with the antigen and selecting clones producing antibodies specifically inhibiting the PTHrP activity from the resulting hybridomas.

## (1) Preparation of antigens

**[0050]** PTHrP used for the immunization of animals includes peptides having the whole or part of the amino acid sequence of PTHrP prepared by recombinant DNA technology or chemical synthesis, and PTHrP derived from supernatants of cancer cells causing hypercalcemia. For example, a peptide [PTHrP(1-34)] comprising the 1st to 34th amino acids of the known PTHrP (Kemp, B.E. et al., Science (1987) 238, 1568-1570) may be used as the antigen. The human PTHrP(1-34) has an amino acid sequence as shown in SEQ ID NO:75.

**[0051]** The resultant PTHrP is attached to a carrier protein such as thyroglobulin followed by addition of an adjuvant. Any adjuvant may be mixed, including Freund's complete and incomplete adjuvants.

## (2) Immunization and collection of antibody producing cells

**[0052]** The above resultant antigen is administered to a mammal, such as mouse, rat, horse, monkey, rabbit, goat or sheep. Immunization may be carried out by any known methods, including intravenous, subcutaneous and intraperitoneal injections. Intervals of injections for immunization are not particularly limited and may be a few days to a few weeks, preferably 4 to 21 days.

**[0053]** Two or three days after final immunization, antibody producing cells are collected. The antibody producing cells include spleen, lymph node and peripheral blood cells; generally, spleen cells are utilized. The single dose amount of antigen used for immunization is 100 µg per mouse.

## (3) Determination of antibody titers

**[0054]** In order to determine the immune response levels of immunized animals and select hybridomas of interest from the cells subjected to cell fusion treatment, the antibody titer in the blood of the immunized animal or the antibody titer in the supernatant of the antibody producing cells is measured.

**[0055]** Methods for detecting the antibodies are known, including EIA (enzyme immunoassay), RIA (radio immunoassay), and ELISA (enzyme linked immunosorbent assay).

## (4) Cell fusion

**[0056]** Myeloma cells used to be fused with antibody producing cells include cell lines which are derived from various animals such as mouse, rat and human, and generally available for those skilled in the art. Suitable cell lines used are those having a drug resistance, incapable of surviving in a selective medium such as HAT medium in the unfused state, and capable of surviving therein only in the fused state. Generally used are 8-azaguanine resistant cell lines, which lack hypoxanthine-guanine-phosphoribosyltransferase and can not grow in a hypoxanthine-aminopterin-thymidine (HAT) medium.

**[0057]** Suitable myeloma cells to be used include various known cell lines, such as P3 (P3x63Ag8.653) (J. Immunol. (1979) 123:1548-1550); P3x63Ag8U.1 (Current Topics in Microbiology and Immunology (1978) 81:1-7); NS-1 (Kohler, G and Milstein, C., Eur. J. Immunol. (1976) 6:511-519); MPC-11 (Margulies, D.H. et al., Cell (1976) 8:405-415); SP2/0 (Shulman, M. et al., Nature (1978) 276:269-270); FO (de St. Groth, S.F. et al., J. Immunol. Methods (1980) 35:1-21); S194 (Trowbridge, I.S., J. Exp. Med. (1978) 148:313-323); and R210 (Galfre, G. et al., Nature (1979) 277:131-133).

**[0058]** Antibody producing cells may be obtained from spleen cells, lymph node cells, or the like. That is, the spleen, lymph node or the like is extracted or removed from any of the aforementioned animals and the tissue is crushed. The resulting crushed materials are suspended in a medium or buffer, such as PBS, DMEM or RPMI1640, filtered through stainless mesh or the like and centrifuged to prepare the desired antibody producing cells.

**[0059]** Then, said myeloma cells and antibody producing cells are subjected to cell fusion.

**[0060]** Cell fusion may be carried out by bringing the myeloma and antibody-producing cells into contact with each other at a ratio of 1:1 to 1:10 in a medium for the culture of animal cells, such as MEM, DMEM or RPME-1640, in the presence of a fusion accelerator at 30 to 37°C for 1 to 15 minutes. To accelerate the cell fusion, any fusion accelerator or virus can be used, such as polyethylene glycol with an average molecular weight of 1,000 to 6,000, polyvinyl alcohol or Sendai virus. The fusion of the antibody producing and myeloma cells may also be performed in a commercially available cell fusion apparatus utilizing an electric stimulation such as electroporation.

## (5) Selection and cloning of hybridomas

[0061] Hybridomas of interest are selected from the cells after the cell fusion, for example, by a method utilizing selective growth of cells in selective media.

[0062] That is, a cell suspension is diluted with a suitable medium and inoculated on a microtiter plate. A selective medium such as HAT medium is added to each well and incubated while properly replacing the selective medium with a fresh one.

[0063] Thus, the growing cells are collected as hybridomas.

[0064] These hybridomas are then screened by the limiting dilution, fluorescence-activated cell sorter or other method. Finally, hybridomas producing a monoclonal antibody are obtained.

## (6) Collection of monoclonal antibodies

[0065] Methods for collecting monoclonal antibodies from the obtained hybridomas include conventional cell culture and ascites formation methods.

[0066] In the cell culture method, the hybridomas are cultivated in a medium for the culture of animal cells, such as RPMI-1640 medium containing 10 to 20% fetal bovine serum, MEM medium or serum-free medium, under conventional conditions (e.g., 37°C, 5% CO<sub>2</sub>) for 2 to 14 days and the antibodies are collected from the supernatant.

[0067] In the formation of ascites, the hybridomas are inoculated intraperitoneally to the same species of mammal as the source of the myeloma cells so that the hybridomas grow abundantly. After 1 to 4 weeks, the ascites or sera are collected.

[0068] When the antibodies are necessary to be purified in these methods, known methods such as the ammonium sulfate precipitation, ion exchange chromatography and affinity chromatography may optionally be selected or combined.

## 2. Construction of chimeric antibodies

(1) Cloning of DNA comprising base sequence coding for V region of mouse monoclonal antibody against human PTHrP

## (i) Preparation of mRNA

[0069] To clone DNA comprising a base sequence coding for V region of mouse monoclonal antibody against human PTHrP, the collected hybridomas are treated in a conventional manner, for example, guanidine-ultracentrifugation (Chirgwin, J.M. et al., Biochemistry (1979) 18, 5294-5299), or AGPC method (Chomczynski, P et al., Analytical Biochemistry (1987) 162, 156-159), to prepare the total RNA, from which mRNA is prepared by e.g. Oligo(dT)-cellulose span column attached to mRNA Purification Kit (Pharmacia). Quick Prep mRNA Purification Kit (Pharmacia AB) can also be used to prepare mRNA without need of extraction of the total RNA.

## (ii) Preparation and amplification of cDNA

[0070] From the mRNA obtained in (i) above, each cDNA in the V regions of L and H chains is synthesized with the use of a reverse transcriptase. In the synthesis of cDNA, Oligo-dT primer or an other appropriate primer which hybridizes to L or H chain C region, for example, MHC2 primer having the base sequence as shown in SEQ ID NO:1, may be used.

[0071] In the cDNA synthesis, said mRNA and primer are mixed and the reaction is effected in the presence of a reverse transcriptase at e.g. 52°C for 30 minutes.

[0072] Amplification of cDNA of both L and H chains can be performed by PCR (polymerase chain reaction) based on 5'-RACE method (Frohman, M.A. et al., Proc. Natl. Acad. Sci. USA, 85, 8998-9002, 1988; Belyavsky, A. et al., Nucleic Acids Res., 17, 2919-2932, 1989) using 5'-Ampli FINDER RACE kit (CLONTECH Inc.). Thus, Ampli FINDER Anchor (SEQ ID NO:42) is linked to 5' end of the cDNA synthesized above and PCR is effected for DNAs comprising base sequences coding for L and H chain V regions. (Hereinafter, the DNA comprising a base sequence coding for L chain V region is sometimes referred to simply as "DNA for L chain V region" or "DNA coding for L chain V region". This also applies to H chain V region, C region etc. similarly.)

[0073] The primer for amplifying DNA for L chain V region which may be used includes, for example, Anchor primer (SEQ ID NO:2) and primers designed from conserved sequences in L $\lambda$  chain constant region (C $\lambda$  region) of mouse antibodies such as MLC primer having the base sequence as shown in SEQ ID NO:4. The primer for amplifying DNA for H chain V region which may be used includes, for example, Anchor primer (SEQ ID NO:2) and MHC-G1 primer (SEQ

ID NO:3) (S.T. Jones, et al., Biotechnology, 9, 88, 1991).

(iii) Purification of DNA and determination of base sequence

- 5 [0074] The PCR products are subjected to agarose gel electrophoresis according to conventional procedures to excise DNA fragments of interest, which are then recovered, purified and ligated to a vector DNA.
- [0075] Purification of DNA may be carried out using commercially available kits such as GENECLEAN II; BIO101. Vector DNA for carrying the DNA fragments which may be used herein is known, for example, pUC19 or Bluescript.
- 10 [0076] Said DNA and vector DNA are ligated using a known ligation kit (Takara Shuzo) to yield a recombinant vector. The resultant recombinant vector is introduced into e.g. Escherichia coli JM109 and ampicillin resistant colonies are selected; thus, a vector DNA is prepared in a known method: J. Sambrook, et al., "Molecular Cloning", Cold Spring Harbor Laboratory Press, 1989. After the vector DNA is digested with restriction enzyme (s), the base sequence of a desired DNA is determined by a known method such as dideoxy method: J. Sambrook, et al., "Molecular Cloning", Cold Spring Harbor Laboratory Press, 1989. In the present invention, an automated base sequence determining apparatus
- 15 (DNA Sequencer 373A; ABI Inc.) may be used.

(iv) Complementarity determining region

- 20 [0077] H and L chain V regions form an antigen binding site and their whole structures have some similarity to each other. That is, four framework region (FR) portions are linked through three hypervariable regions, or complementarity determining region (CDR). The amino acid sequence in the FR is relatively well conserved while variability of the amino acid sequence in the CDR region is very high: Kabat, E.A. et al, "Sequence of Proteins of Immunological Interest" US Dept. Health and Human Services, 1983.
- [0078] Many portions of the four FRs have  $\beta$  sheet structure and, as a result, three CDRs form a loop. The CDR may sometimes form a part of the  $\beta$  sheet structure. Therefore, three CDRs are sterically held at very near positions to each other by FRs, which form an antigen binding site together with the three CDRs in the paired regions.
- 25 [0079] In view of such facts, CDR regions can be found by comparison between the amino acid sequence in the variable region of a mouse monoclonal antibody against human PTHrP and the database of amino acid sequences for antibodies prepared by Kabat et al. ( "Sequence of Proteins of Immunological Interest" US Dept. Health and Human Services, 1983) to investigate the homology therebetween.
- 30

(2) Construction of expression vector of chimeric antibody

- [0080] Once DNA fragments coding for L and H chain V regions of mouse monoclonal antibody (hereinafter L or H chain of an antibody may sometimes be referred to as mouse L chain" etc. for mouse antibodies and "human H chain" etc. for human antibodies) are cloned, the DNAs coding for mouse V regions and DNAs coding for human antibody constant regions are ligated and expressed to yield chimeric anti-human PTHrP antibodies.
- 35 [0081] A standard method for preparing chimeric antibodies involves ligating a mouse leader sequence and V region sequence present in a cloned cDNA to a sequence coding for a human antibody C region already present in an expression vector of a mammalian cell. Alternatively, a mouse leader sequence and V region sequence present in a cloned cDNA are ligated to a sequence coding for a human antibody C region followed by ligation to a mammalian cell expression vector.
- 40 [0082] The polypeptide comprising human antibody C region can be any of H or L chain C regions of human antibodies, including, for example, C $\gamma$ 1, C $\gamma$ 2, C $\gamma$ 3 or C $\gamma$ 4 for human H chains or C $\lambda$  or C $\kappa$  for L chains.
- 45 [0083] To prepare a chimeric antibody, two expression vectors are first constructed; that is, an expression vector containing DNAs coding for mouse L chain V region and human L chain C region under the control of an expression control region such as an enhancer/promoter system, and an expression vector containing DNAs coding for mouse H chain V region and human H chain C region under the control of an expression control region such as an enhancer/promoter system, are constructed. Then, host cells such as mammalian cells are cotransformed with these expression vectors
- 50 and the transformed cells are cultivated in vitro or in vivo to produce a chimeric antibody: see, for example, WO91/16928.
- [0084] Alternatively, the mouse leader sequence present in the cloned cDNA and DNAs coding for mouse L chain V region and human L chain C region as well as the mouse leader sequence and DNAs coding for mouse H chain V region and human H chain C region are introduced into a single expression vector (see, for example, WO94/11523) and said vector is used to transform a host cell; then, the transformed host is cultivated in vivo or in vitro to produce a desired chimeric antibody.
- 55



## (i) Production of chimeric antibody H chain

**[0085]** The vector for the expression of H chain of a chimeric antibody can be obtained by introducing cDNA comprising a base sequence coding for mouse H chain V region (hereinafter referred to also as "cDNA for H chain V region") into a suitable expression vector containing the genomic DNA comprising a base sequence coding for H chain C region of human antibody (hereinafter referred to also as "genomic DNA for H chain C region") or cDNA coding for said region (hereinafter referred to also as "cDNA for H chain C region"). The H chain C region includes, for example, C<sub>γ</sub>1, C<sub>γ</sub>2, C<sub>γ</sub>3 or C<sub>γ</sub>4 regions.

## (i-a) Construction of chimeric H chain expression vector containing genomic DNA coding for H chain C region

**[0086]** The expression vectors having the genomic DNA coding for H chain C region, in particular, those coding for C<sub>γ</sub>1 region, include, for example, HEF-PMh-g γ 1 (WO92/19759) and DHER- Δ E-RVh-PM1-f (WO92/19759).

**[0087]** When cDNA coding for mouse H chain V region is inserted into these expression vectors, an appropriate base sequence can be introduced into said cDNA through PCR method. For instance, PCR may be effected using a PCR primer which is designed such that said cDNA has a recognition sequence for a suitable restriction enzyme at its 5'-end and Kozak consensus sequence immediately before the initiation codon thereof so as to improve the transcription efficiency, as well as a PCR primer which is designed such that said cDNA has a recognition sequence for a suitable restriction enzyme at its 3'-end and a splice donor site for properly splicing the primary transcription products of the genomic DNA to give a mRNA, to introduce these appropriate base sequences into the expression vector.

**[0088]** After the thus constructed cDNA coding for mouse H chain V region is treated with a suitable restriction enzyme(s), it is inserted into said expression vector to construct a chimeric H chain expression vector containing the genome DNA coding for H chain C region (C<sub>γ</sub>1 region).

## (i-b) Construction of chimeric H chain expression vector containing cDNA comprising base sequence coding for H chain

**[0089]** The expression vectors having the cDNA coding for H chain C region, such as C<sub>γ</sub>1 region, may be constructed in the following manner: mRNA is prepared from CHO cells into which an expression vector DHFR-ΔE-RVh-PM1-f (see WO92/19759) comprising DNA coding for H chain V region of a humanized PM1 antibody and genomic DNA of H chain C region C<sub>γ</sub>1 of a human antibody (N. Takahashi, et al., Cell, 29, 671-679 (1982)) and an expression vector RV1-PM1a (see WO92/19759) comprising genomic DNA coding for L chain V region of the humanized PM1 antibody and genomic DNA of L chain C region of a human antibody have been introduced, and cDNA coding for the H chain V region of the humanized PM1 antibody and cDNA coding for the H chain C region (C<sub>γ</sub>1) of the human antibody are cloned by RT-PCR method and ligated to an animal cell expression vector which has been treated with a suitable restriction enzyme(s), to construct a desired expression vector.

**[0090]** When cDNA coding for mouse H chain V region is directly ligated to cDNA coding for H chain C region C<sub>γ</sub>1 of a human antibody, appropriate base sequences can be introduced into a fragment comprising cDNA coding for H chain V region through PCR method. For instance, PCR may be effected using a PCR primer which is designed such that said cDNA has a recognition sequence for a suitable restriction enzyme at its 5'-end and Kozak consensus sequence immediately before the initiation codon thereof so as to improve the transcription efficiency, as well as a PCR primer which is designed such that said cDNA has a recognition sequence for a suitable restriction enzyme at its 3'-end for directly ligating to the H chain C region C<sub>γ</sub>1, to introduce these appropriate base sequences into said cDNA.

**[0091]** The thus constructed cDNA coding for mouse H chain V region is treated with a suitable restriction enzyme(s), ligated to cDNA coding for said H chain C region C<sub>γ</sub>1, and inserted into an expression vector such as pCOS1 or pCHO1 to construct an expression vector containing the cDNA coding for a chimeric H chain.

## (ii) Production of chimeric antibody L chain

**[0092]** The vector for the expression of L chain of a chimeric antibody can be obtained by ligating a cDNA coding for mouse L chain V region and a genomic DNA or cDNA coding for L chain C region of a human antibody and introducing into a suitable expression vector. The L chain C region includes, for example, κ chain and λ chain.

## (ii-a) Construction of expression vector containing cDNA coding for chimeric Lλ chain

**[0093]** When an expression vector containing cDNA coding for mouse L chain V region is constructed, appropriate base sequences can be introduced into said expression vector through PCR method. For instance, PCR may be effected using a PCR primer which is designed such that said cDNA has a recognition sequence for a suitable restriction enzyme at its 5'-end and Kozak consensus sequence for improving the transcription efficiency, as well as a PCR

primer which is designed such that said cDNA has a recognition sequence for a suitable restriction enzyme at its 3'-end, to introduce these appropriate base sequences into said cDNA.

[0094] The whole base sequence of cDNA coding for human  $\Lambda$  chain C region may be synthesized by a DNA synthesizer and constructed through PCR method. The human  $\Lambda$  chain C region is known to have at least 4 different isotypes and each isotype can be used to construct an expression vector. For example, based on a search for the homology with  $\Lambda$  chain C regions of cloned mouse monoclonal antibodies, an isotype Mcg+Ke+Oz- of the fragment of human  $\Lambda$  chain C region (accession No. X57819) (P. Dariavach et al., Proc. Natl. Acad. Sci. USA, 84, 9074-9078, 1987) can be selected and used to construct an expression vector. To construct cDNA for the known human  $\Lambda$  chain C region such as Mcg+Ke+Oz-, for example, the following four primers as shown in SEQ ID NOs:11-14 are designed:

The primers MBC1HGP1 (SEQ ID NO:11) and MBC1HGP3 (SEQ ID NO:13) have sense DNA sequences and the primers MBC1HGP2 (SEQ ID NO:12) and MBC1HGP4 (SEQ ID NO:14) have antisense DNA sequences wherein each primer has a 20 to 23 bp complementary sequence at either end thereof.

[0095] MBC1HGPs (SEQ ID NO:15) and MBC1HGPRs (SEQ ID NO:16) are called external primers, have sequences homologous with MBC1HGP1 and MBC1HGP4, respectively, and have each a recognition sequence for a suitable restriction enzyme. Through PCR method, the four primers are assembled to synthesize full length cDNA and the external primers are added to amplify the cDNA.

[0096] The assembly through PCR method means that MBC1HGP1 and MBC1HGP2 or MBC1HGP3 and MBC1HGP4 are annealed through their complementary sequences to synthesize MBC1HGP1-MBC1HGP2 fragment and MBC1HGP3-MBC1HGP4 fragment and each fragment is again annealed through their complementary sequences to synthesize a cDNA coding for the full length human  $\Lambda$  chain C region.

[0097] The thus constructed cDNA coding for human  $\Lambda$  chain C region and the above constructed cDNA coding for mouse L chain V region can be ligated between suitable restriction enzyme sites and inserted into an expression vector such as pCOS1 or pCHO1, to construct an expression vector containing cDNA coding for a  $\Lambda$  chain of a chimeric antibody.

#### (ii-b) Construction of expression vector containing cDNA coding for chimeric L $\kappa$ chain

[0098] When an expression vector containing cDNA coding for mouse L chain V region is constructed, appropriate base sequences can be introduced into said cDNA through PCR method. For instance, PCR may be effected using a PCR primer which is designed such that said cDNA has a recognition sequence for a suitable restriction enzyme at its 5'-end and Kozak consensus sequence for improving the transcription efficiency, and a PCR primer which is designed such that said cDNA has a recognition sequence for a suitable restriction enzyme at its 3'-end, to introduce these appropriate base sequences into said cDNA.

[0099] The DNA coding for human L $\kappa$  chain C region to be ligated to the DNA coding for mouse L chain V region can be constructed from, for example, HEF-PM1k-gk containing the genomic DNA (see WO92/19759).

[0100] Recognition sequences for suitable restriction enzymes can be introduced, through PCR method, into 5'- and 3'-ends of DNA coding for L $\kappa$  chain C region, and the DNA coding for mouse L chain V region as constructed above and the DNA coding for L $\kappa$  chain C region can be ligated to each other and inserted into an expression vector such as pCOS1 or pCHO1 to construct an expression vector containing cDNA coding for L $\kappa$  chain of a chimeric antibody.

### 3. Production of humanized antibodies

#### (1) Search for homology with human antibodies

[0101] In order to make a humanized antibody in which CDR of a mouse monoclonal antibody is grafted to a human antibody, it is desirable that there exists a high homology between FR of the mouse monoclonal antibody and FR of the human antibody. Accordingly, a comparison is made between V regions of H and L chains of mouse anti-human PTHrP monoclonal antibody and the V regions of all the known antibodies whose structures have been elucidated with the use of Protein Data Bank. Further, they are simultaneously compared with the human antibody subgroups (HSG: Human subgroup) classified by Kabat et al. based on the length of antibody FR, the homology of amino acids, and the like: Kabat, E.A. et al, US Dep, Health and Human Services, US Government Printing Offices, 1991.

[0102] Human H chain V regions may be classified into HSG I to III according to the HSG classification by Kabat et al. and mouse anti-human PTHrP monoclonal antibody H chain V regions have a homology of 82.7% with the consensus sequence of HSG III. On the other hand, human  $\Lambda$  chain V regions may be classified into HSG I to VI according to the HSG classification by Kabat et al. and mouse anti-human PTHrP monoclonal antibody  $\Lambda$  chain V regions do not have a high homology with the consensus sequences of human  $\Lambda$  chain V regions belonging to any subgroups.

[0103] When mouse anti-human PTHrP monoclonal antibody is to be humanized, therefore, it is desirable to use human H chain V region which belongs to HSG III and has the highest homology, or human H chain V region having a

FR structure with a corresponding canonical structure (Chothia C, et al., J. Mol. Biol., 196, 901-917, 1987), as the human H chain V region, to construct a humanized antibody. Further, since there is no consensus sequence with a high homology in subgroups of human L $\lambda$  chain V regions, it is desirable to use human antibody L $\lambda$  chain V region with a highest homology registered in Protein Data Bank upon construction of a humanized antibody.

## (2) Design of DNA coding for humanized antibody V region

**[0104]** The first step for designing DNA coding for a humanized antibody V region is to select a human antibody V region as a basis for the designing.

**[0105]** In the present invention, FR of a human antibody V region having a homology of higher than 80% with FR of a mouse antibody V region can be used in the humanized antibody. The FR of H chain V region as a fragment of a substantially identical FR may include FR derived from those belonging to the subgroup III, such as S31679: NBRF-PDB, Cuisinier A.M. et al., Eur. J. Immunol., 23, 110-118, 1993. Further, the FR of L chain V region as a fragment of a substantially identical FR may include, for example, FR1, FR2 and FR3 derived from human antibody HSU03868 (GENBANK, Deftos M. et al., Scand. J. Immunol., 39, 95-103, 1994) and FR4 derived from human antibody S25755 (NBRF-PDB).

**[0106]** The human antibody S31679 was cloned from cDNA library of human fetal livers while the human antibody HSU03868 was cloned as a novel gene for human L $\lambda$  chain V region.

## (3) Preparation of polypeptides comprising humanized antibody V region

**[0107]** In the humanized antibody of the present invention, the C region and the framework (FR) regions of the V region of said antibody are originated from human and the complementarity determining regions (CDR) of the V region are originated from mouse (Fig. 1). A polypeptide comprising the V region of the humanized antibody according to the present invention can be made in the manner called CDR-grafting by PCR method so long as a DNA fragment of a human antibody would be available as a template. The "CDR-grafting" refers to a method wherein a DNA fragment coding for a mouse-derived CDR is made and replaced for the CDR of a human antibody as a template.

**[0108]** If a DNA fragment of a human antibody to be used as a template is not available, a base sequence registered in a database may be synthesized in a DNA synthesizer and a DNA for a V region of a humanized antibody can be made by the PCR method. Further, when only an amino acid sequence is registered in the database, the whole base sequence may be deduced from the amino acid sequence on the basis of knowledge on the codon usage in antibodies as reported by Kabat, E.A. et al. in US Dep. Health and Human Services, US Government Printing Offices, 1991. This base sequence is synthesized in a DNA synthesizer and a DNA of a humanized antibody V region can be prepared by PCR method and introduced into a suitable host followed by expression thereof to produce the desired polypeptide.

**[0109]** Now, general procedures of CDR-grafting by PCR method are described below when a DNA fragment of a human antibody as a template is available.

### (i) CDR-grafting

**[0110]** Now suppose DNA encoding V region comprises DNAs coding for FR1, CDR1, FR2, CDR2, FR3, CDR3 and FR4 which are linked to each other in this order, as shown in Fig. 2.

**[0111]** First, mouse derived DNA fragments corresponding to respective CDRs are synthesized. CDRs 1 to 3 are synthesized on the basis of the base sequences of the previously cloned mouse H and L chain V regions. Grafting primers B and E are synthesized such that the primer B should have a sequence hybridizing to the mouse CDR1 and human antibody FR2 in the sense direction and the primer E should have a sequence hybridizing to the CDR1 and human antibody FR1 in the antisense direction (Fig. 2 (1)). Similarly, the grafting primers C and F and the primers D and G are synthesized. Further, suitable primers, called "external primers" and corresponding to A and H in Fig. 2 (1), which can hybridize to the regions upstream from FR1 and downstream from FR4, respectively, are also synthesized. Isolation and extraction of the grafting primers may be carried out in known procedures: Sambrook, et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, 1989.

**[0112]** Then, first PCR is performed using the grafting primer E and external primer A, the grafting primers B and F, the grafting primers C and G as well as the grafting primer D and external primer H resulting in the formation of fragments A-E, B-F, C-G and D-H, respectively, (Fig. 2 (2)).

**[0113]** Since the upstream region of the grafting primer B and a part of the downstream region of the grafting primer E have been designed to overlap with each other (the same being true in the grafting primers C and F as well as D and G), these fragments may be annealed with respective complementary sequences by reacting under suitable temperature conditions and assembled to a DNA having a length from A to H by PCR. Once a DNA fragment coding for the V region is obtained, the external primers A and H may be added and second PCR may be performed to yield a DNA cod-

ing for the V region of a humanized antibody in which FRs 1 to 4 are human derived and CDRs 1 to 3 are mouse derived. Then, it may be introduced into a suitable host to express to yield the desired polypeptide (Fig. 2 (3)).

(ii) Construction of DNA and expression vector coding for humanized H chain V region

**[0114]** In the present invention, the whole base sequence of a DNA coding for H chain V region of a human antibody to be used as a template for a humanized antibody may be synthesized by a DNA synthesizer and constructed by PCR method although said DNA is not available from the natural source.

**[0115]** The H chain V region of a mouse anti-human PTHrP monoclonal antibody has a high homology with S31679 belonging to human subgroup III. In order to employ this human antibody as a template to construct a DNA coding for a humanized H chain V region, four primers as shown in SEQ ID NOs:23-26, for example, are used. The primers MBC1HGP1 (SEQ ID NO:23) and MBC1HGP3 (SEQ ID NO:24) have sense DNA sequences and MBC1HGP2 (SEQ ID NO:25) and MBC1HGP4 (SEQ ID NO:26) have antisense DNA sequences. They are designed to each have a 15 to 21 bp complementary sequence at either end thereof.

**[0116]** External primers MBC1HVS1 (SEQ ID NO:27) and MBC1HVR1 (SEQ ID NO:28) have a homologous sequence with MBC1HGP1 and MBC1HGP4, respectively, and each comprises a recognition sequence for a respective suitable restriction enzyme. The four primers are assembled by PCR method to synthesize a full length cDNA, and the external primers are added to amplify the DNA. The "assembling by PCR method" herein involves annealing MBC1HGP1 and MBC1HGP2 or MBC1HGP3 and MBC1HGP4 through their complementary sequences to synthesize a MBC1HGP1-MBC1HGP3 fragment and a MBC1HGP2-MBC1HGP4 fragment and further annealing the fragments through their complementary sequences to synthesize the full length DNA for a humanized H chain V region.

**[0117]** Human antibody H chain C region may be any human H chain C region such as, for example, human H chain C $\gamma$ 1, C $\gamma$ 2, C $\gamma$ 3 or C $\gamma$ 4.

**[0118]** The DNA for H chain V region of a humanized antibody constructed as above described may be ligated to DNA for any human antibody H chain C region, for example, human H chain C $\gamma$ 1 region. As mentioned in the section "Production of H chain of chimeric antibody", the DNA for H chain V region may be treated with a suitable restriction enzyme and ligated to a DNA coding for a human H chain C region under an expression control region such as an enhancer/promoter system to make an expression vector containing DNAs for a humanized H chain V region and a human H chain C region.

(iii) Construction of DNA and expression vector coding for humanized L chain V region

**[0119]** In the present invention, the whole base sequence of DNA coding for L chain V region of a human antibody to be used as a template may be synthesized by a DNA synthesizer and constructed by PCR method although the DNA for L chain V region is not available as in the case of the DNA coding for H chain V region.

**[0120]** In order to construct a DNA for a humanized L chain V region using as a template a human antibody SU03868 having a highest homology with the L chain V region of a mouse anti-human PTHrP monoclonal antibody, four primers as shown in SEQ ID NOs:29-32, for example, are used. The primers MBC1LGP1 (SEQ ID NO:29) and MBC1LGP3 (SEQ ID NO:30) have sense DNA sequences and MBC1LGP2 (SEQ ID NO:31) and MBC1LGP4 (SEQ ID NO:32) have antisense DNA sequences. They are designed to each have a 15 to 21 bp complementary sequence at either end thereof.

**[0121]** External primers MBC1LVS1 (SEQ ID NO:33) and MBC1LVR1 (SEQ ID NO:34) have a homologous sequence with MBC1LGP1 and MBC1LGP4, respectively, and each comprises a recognition sequence for a respective suitable restriction enzyme. The four primers are assembled by PCR method to synthesize a full length DNA, and the external primers are added to amplify the DNA. The "assembling by PCR method" herein involves annealing MBC1LGP1 and MBC1LGP3 or MBC1LGP2 and MBC1LGP4 through their complementary sequences to synthesize a MBC1LGP1-MBC1LGP3 fragment and a MBC1LGP2-MBC1LGP4 fragment and further annealing the fragments through their complementary sequences to synthesize a full length DNA coding for a humanized L chain V region.

**[0122]** Human antibody L chain C region may be any human L chain C region such as, for example, human L chain C $\lambda$  or C $\kappa$ .

**[0123]** The DNA for L chain V region of a humanized antibody constructed as above described may be ligated to DNA for any human antibody L chain C region, for example, human L chain C $\lambda$  region. The DNA for L chain V region may be treated with a suitable restriction enzyme and ligated to a DNA coding for a human L $\lambda$  chain C region under an expression control region such as an enhancer/promoter system to make an expression vector containing DNAs coding for a humanized L chain V region and a human L $\lambda$  chain C region.

**[0124]** Even if a polypeptide comprising a V region of a humanized antibody could be produced as above described, it is not necessarily clear whether or not said polypeptide would have an activity as an antibody, such as binding or neutralizing activity against its antigen. Particularly in the case of L chain, since the L chain V region of a mouse anti-human

PTHrP monoclonal antibody is derived from a very rare  $V\lambda_x$  gene, it should be necessary to investigate the presence or absence of the activity by combining it with a humanized H chain and expressing in an animal cell such as COS-7.

**[0125]** As a method for elucidating which FR in a humanized antibody V region may contribute to the binding and neutralizing activity of the humanized antibody, construction of a hybrid V region (Ohtomo, T. et al., Molecular Immunology, 32, 407-416, 1995) and confirmation may be effective. In order to elucidate which amino acid in the L chain V region of the humanized antibody according to the present invention should be mutated to provide one having the activity, a DNA in which a fragment of an FR region of a humanized antibody is recombined with a fragment of a mouse derived FR region is constructed and each region is assessed for humanization.

**[0126]** As shown in Fig. 3, an antibody having a polypeptide comprising a recombinant V region in which FR1 and FR2 are derived from a human antibody and FR3 and FR4 are derived from a mouse antibody (such an antibody having a recombinant fragment being referred to as a "hybrid antibody"), a hybrid antibody in which only FR1 is human derived, and a hybrid antibody in which only FR2 is human derived, are made. Each of DNAs coding for these hybrid antibodies is introduced into an expression vector and the humanized antibodies are temporarily expressed to investigate the presence of antibody activities.

**[0127]** Using this method, the present inventor has investigated polypeptides comprising L chain V regions for antigen binding and neutralizing activities and finally found that certain amino acids to be replaced exist in FR2 and FR3.

**[0128]** Having found that amino acids contributing to the activity exist in FR2 and FR3 regions, the present inventor has elucidated that the 36th, 45th and 49th amino acids in FR2 region and the 87th amino acid in FR3 region (the numbering of amino acids of antibodies having been determined by Kabat, E.A. et al., US Dep, Health and Human Services, US Government Printing Offices, 1991) contribute to the activity.

**[0129]** Thus, a polypeptide comprising a V region in which such amino acid(s) is/are mutated (e.g., replaced) is made in the present invention.

**[0130]** First, a polypeptide comprising a V region having an amino acid sequence as a base into which a mutation of amino acid(s) is to be introduced is prepared by the aforementioned CDR-grafting. This base polypeptide comprises the amino acid sequence as shown in SEQ ID NO:47 and is referred to as "version a" (a in Table 1).

**[0131]** Then, from the version a as a base, various variant fragments in which one or some amino acids of FR are mutated are made.

**[0132]** The introduction of mutation may be carried out by designing an oligonucleotide primer (mutagenic primer) coding for an amino acid to be introduced as a desired mutation and performing PCR using said primer.

**[0133]** Thus, polypeptides comprising V regions (versions b to t) in which a specific amino acid(s) in FR2 and FR3 is/are mutated are made (b to t in Table 1).

Table 1:  
[0134]

Table 1

|               | FR1                              | 1                 | 2    | 3  | CDR1        |
|---------------|----------------------------------|-------------------|------|----|-------------|
| MBC II. PEP   | 123456789012345678901234567890   | 12345             |      |    |             |
|               | EVQLVESGGDLVKPGGSLKLSCAASGFTFS   |                   |      |    | SYGMS       |
|               | * ** * * *                       |                   |      |    |             |
| S31679        | QVQLVESGGGVVQPGRSLRLSCAASGFTFS   |                   |      |    | SYAMII      |
| hMBC1-II. pep | -----                            |                   |      |    | SYGMS       |
|               | FR2                              | 4                 | CDR2 | 5  | 6           |
| MBC II. PEP   | 67890123456789                   | 012A3456789012345 |      |    |             |
|               | WIRQTPDKRLEWVA                   | TISSGGSYYTPDSVKG  |      |    |             |
|               | * * * *                          |                   |      |    |             |
| S31679        | WVRQAPGKGLEWVA                   | VISYDGSNKYYADSVKG |      |    |             |
| hMBC1-II. pep | -----                            | TISSGGSYYTPDSVKG  |      |    |             |
|               | FR3                              | 7                 | 8    | 9  | 10          |
| MBC II. PEP   | 67890123456789012ABC345678901234 |                   |      |    |             |
|               | RFTISRDNKNTLYLQMSSLKSEDTAMFYCAR  |                   |      |    | QTTMTYFAY   |
|               | * * * * *                        |                   |      |    |             |
| S31679        | RFTISRDNKNTLYLQMNSLRAEDTAVYYCAR  |                   |      |    | ESRGDY      |
| hMBC1-II. pep | -----                            |                   |      |    | QTTMTYFAY   |
|               | FR4                              |                   |      | 11 |             |
|               |                                  |                   |      |    | 34567890123 |
|               |                                  |                   |      |    | WGQGLTVTVSA |
|               |                                  |                   |      |    | * * * *     |
|               |                                  |                   |      |    | WGQGLTVTVSS |
|               |                                  |                   |      |    | -----       |

|              | FR1                     | CDR1           | FR2             | CDR2         |
|--------------|-------------------------|----------------|-----------------|--------------|
|              | 1 2                     | 3              | 4               | 5            |
| MBC L. PEP   | 12345678901234567890123 | 4567A8901234   | 567890123456789 | 01234ABCD56  |
|              | QLVLTQSSS-ASFSLGASAKLTC | TLSSQIISTYTIET | WYQQQPLKPPKYVMD | LKQDGSIHSTGD |
|              | * * * *                 |                | * * * * *       |              |
| HSU03868     | QLVLTQSPS-ASASLGASVKLTC | TLSSGIISYAIA   | WIQQQPEKGPRLMK  | LNSDGSISKGD  |
| hMBC1-L. pep |                         | TLSSQIISTYTIET |                 | LKQDGSIHSTGD |
| a            |                         |                |                 |              |
| b            |                         |                | P---            | D            |
| c            |                         |                |                 |              |
| d            |                         |                |                 |              |
| e            |                         |                | P---            | D            |
| f            |                         |                |                 |              |
| g            |                         |                | Y               |              |
| h            |                         |                | Y               |              |
| i            |                         |                | Y               | K            |
| j            |                         |                | Y               | K            |
| k            |                         |                | Y               | K            |
| l            |                         |                | Y               | K            |
| m            |                         |                | Y               | D            |
| n            |                         |                | Y               | V            |
| o            |                         |                | Y               | V            |
| p            |                         |                | Y               | K            |
| q            |                         |                | Y               | K            |
| r            |                         |                | Y               | D            |
| s            |                         |                | Y               | K            |
| t            |                         |                | Y               | V            |

**[0135]** The DNA coding for each version of L chain V region of a humanized antibody as constructed above may be ligated to a DNA of any L chain C region of a human antibody, such as human L chain C $\lambda$  region. Thus, it is treated with a suitable restriction enzyme and ligated to a DNA coding for a human L $\lambda$  chain C region under the control of an expression control region such as an enhancer/promoter system to construct an expression vector comprising a DNA coding for each version of the humanized L chain V region and a DNA coding for the humanized L $\lambda$  chain C region.

**[0136]** The DNA coding for H chain V region of a humanized antibody and a human H chain C region as previously



constructed and the DNA coding for a humanized L chain V region and human L chain C region may also be introduced into a single expression vector such as that disclosed in WO94/11523, said vector may be used to transform a host cell, and the transformed host may be cultivated in vivo or in vitro to produce a desired humanized antibody.

#### 4. Production of chimeric antibody and humanized antibody

**[0137]** To produce a chimeric or humanized antibody, two expression vectors as above mentioned should be prepared. Thus, with respect to a chimeric antibody, an expression vector comprising a DNA coding for a mouse H chain V region and a human H chain C region under the control of an expression control region such as an enhancer/promoter system, and an expression vector comprising a DNA coding for a mouse L chain V region and a human L chain C region under the control of an expression control region such as an enhancer/promoter system are constructed. With respect to a humanized antibody, an expression vector comprising a DNA coding for a humanized H chain V region and a human H chain C region under the control of an expression control region such as an enhancer/promoter system, and an expression vector comprising a DNA coding for a humanized L chain V region and a human L chain C region under the control of an expression control region such as an enhancer/promoter system are constructed.

**[0138]** Then, a host cell such as a mammalian cell is cotransformed with these expression vectors and the resulting transformed cell is cultivated in vitro or in vivo to produce the chimeric or humanized antibody (see, for example, WO91/16928).

**[0139]** Alternatively, a DNA coding for H chain V and C regions and a DNA coding for L chain V and C regions may be ligated to a single vector and transformed into a suitable host cell to produce an antibody. Thus, in the expression of a chimeric antibody, a DNA coding for a mouse leader sequence present in the cloned cDNA, a mouse H chain V region and a human H chain C region as well as a DNA coding for a mouse leader sequence, a mouse L chain V region and a human L chain C region, are introduced into a single expression vector such as one disclosed in e.g. WO94/11523. In the expression of a humanized antibody, a DNA coding for a humanized H chain V region and a human H chain C region and a DNA coding for a humanized L chain V region and a human L chain C region are introduced into a single expression vector such as one disclosed in e.g. WO94/11523. Such a vector is used to transform a host cell and the transformed host is cultivated in vivo or in vitro to produce a chimeric or humanized antibody of interest.

**[0140]** The chimeric or humanized antibody of interest which is thus produced by cultivating the transformant transformed with a DNA coding for said chimeric or humanized antibody may be isolated from the interior or exterior of the cell and purified to uniformity.

**[0141]** The isolation and purification of the chimeric or humanized antibody of interest according to the present invention may be carried out by using a protein A agarose column, but may also be performed by any methods used in isolation and purification of conventional proteins and thus is not limited. For instance, various chromatography, ultrafiltration, salting out and dialysis may optionally be selected or combined to isolate and purify the chimeric or humanized antibody.

**[0142]** Any expression system may be used to produce the chimeric or humanized antibody against human PTHrP according to the present invention. For example, eukaryotic cells include animal cells such as established mammalian cell lines, mold and fungal cells, and yeast cells; prokaryotic cells include bacterial cells such as *Escherichia coli* cells. Preferably, the chimeric or humanized antibody of the present invention is expressed in a mammalian cell such as COS or CHO cell.

**[0143]** Any conventional promoters useful for the expression in mammalian cells may be used. For example, human cytomegalovirus immediate early (HCMV) promoter is preferably used. Examples of expression vectors comprising HCMV promoter include HCMV-VH-HC $\gamma$  1 and HCMV-VL-HCK derived from pSV2neo (WO92/19759).

**[0144]** In addition, promoters for gene expression in mammalian cells which can be used in the present invention may include virus promoters, such as those of retrovirus, polyoma virus, adenovirus and simian virus (SV) 40, and mammalian cell derived promoters, such as those of human polypeptide chain elongation factor-1 $\alpha$  (HEF-1 $\alpha$ ). For example, SV40 promoter may be readily used according to Mulligan et al. method (Nature, 277, 108, 1979); Mizushima, S. et al. method (Nucleic Acids Research, 18, 5322, 1990) may be easily used with HEF-1 $\alpha$  promoter.

**[0145]** Origin of replication usable herein includes those derived from SV40, polyoma virus, adenovirus or bovine papilloma virus (BPV). Further, the expression vector may comprise a gene for phosphotransferase APH(3') II or I (neo), thymidine kinase (TK), *E. coli* xanthine-guanine phosphoribosyltransferase (Ecogpt) or dihydrofolate reductase (DHFR) as a selective marker for increasing the gene copy number in a host cell system.

#### 5. Evaluation of antigen binding and neutralizing activity of chimeric and humanized antibodies

##### (1) Determination of antibody concentration

**[0146]** The concentration of the resulting purified antibody can be determined by ELISA.

**[0147]** ELISA plates for determining the antibody concentration are prepared in the following manner: 100  $\mu$ l of a goat anti-human IgG antibody prepared at a concentration of e.g. 1  $\mu$ g/ml is immobilized in each well of a 96 well plate for ELISA (for example, Maxisorp, NUNC). After blocking with 200  $\mu$ l of a diluting buffer (for example, 50 mM Tris-HCl, 1 mM MgCl<sub>2</sub>, 0.1 M NaCl, 0.05% Tween20, 0.02% NaN<sub>3</sub>, 1% bovine serum albumin (BSA), pH 7.2), a stepwise diluted supernatant of COS-7 or CHO cells in which the chimeric, hybrid or humanized antibody has been expressed, or purified chimeric, hybrid or humanized antibody is added to each well, 100  $\mu$ l of an alkaline phosphatase-conjugated goat anti-human IgG antibody is added, and 1 mg/ml of a substrate solution (Sigma 104, p-nitrophenylphosphoric acid, SIGMA) is then added, after which the absorbance at 405 nm is measured by a microplate reader (Bio Rad). Hu IgG1 $\lambda$  Purified (The Binding Site) may be used as a standard for the determination of concentrations.

## (2) Determination of antigen binding ability

**[0148]** ELISA plates for determining the antigen binding ability are prepared in the following manner: 100  $\mu$ l of human PTHrP (1-34) prepared at a concentration of 1  $\mu$ g/ml is immobilized to each well of a 96 well plate for ELISA. After blocking with 200  $\mu$ l of a diluting buffer, a stepwise diluted supernatant of COS-7 or CHO cells in which the chimeric, hybrid or humanized antibody has been expressed, or purified chimeric, hybrid or humanized antibody is added to each well, 100  $\mu$ l of an alkaline phosphatase-conjugated goat anti-human IgG antibody is added, and 1 mg/ml of a substrate solution (Sigma 104, p-nitrophenylphosphoric acid, SIGMA) is then added, after which the absorbance at 405 nm is measured by a microplate reader (BioRad).

## (3) Determination of neutralizing activity

**[0149]** Determination of the neutralizing activity of the mouse, chimeric and humanized antibodies can be carried out by, e.g., using rat osteosarcoma cell line ROS17/2.8-5 cell (Sato, K. et al., Acta Endocrinology, 116, 113-120, 1987). Thus, ROS17/2.8-5 cells are stimulated by 4mM hydrocortisone to induce PTH/PTHrP receptor. The degradative enzyme for cAMP is inhibited with 1 mM of isobutyl-1-methyl xanthine (IBMX, SIGMA). The mouse, chimeric or humanized antibody to be determined for neutralizing activity is mixed with an equal amount of PTHrP (1-34) and the resulting mixture of each antibody and PTHrP (1-34) is added to each well. The neutralizing ability of the mouse, chimeric or humanized antibody can be estimated by measuring the amount of cAMP produced by rat osteosarcoma cell lines ROS17/2.8-5 cells due to stimulation with PTHrP.

## (4) Kinetic analysis of interactions between PTHrP and anti-PTHrP antibody

**[0150]** In the present invention, the kinetics in the interactions between PTHrP and anti-PTHrP may be analyzed by a variety of means and procedures. Specifically, dissociation constants, dissociation rate constants and association rate constants may be measured by Scatchard analysis and a surface plasmon resonance sensor called BIACORE (developed and commercialized by Pharmacia Biotech). Analysis by a surface plasmon resonance sensor called BIACORE will be described hereinbelow as one example.

**[0151]** The basic structure of BIACORE comprises an optical source, a prism, a detector and a micro-passage. In practice, a ligand is immobilized on a cassette-type sensor tip and an analyte is injected thereinto. When there is any affinity between them, the binding amount is optically detected.

**[0152]** The detecting principle is a phenomenon called surface plasmon resonance. Thus, of incident light injected to the interface between a glass and a metal film so that total reflection should occur, the incident light at a certain angle is used to excite surface plasmon and damped. The angle vary depending upon the change in concentration of a solvent in contact with the metal film (sensor). BIACORE detects this change.

**[0153]** In BIACORE, this change is called a resonance signal (SPR signal) and a change of 0.1 degree is 1000 RU (resonance units). 1000 RU corresponds to a change in the binding of about 1 ng of a protein onto a thin gold sensor of 1 mm<sup>2</sup> in surface area. For a protein, a change of about 50 RU (50 pg) can be fully detected.

**[0154]** The detected signals are converted into a binding curve called a sensorgram by a computer attached to BIACORE, which is drawn on a computer display in real time: Natsume, T., et al. (1995) Experimental Medicine, 13, 563-569; Karlsson, R., et al. (1991) J. Immunol. Methods 145, 229-240.

**[0155]** Kinetics parameters, i.e., dissociation constant (KD), dissociation rate constant (K<sub>diss</sub>) and association rate constant (K<sub>ass</sub>), of the anti-PTHrP antibodies of the present invention may be measured by the above mentioned BIACORE.

**[0156]** The anti-PTHrP antibodies of the present invention preferably have as small a dissociation constant (KD value) as possible in view of neutralizing activity. Preferably, the anti-PTHrP antibodies of the present invention have a KD value  $1.86 \times 10^{-7}$  or less, more preferably  $1.86 \times 10^{-8}$  or less, most preferably  $3.58 \times 10^{-10}$  or less.

**[0157]** The KD values are determined from two parameters, dissociation rate constants (K<sub>diss</sub>) and association rate

constants (Kass) ( $KD = K_{diss}/K_{ass}$ ). Apparently, therefore, the KD values are smaller when the K<sub>diss</sub> values are smaller and the Kass values are larger.

[0158] Specifically, the K<sub>diss</sub> values of the anti-PTHrP antibodies according to the present invention may be  $1.22 \times 10^{-1}$  [l/Sec] or less. Preferably, the K<sub>diss</sub> values are  $1.22 \times 10^{-2}$  or less, more preferably  $3.16 \times 10^{-4}$  or less, most preferably  $2.32 \times 10^{-4}$  [l/Sec] or less.

[0159] On the other hand, the Kass values may be  $6.55 \times 10^4$  [l/M.Sec] or more. Preferably, the Kass values are  $6.55 \times 10^5$  or more, more preferably  $0.883 \times 10^6$  or more, most preferably  $1.03 \times 10^6$  [l/M.Sec] or more.

[0160] Further, also preferred are anti-PTHrP antibodies having a K<sub>diss</sub> value of  $1.22 \times 10^{-1}$  [l/Sec] and a Kass value of  $6.55 \times 10^4$  [l/M.Sec] or more.

[0161] More specifically, the anti-PTHrP antibodies of the present invention have a KD value in the range of  $1.02 \times 10^{-11}$  to  $1.86 \times 10^{-7}$  [M], preferably  $1.02 \times 10^{-10}$  to  $1.86 \times 10^{-8}$  [M], more preferably  $1.34 \times 10^{-10}$  to  $3.58 \times 10^{-10}$  [M], most preferably  $2.25 \times 10^{-10}$  to  $3.58 \times 10^{-10}$  [M].

[0162] The K<sub>diss</sub> values are in the range of  $7.38 \times 10^{-6}$  to  $1.22 \times 10^{-1}$  [l/Sec], preferably  $7.38 \times 10^{-5}$  to  $1.22 \times 10^{-2}$  [l/Sec], more preferably  $1.66 \times 10^{-4}$  to  $3.16 \times 10^{-4}$  [l/Sec], most preferably  $1.66 \times 10^{-4}$  to  $2.32 \times 10^{-4}$  [l/Sec].

[0163] The Kass values are in the range of  $6.55 \times 10^4$  to  $1.24 \times 10^7$  [l/M.Sec], preferably  $6.55 \times 10^5$  to  $1.24 \times 10^6$  [l/M.Sec], more preferably  $7.23 \times 10^5$  to  $1.03 \times 10^6$  [l/M.Sec], most preferably  $0.883 \times 10^6$  to  $1.03 \times 10^6$  [l/M.Sec].

[0164] These KD, K<sub>diss</sub> and Kass values may be obtained by Scatchard analysis or a surface plasmon resonance sensor such as BIACORE, preferably by BIACORE.

6. Pharmaceutical composition and hypercalcemia-suppressing agent comprising anti-PTHrP or humanized antibody as effective ingredient.

[0165] The therapeutic effect of the humanized antibody on PTHrP may be confirmed by administering the antibody against PTHrP or the humanized antibody to an animal exhibiting hypercalcemia and measuring an index for hypercalcemia. In animals exhibiting hypercalcemia and patients suffering from hypercalcemia, hypophosphatemia is often observed; the antibodies of the present invention may also be used to improve the hypophosphatemia.

[0166] The antibody used in the present invention is an anti-PTHrP antibody including human, chimeric and primate antibodies or a humanized antibody against PTHrP having the dissociation constant, dissociation rate constant and association rate constant. The antibody will neutralize the activity of PTHrP by binding to PTHrP and preferably includes, in particular, humanized #23-57-137-1 antibody. The method for producing the humanized #23-57-137-1 antibody will be described in Examples 1 to 3.

[0167] The antibody used in the present invention can be purified to a high purity by any combination of conventional purification means such as salting out, gel filtration using HPLC etc., and affinity chromatography using a protein A column etc. Recognition of PTHrP by the thus purified antibody with a high accuracy may be confirmed by any conventional immunological means such as radioimmunoassay (RIA), enzyme immunoassay (EIA, ELISA) or immunofluorescence analysis.

[0168] The animal exhibiting hypercalcemia which may be used includes a model animal prepared by transplanting PTHrP-producing tumor cells to an experimental animal with reduced or deleted immunological function. The tumor cells transplanted are preferably human derived ones including, for example, human pancrea cancer PAN-7. The animal with reduced or deleted immunological function to which the tumor cells are transplanted includes nude mouse and SCID mouse.

[0169] Suppression of hypercalcemia may be evaluated by observing the concentration of calcium in the blood, the reduction of body weight or the reduction of extent of movement with the lapse of time and determining the degree of improvement.

[0170] The pharmaceutical composition and hypercalcemia suppressing agent comprising the antibody or humanized antibody against PTHrP as an effective ingredient according to the present invention may be parenterally administered systemically or topically. For example, intravenous injection including drip, intramuscular injection, intraperitoneal injection or subcutaneous injection may be selected. The method of administration may be properly selected depending on the age of a patient and the conditions of disease. An effective single dose may be selected from the range of 0.01 to 1,000 mg per kg of body weight. Alternatively, the dose to a patient may be 5 to 10,000 mg/body, preferably 50 to 1,000 mg/body.

[0171] The pharmaceutical composition and hypercalcemia suppressing agent comprising the antibody or humanized antibody against PTHrP as an effective ingredient according to the present invention may further comprise a pharmaceutically acceptable carrier and/or additive(s) depending upon the administration route. Examples of such carrier and additive may include water, pharmaceutically acceptable organic solvents, collagen, polyvinyl alcohol, polyvinyl pyrrolidone, carboxyvinyl polymer, sodium carboxymethyl cellulose, poly(sodium acrylate), sodium arginate, water soluble dextran, sodium carboxymethyl starch, pectin, methyl cellulose, ethyl cellulose, xanthane gum, gum arabic, casein, gelatin, agar, diglycerin, glycerin, propylene glycol, polyethylene glycol, vaseline, paraffin, stearyl alcohol, stearic acid,

human serum albumin (HSA), mannitol, sorbitol, lactose, and surfactants acceptable as pharmaceutical additives. The additives used may be properly selected from the above either alone or in combination, but not limited thereto.

[0172] The antibody of the present invention may be used widely in hypercalcemia associated with various cancers (malignant tumors). These cancers are not particularly limited and include not only a single cancer but also a combination of a plurality of cancers. The cancers may include for example pancreas, lung, pharynx, larynx, tongue, gingiva, esophagus, stomach, biliary duct, breast, kidney, urinary bladder, uterus and prostate cancers, and malignant lymphoma.

#### BRIEF DESCRIPTION OF DRAWINGS

[0173]

FIG. 1 is a schematic illustration of the antibody according to the present invention;

FIG. 2 is a schematic illustration of the CDR-grafting;

FIG. 3 is an illustration of the determination of the FRs and the CDRs of the V region;

FIG. 4 is a graph showing the measurement result of the antigen-binding activity of the antibodies;

FIG. 5 is a graph showing the measurement result of the antigen-binding activity of the antibodies;

FIG. 6 is a graph showing the measurement result of the antigen-binding activity of the antibodies;

FIG. 7 is a graph showing the measurement result of the antigen-binding activity of the antibodies;

FIG. 8 is a graph showing the measurement result of the antigen-binding activity of the antibodies;

FIG. 9 is a graph showing the measurement result of the antigen-binding activity of the antibodies;

FIG. 10 is a graph showing the measurement result of the antigen-binding activity of the antibodies;

FIG. 11 is a graph showing the measurement result of the antigen-binding activity of the antibodies;

FIG. 12 is a graph showing the neutralizing activity of the humanized antibodies;

FIG. 13 is a graph showing the neutralizing activity of the humanized antibodies;

FIG. 14 is a graph showing the neutralizing activity of the humanized antibodies;

FIG. 15 are graphs illustrating the efficacy of the antibodies of the present invention against a hypercalcemic model animal;

FIG. 16 are graphs illustrating the efficacy of the antibodies of the present invention on a hypercalcemic model animal;

FIG. 17 are graphs illustrating the efficacy of the antibodies of the present invention on a hypercalcemic model animal;

FIG. 18 are graphs illustrating the efficacy of the antibodies of the present invention on a hypercalcemic model animal;

FIG. 19 is a sensorgram illustrating the immobilization of PTHrP onto sensor tip;

FIG. 20 is a graph showing the results of the kinetic analysis of the antibody according to the invention;

FIG. 21 is a graph showing the results of the kinetic analysis of the antibody according to the invention;

FIG. 22 is a graph showing the results of the kinetic analysis of the antibody according to the invention;

FIG. 23 is a graph showing the results of the kinetic analysis of the antibody according to the invention;

FIG. 24 is a graph showing the results of the kinetic analysis of the antibody according to the invention;

FIG. 25 is a graph showing the test results of the effect of the humanized antibody according to the invention on fractional excretion of phosphate;

FIG. 26 is a graph showing the test result of the effect of the humanized antibody according to the invention on phosphorus concentration in plasma;

FIG. 27 is a photograph showing the apparent clinical symptoms of hypercalcemia model mice developed after administration of the anti-PTHrP antibody according to the invention (morphology of living animal);

FIG. 28 is a photograph showing the apparent clinical symptoms of hypercalcemia model mice developed after administration of the anti-PTHrP antibody according to the invention (morphology of living animal);

FIG. 29 is a graph showing the change in spontaneous activity of a hypercalcemia model animal over time after administering the anti-PHThrP antibody according to the invention in comparison with that of a control model animal administered with physiological saline;

FIG. 30 is a graph showing the change in body temperature of a hypercalcemia model animal over time after administering the anti-PHThrP antibody according to the invention in comparison with that of a control model animal administered with physiological saline; and

FIG. 31 is a graph showing the change in blood pH of a hypercalcemia model animal over time after administering the anti-PHThrP antibody according to the invention in comparison with that of a control model animal administered with physiological saline.

## EXAMPLE

[0174] Hereinbelow, the present invention will be described in more detail with reference to the following Examples, which should not be construed as limiting the scope of the invention.

## REFERENCE EXAMPLE 1

## Preparation of Anti-PTHrP (1-34) Mouse Monoclonal Antibody Producing Hybridoma

[0175] Hybridomas capable of producing a monoclonal antibody against human PTHrP (1-34), #23-57-154 and #23-57-137-1, were prepared in accordance with the method reported by Kanji Sato et al. (Sato, K. et al., J. Bone Miner. Res. 8, 849-860, 1993).

[0176] The immunogen used was PTHrP (1-34) (Peninsula), to which a carrier protein, thyroglobulin, was conjugated using carbodiimide (Dojinn). The thyroglobulin-conjugated PTHrP (1-34) was dialyzed to obtain a solution having a protein concentration of 2 µg/ml. The resultant solution was mixed with Freund's adjuvant (Difco) in a mixing ratio of 1:1 to obtain an emulsion. This emulsion was injected to each of 16 female BALB/C mice dorsal-subcutaneously or intraperitoneally in a dose amount of 100 µg/mouse to immunize the mice. The injection was conducted 11 times. With respect to the adjuvant, Freund's complete adjuvant was used in the injection for the first immunization, and Freund's incomplete adjuvant was used in the injection for subsequent immunizations.

[0177] Each of the mice immunized was determined for its antibody titers in the sera in the following manner:

[0178] Each of the mice was blood-drawn from its tail vein and the blood was then subjected to centrifugation to obtain a serum. The serum was diluted with a RIA buffer, mixed with <sup>125</sup>I-labeled PTHrP (1-34), and subjected to determination of its binding activity. The mice which have been confirmed to have a satisfactorily high antibody titer were injected with PTHrP (1-34) without the carrier protein intraperitoneally in a dose amount of 50 µg/mouse for the final immunization.

[0179] Three days after the final immunization, the mice were sacrificed and excised their spleens. Thereafter, spleen cells were subjected to cell fusion with mouse myeloma cell line P3xG3Ag8U. 1 in accordance with a conventional known method using 50% polyethylene glycol 4000. The fused cells thus prepared were inoculated into each well of 85 of 96-well plates in an amount of  $2 \times 10^4$ /well. The screening of hybridomas of interest was conducted using a HAT medium as follows.

[0180] The screening of the hybridomas was conducted by determining for the presence of PTHrP-recognition antibodies in the culture supernatant with respect to the wells in which cell growth had been observed in the HAT medium by a solid phase RIA method. The hybridomas were collected from the wells in which the binding ability to the PTHrP-recognition antibody was confirmed. The hybridomas thus obtained was suspended into a RPMI-1640 medium containing 15% FCS and supplemented with OPI-supplement (Sigma), followed by unification of the hybridomas by a limiting dilution method, thereby obtaining two types of hybridoma clones, #23-57-154 and #23-57-137-1 both exhibiting a strong binding ability to PTHrP (1-34).

[0181] Hybridoma clone #23-57-137-1, which was designated "mouse-mouse hybridoma #23-57-137-1", has been deposited under the terms of the Budapest Treaty on August 15, 1996 at the National Institute of Bioscience and Human-technology, Agency of Industrial Science and Technology, Japan (1-3, Higashi 1-chome, Tsukuba-shi, Ibaragi-ken, Japan) under the accession No. FERM BP-5631.

## EXAMPLE 1

## Cloning of DNA coding for V region of Mouse Monoclonal Antibody against Human PTHrP (1-34)

[0182] Cloning of the DNA coding for the V region of the mouse monoclonal antibody against human PTHrP (1-34) obtained above, #23-57-137-1, was conducted in the following manner.

## (1) Preparation of mRNA

[0183] mRNA was prepared from hybridoma #23-57-137-1 using Quick Prep mRNA Purification Kit (Pharmacia Biotech) as follows.

[0184] The cells of hybridoma #23-57-137-1 obtained above were fully homogenized with an extraction buffer, and mRNA was extracted therefrom using an oligo(dT)-Cellulose Spun Column in accordance with the procedure by the manufacturer of the kit. The extraction solution was subjected to ethanol precipitation to obtain the mRNA as precipitates. The mRNA precipitates were dissolved in an elution buffer.

## (2) Preparation and amplification of cDNA of the gene coding for mouse H chain V region

## (i) Cloning of cDNA for H chain V region of #23-57-137-1 antibody

**[0185]** A DNA coding for the H chain V region of the mouse monoclonal antibody against human PTHrP was cloned by a 5'-RACE method (Frohman, M.A. et al., Proc. Natl. Acad. Sci. USA, 85, 8998-9002, 1988; Belyavsky, A. et al., Nucleic Acids Res. 17, 2919-2932, 1989). This method was conducted using 5'-Ampli FINDER RACE Kit (CLONETECH) in accordance with the procedure by the manufacturer. In this method, the primer used for synthesis of cDNA was MHC2 primer (SEQ ID NO: 1) which is hybridizable with mouse H chain C region. About 2 µg of the above-obtained mRNA, which was a template for cDNA synthesis, was mixed with 10 pmoles of MHC2 primer. The resultant mixture was reacted with a reverse transcriptase at 52°C for 30 min to prepare a cDNA which was complementary to the mRNA.

**[0186]** The resultant was mixed with 6N NaOH to hydrolyze the mRNA therein (at 65°C for 30 min.) and then subjected to ethanol precipitation to isolate the cDNA as precipitates. The cDNA thus isolated was ligated to Ampli FINDER Anchor (SEQ ID NO: 42) on its 5'-end by reacting with T4 RNA ligase at 37°C for 6 hours and additionally at room temperature for 16 hours. As the primers for amplification of the cDNA by a PCR method, Anchor primer (SEQ ID NO: 2) and MHC-G1 primer (SEQ ID NO: 3) (S.T. Jones, et al., Biotechnology, 9, 88, 1991) were used.

**[0187]** The PCR solution (50 µl) used in this method comprised 10 mM Tris-HCl (pH 8.3), 50 mM KCl, 0.25 mM dNTPs (dATP, dGTP, dCTP, dTTP), 1.5 mM MgCl<sub>2</sub>, 2.5 units of TaKaRa Taq (Takara Shuzo), 10 pmoles Anchor primer, and 1 µl of the reaction mixture of the cDNA to which MHC-G1 primer and Ampli FINDER Anchor primer had been ligated, over which 50 µl of mineral oil was layered. Thirty cycles of the PCR reaction was conducted using Thermal Cycler Model 480J (Perkin Elmer) and a temperature cycle of 94°C for 45 sec.; 60°C for 45 sec.; and 72°C for 2 min.

## (ii) Cloning of cDNA for #23-57-137-1 antibody L chain V region

**[0188]** A DNA coding for L chain V region of the mouse monoclonal antibody against human PTHrP was cloned by the 5'-RACE method (Frohman, M.A. et al., Proc. Natl. Acad. Sci. USA, 85, 8998-9002, 1988; Belyavsky, A. et al., Nucleic Acids Res. 17, 2919-2932, 1989). This method was conducted using 5'-Ampli Finder RACE Kit (Clontech) in accordance with the procedure by the manufacturer. In this method, oligo-dT primer was used as the primer for synthesizing a cDNA. About 2 µg of the above-mentioned mRNA (which was a template for cDNA synthesis) was mixed with oligo-dT primer. The resultant mixture was reacted with a reverse transcriptase at 52°C for 30 min. to prepare a cDNA. The resultant was mixed with 6N NaOH to hydrolyze the RNA therein (at 65°C for 30 min.). The resultant mixture was subjected to ethanol precipitation to isolate the cDNA as precipitates. The cDNA thus synthesized was ligated to the Ampli FINDER Anchor on its 5'-end by reacting with T4 RNA ligase at 37°C for 6 hours and additionally at room temperature for 16 hours.

**[0189]** PCR primer MLC (SEQ ID NO: 4) was designed based on the conserved sequence of a mouse L chain λ chain C region and then synthesized using 394 DNA/RNA Synthesizer (ABI). The PCR solution (100 µl) used for the synthesis of the primer comprised 10 mM Tris-HCl (pH 8.3), 50 mM KCl, 0.25 mM dNTPs (dATP, dGTP, dCTP, dTTP), 1.5 mM MgCl<sub>2</sub>, 2.5 units of AmpliTaq (PERKIN ELMER), 50 pmoles of Anchor primer (SEQ ID NO: 2), and 1 µl of the reaction mixture of the cDNA to which MLC (SEQ ID NO: 4) and Ampli FINDER Anchor were ligated, over 50 µl of mineral oil was layered. Thirty-five cycles of the PCR reaction was conducted using Thermal Cycler Model 480J (Perkin Elmer) and a temperature cycle of 94°C for 45 sec.; 60°C for 45 sec.; and 72°C for 2 min.

## (3) Purification and fragmentation of the PCR product

**[0190]** Each of the DNA fragments amplified by the PCR methods described above was separated by agarose gel electrophoresis using 3% Nu Sieve GTG agarose (FMC Bio. Products). For each of the H chain V region and the L chain V region, agarose gel fraction containing a DNA fragment of about 550 bp in length was excised from the gel, respectively. Each of the gel fractions obtained was subjected to purification of the DNA therefrom using GENECLEAN II Kit (BIO101) in accordance with the procedure by the manufacturer. The purified DNA was precipitated from the solution with ethanol and then dissolved in 20 µl of a solution containing 10 mM Tris-HCl (pH 7.4) and 1 mM EDTA. One µl of the DNA solution thus prepared was digested with restriction enzyme XmaI (New England Biolabs) at 37°C for 1 hour and additionally with restriction enzyme EcoRI (Takara Shuzo) at 37°C for 1 hour. The digestion mixture was subjected to extraction with phenol and chloroform and then precipitation with ethanol to collect the DNA.

**[0191]** In this manner, obtained a DNA coding for the mouse H chain V region and a DNA coding for the mouse L chain V region, both which had an EcoRI recognition sequence on the 5'-end and an XmaI recognition sequence on the 3'-end thereof were obtained.

**[0192]** Each of the EcoRI-XmaI DNA fragments containing a DNA coding for the mouse H chain V region and a DNA

coding for the mouse L chain V region, respectively, was reacted with pUC19 vector, which had been digested with EcoRI and XmaI, at 16°C for 1 hour using DNA Ligation Kit ver.2 (Takara Shuzo) in accordance with the procedure by the manufacturer to ligate to each other. The ligation mixture (10 µl) thus obtained was added to 100 µl of a solution containing competent cells of E. coli, JM 109 (Nippon Gene). The cell mixture was allowed to stand for 15 min. on ice, at 42°C for 1 min, and further for 1 min. on ice. The resultant was mixed with 300 µl of SOC culture medium (Molecular Cloning: A Laboratory Manual, Sambrook, et al., Cold Spring Harbor Laboratory Press, 1989) and then incubated at 37°C for 30 min. The resultant cell solution was spread on a LB or 2xYT agar medium (Molecular Cloning: A Laboratory Manual, Sambrook, et al., Cold Spring Harbor Laboratory Press, 1989) supplemented with 100 or 50 µg/ml of ampicillin, 0.1 mM of IPTG and 20 µg/ml of X-gal and then incubated at 37°C overnight. In this manner, E. coli transformants were prepared.

[0193] The transformants were cultured overnight in 2 ml of a LB or 2xYT medium containing 100 or 50 µg/ml of ampicillin at 37°C and then plasmid DNA was prepared from the cell fraction using Plasmid Extractor PI-100Σ (Kurabou) or QIAprep Spin Plasmid Kit (QIAGEN). The plasmid DNAs thus obtained were determined for their DNA sequences.

#### (4) Sequencing of cDNA coding for V region of mouse antibody

[0194] The sequence of the cDNA coding region carried on the plasmid was determined by DNA Sequencer 373A (ABI; Perkin-Elmer) using Dye Terminator Cycle Sequencing Kit (Perkin-Elmer). This DNA sequence was determined by confirming the base sequence in the both orientations using primers, M13 Primer M4 (Takara Shuzo) (SEQ ID NO: 5) and M13 Primer RV (Takara Shuzo) (SEQ ID NO: 6).

[0195] The plasmids thus obtained, which contained a cDNA coding for the mouse H chain V region and a cDNA coding for the mouse L chain V region derived from hybridoma #23-57-137-1, were designated "MBC1H04" and "MBC1L24", respectively. The sequences (including the corresponding amino acids sequences) of the DNA coding for the H chain V region and the DNA coding for the L chain V region of mouse #23-57-137-1 antibody (respectively carried on plasmid MBC1H04 and plasmid MBC1L24) were shown in SEQ. ID NOs: 57 and 65, respectively. Both of the polypeptides for the H chain V region fragment and for the L chain V region fragment were translated starting from the 58th base (which coding for glutamine) in the DNA sequences shown in SEQ ID NOs: 57 and 65. The amino acid sequences for the H chain V region and the L chain V region were shown in SEQ. ID NOs: 46 and 45, respectively.

[0196] The E. coli having plasmid MBC1H04 and the E. coli having plasmid MBC1L24 were designated "Escherichia coli JM109 (MBC1H04)" and "Escherichia coli JM109 (MBC1L24)", respectively. These E. coli strains have been deposited under the terms of the Budapest Treaty at the National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology, Japan (1-3, Higashi 1-chome, Tsukuba-shi, Ibaragi-ken, Japan) on August 15, 1996 under the Accession No. FERM BP-5628 for Escherichia coli JM109 (MBC1H04) and FERM BP-5627 for Escherichia coli JM109 (MBC1L24), respectively.

#### (5) Determination of CDR of mouse monoclonal antibody #23-57-137-1 against human PTHrP

[0197] The general structures of the H chain V region and the L chain V region are similar to each other. That is, both structures have four framework regions ligated through three hypervariable regions [i.e., complementarity determining regions (CDRs)]. The amino acid sequences of the framework regions are relatively well conserved, while the amino acid sequences of the CDR regions exhibit an extremely high mutagenicity (Kabat, E.A. et al., "Sequence of Proteins of Immunological Interest", US Dept. Health and Human Services, 1983).

[0198] On the basis of the above-mentioned facts, the CDRs were determined by searching the homology of amino acid sequences of the mouse monoclonal antibody V region by reference to the Date Base of amino acid sequences for antibodies established by Kabat et al.

[0199] The amino acid sequences of CDRs 1-3 in the L chain V region are shown in SEQ ID Nos: 59-61, respectively, and the amino acid sequences of CDRs 1-3 in the H chain V region are shown in SEQ ID Nos: 62-64, respectively.

Table 2

| V region         | SEQ ID NO. | CDR1  | CDR2  | CDR3   |
|------------------|------------|-------|-------|--------|
| H chain V region | 57         | 31-35 | 50-66 | 99-107 |
| L chain V region | 65         | 23-34 | 50-60 | 93-105 |

## EXAMPLE 2

## Construction of Chimeric Antibody

## (1) Construction of chimeric antibody H chain

## (i) Construction of H chain V region

**[0200]** The cloned cDNA coding for mouse H chain V region was modified by a PCR method to ligate it to an expression vector carrying the genomic DNA for the human H chain C region C $\lambda$ 1. The downstream-side primer MBC1-S1 (SEQ ID NO: 7) used was designed so as to be hybridizable to the DNA coding for the 5'-end region of the leader sequence of the V region and to have both a Kozak consensus sequence (Kozak, M. et al., J. Mol. Biol., 196, 947-950, 1987) and a HindIII-recognition sequence. The upstream-side primer, MBC1-a (SEQ ID NO: 8), used was designed so as to be hybridizable to the DNA coding for the 3'-end region of the J region and to have both a splice donor sequence and a BamHI-recognition sequence. The PCR reaction was conducted using TaKaRa Ex Taq (Takara Shuzo) and a buffer appended thereto. The PCR solution (50  $\mu$ l) used comprised 0.07  $\mu$ g of plasmid MBC1H04 as a template DNA, 50 pmoles of MBC1-a and 50 pmoles of MBC1-S1 as primers, 2.5U of TaKaRa Ex Taq and 0.25 mM dNTP in the buffer, over which 50  $\mu$ l of mineral oil was layered. Thirty cycles of the PCR reaction was conducted using a temperature cycle of 94°C for 1 min.; 55°C for 1 min.; 72°C for 2 min. The DNA fragments thus amplified by the PCR reaction were separated by agarose gel electrophoresis using 3% Nu Sieve GTG Agarose (FMC Bio. Products).

**[0201]** Then, an agarose gel fragment containing a DNA fragment of 437 bp in length was excised and the DNA fragment was purified therefrom using GENECLAN II Kit (BIO101) in accordance with an instruction included in the kit. The purified DNA was collected by ethanol precipitation, and then dissolved in 20  $\mu$ l of a solution comprising 10 mM Tris-HCl (pH 7.4) and 1 mM EDTA. One  $\mu$ l of the resultant DNA solution was digested with restriction enzymes BamHI and HindIII (Takara Shuzo) at 37°C for 1 hour. The digestion mixture was extracted with phenol and chloroform and then precipitated with ethanol to collect a DNA.

**[0202]** The obtained HindIII-BamHI DNA fragment, which contains a DNA coding for the mouse H chain V region, was subcloned into pUC19 vector which had been digested with HindIII and BamHI. The resultant plasmid was sequenced by DNA Sequencer 373A (Perkin-Elmer) using M13 Primer M4 and M13 Primer RV as primers, and Dye Terminator Cycle Sequencing Kit (Perkin-Elmer). The plasmid contained a DNA of correct base sequence coding for the mouse H chain V region derived from hybridoma #23-57-137-1 and had a HindIII-recognition sequence and a Kozak sequence on its 5'-end region and a BamHI-recognition sequence on its 3'-end region was designated "MBC1H/pUC19".

## (ii) Construction of H chain V region to be used for the preparation of cDNA-type of mouse-human chimeric H chain

**[0203]** The DNA coding for the mouse H chain V region constructed in the above step was modified by a PCR method to ligate it to a cDNA for the human H chain C region C $\lambda$ 1. The backward primer, MBC1HVS2, (SEQ ID NO: 9) used for the modification of H chain V region was designed so as to replace the second amino acid (i.e., asparagine) of the sequence coding for the front portion of the leader sequence of the V region with glycine and to have a Kozak consensus sequence (Kozak, M. et al., J. Mol. Biol., 196, 947-950, 1987) and the HindIII- and EcoRI-recognition sequences. The forward primer MBC1HVR2 (SEQ ID NO: 10) used for the modification of H chain V region was designed so as to be hybridizable to the DNA sequence coding for the 3'-end region of the J region, to coding for the 5'-end region of the C region and to have ApaI- and SmaI-recognition sequences.

**[0204]** The PCR reaction was conducted using TaKaRa Ex Taq (Takara Shuzo) and a buffer appended thereto. The PCR solution (50  $\mu$ l) used comprised 0.6  $\mu$ g of plasmid MBC1H/pUC19 as a template DNA, 50 pmoles of MBC1HVS2 and 50 pmoles of MBC1HVR2 as primers, 2.5U of TaKaRa Ex Taq and 0.25 mM of dNTP in the buffer, over which 50  $\mu$ l of mineral oil was layered. Thirty cycles of the PCR reaction was conducted using a temperature cycle of 94°C for 1 min.; 55°C for 1 min.; 72°C for 1 min. The DNA fragments amplified by the PCR reaction were separated by agarose gel electrophoresis using 1% Sea Kem GTG Agarose (FMC Bio. Products). Then, an agarose gel fragment containing a DNA fragment of 456 bp in length was excised and the DNA fragment was purified therefrom using GENECLAN II Kit (BIO101) in accordance with the procedure by the manufacturer. The purified DNA fragments were precipitated with ethanol and then dissolved in 20  $\mu$ l of a solution comprising 10 mM Tris-HCl (pH 7.4) and 1 mM EDTA.

**[0205]** One  $\mu$ l of the resultant DNA solution was digested with restriction enzymes EcoRI and SmaI (Takara Shuzo) at 37°C for 1 hour. The digestion mixture solution was extracted with phenol and chloroform and then precipitated with ethanol to collect the DNA. The obtained EcoRI-SmaI DNA fragments, which contains a DNA coding for the mouse H chain V region, was subcloned into pUC19 vector which had been prepared by digesting the plasmid with EcoRI and SmaI. The resultant plasmid was sequenced by DNA Sequencer 373A (Perkin-Elmer) using M13 Primer M4 and M13



Primer RV as primers, and Dye Terminator Cycle Sequencing Kit (Perkin-Elmer). The plasmid which contained a DNA of correct base sequence coding for the mouse H chain V region derived from hybridoma #23-57-137-1 and had a HindIII-recognition sequence and a Kozak sequence on its 5'-end region and Apal- and SmaI-recognition sequences on its 3'-end region was designated "MBC1Hv/pUC19".

### (iii) Construction of expression vector for chimeric antibody H chain

[0206] cDNA containing human antibody H chain C region  $C\gamma 1$  was prepared as follows.

[0207] mRNA was prepared from a CHO cell into which both an expression vector DHFR- $\Delta$ E-RVh-PM-1-f (see WO92/19759) coding for the genomic DNAs of the humanized PM1 antibody H chain V region and the human antibody H chain C region IgG1 and an expression vector RV1-PM1a (see WO92/19759) coding for the genomic DNAs of the humanized PM1 antibody L chain V region and the human antibody L chain  $\kappa$  chain C region had been introduced. Using the mRNA obtained, was cloned a cDNA containing the humanized PM1 antibody H chain V region and the human antibody C region  $C\gamma 1$  by a RT-PCR method, and then subcloned into plasmid pUC19 on the HindIII-BamHI site. The plasmid subcloned was determined for its DNA sequence and the plasmid which had a correct base sequence was designated "pRVh-PM1f-cDNA".

[0208] Expression vector DHFR- $\Delta$ E-RVh-PM-1-f which had deletions of in the HindIII site between SV40 promoter and DHFR gene and the EcoRI site between EF-1 $\alpha$  promoter and the humanized PM1 antibody H chain V region was prepared for the construction of an expression vector for cDNA containing the humanized PM1 antibody H chain V region and the human antibody C region  $C\gamma 1$ .

[0209] The plasmid pRVh-PM1f-cDNA obtained was digested with BamHI, blunt-ended with Klenow fragment, and further digested with HindIII, to thereby obtain a blunt-ended HindIII-BamHI fragment. This blunt-ended HindIII-BamHI fragment was ligated to the above-mentioned HindIII site- and EcoRI site-deleted expression vector DHFR- $\Delta$ E-RVh-PM1-f which had been digested with HindIII and BamHI to construct expression vector RVh-PM1f-cDNA containing cDNAs coding for the humanized PM1 antibody H chain V region and the human antibody C region  $C\gamma 1$ , respectively.

[0210] The expression vector RVh-PM1f-cDNA containing cDNAs coding for the humanized PM1 antibody H chain V region and the human antibody C region  $C\gamma 1$  was digested with Apal and BamHI, and the DNA fragment containing the H chain C region was collected therefrom. The resultant DNA fragment was introduced into the above-mentioned plasmid MBC1Hv/pUC19 which had been digested with Apal and BamHI. The plasmid thus prepared was designated "MBC1HcDNA/pUC19". This plasmid is a plasmid contained cDNAs coding for the mouse antibody H chain V region and the human antibody C region  $C\gamma 1$ , respectively, and having EcoRI- and HindIII-recognition sequences on its 5'-end and a BamHI-recognition sequence on its 3'-end.

[0211] The plasmid MBC1HcDNA/pUC19 was digested with EcoRI and BamHI to obtain a DNA coding for the chimeric antibody H chain. The resultant DNA fragment was introduced into expression vector pCOS1 which had been digested with EcoRI and BamHI. The expression vector for the chimeric antibody thus obtained was designated "MBC1HcDNA/pCOS1". Here, the expression vector pCOS1, was constructed using HEF-PMh- $\gamma 1$  (see WO92/19759) by deleting therefrom the antibody gene by means of the digestion with EcoRI and SmaI, and then ligating it to EcoRI-NotI-BamHI Adaptor (Takara Shuzo).

[0212] For preparing a plasmid for the expression in a CHO cell, the plasmid MBC1HcDNA/pUC19 was digested with EcoRI and BamHI to obtain a DNA coding for the chimeric antibody H chain, which was then introduced into expression plasmid pCHO1 which had been digested with EcoRI and BamHI. The expression plasmid for the chimeric antibody thus obtained was designated "MBC1HcDNA/pCHO1". Here, the expression vector pCHO1 was constructed using DHFR- $\Delta$ E-rvH-PM1-f (see WO92/19759) by deleting therefrom the antibody gene by means of the digestion with EcoRI and SmaI, and then ligating it to EcoRI-NotI-BamHI Adaptor (Takara Shuzo).

## (2) Construction of human L chain C region

### (i) Preparation of cloning vector

[0213] To construct pUC19 vector containing the human L chain C region, a HindIII site-deleted pUC19 vector was prepared. Two  $\mu$ g of pUC19 vector was digested in 20  $\mu$ l of a reaction solution comprising 20 mM Tris-HCl (pH 8.5), 10 mM  $MgCl_2$ , 1 mM DTT, 100 mM KCl, 8 U of HindIII (Takara Shuzo) at 37°C for 1 hour. The resultant digestion mixture solution was extracted with phenol and chloroform and then was subjected to ethanol precipitation to collect the DNA of interest.

[0214] The DNA thus collected was reacted in 50  $\mu$ l of a reaction solution comprising 50 mM Tris-HCl (pH 7.5), 10 mM  $MgCl_2$ , 1 mM DTT, 100 mM NaCl, 0.5 mM dNTP and 6U of Klenow fragment (GIBCO BRL) at room temperature for 20 min, to thereby render the ends of the DNA blunt. This reaction mixture was extracted with phenol and chloroform

and then subjected to ethanol precipitation to collect the vector DNA.

[0215] The vector DNA thus collected was reacted in 10  $\mu$ l of a reaction solution comprising 50 mM Tris-HCl (pH 7.6), 10 mM MgCl<sub>2</sub>, 1 mM ATP, 1 mM DTT, 5% (v/v) polyethylene glycol-8000 and 0.5 U of T4 DNA ligase (GIBCO BRL) at 16°C for 2 hours to cause self-legation of the vector DNA. 5  $\mu$ l of the reaction solution was added to 100  $\mu$ l of a solution containing competent cells of *E. coli* strain JM109 (Nippon Gene) and the resultant solution was allowed to stand on ice for 30 min., at 42°C for 1 min. and further on ice for 1 min. 500  $\mu$ l of SOC culture medium was added to the reaction solution, and then incubated at 37°C for 1 hour. The resultant solution was plated on a 2xYT agar medium (containing 50  $\mu$ g/ml of ampicillin) which had been applied with X-gal and IPTG on its surface (Molecular Cloning: A Laboratory Manual, Sambrook, et al., Cold Spring Harbor Laboratory Press, 1989), and then cultured at 37°C overnight, thereby obtaining a transformant.

[0216] The transformant was cultured on a 2xYT medium containing 50  $\mu$ g/ml of ampicillin at 37°C overnight. From the cell fraction of the culture medium, was purified a plasmid DNA using Plasmid Mini Kit (QIAGEN) in accordance with an instruction included in the kit. The purified plasmid was digested with HindIII. The plasmid which was confirmed to have a HindIII site-deletion was designated "pUC19  $\Delta$ HindIII".

## (ii) Construction of DNA coding for human L chain $\lambda$ chain C region

[0217] The human antibody L chain  $\lambda$  chain C region has been known to have at least four isotypes including Mcg<sup>+</sup>Ke<sup>+</sup>Oz<sup>-</sup>, Mcg<sup>-</sup>Ke<sup>-</sup>Oz<sup>-</sup>, Mcg<sup>-</sup>Ke<sup>+</sup>Oz<sup>+</sup> and Mcg<sup>-</sup>Ke<sup>-</sup>Oz<sup>+</sup> (P. Dariavach, et al., Proc. Natl. Acad. Sci. USA, 84, 9074-9078, 1987). The search was made for a human antibody L chain  $\lambda$  chain C region homologous to the #23-57-137-1 mouse L chain  $\lambda$  chain C region based on the EMBL data base. As a result, it was found that the isotype Mcg<sup>+</sup>Ke<sup>+</sup>Oz<sup>-</sup> (Accession No. X57819) (P. Dariavach, et al., Proc. Natl. Acad. Sci. USA, 84, 9074-9078, 1987) of the human antibody L chain  $\lambda$  chain exhibited the highest homology with the #23-57-137-1 mouse L chain  $\lambda$  chain C region and showed 64.4% homology in terms of amino acid sequence and 73.4% homology in terms of DNA sequence.

[0218] Then, the construction of the DNA coding for the human antibody L chain  $\lambda$  chain C region was conducted by a PCR method. Each of the following primers used was synthesized using 394 DNA/RNA Synthesizer (ABI). The primers synthesized were HLAMB1 (SEQ ID NO: 11) and HLAMB3 (SEQ ID NO: 13) both having a sense DNA sequence and HLAMB2 (SEQ ID NO: 12) and HLAMB4 (SEQ ID NO: 14) both having an antisense DNA sequence, each primer containing a complementary sequence of 20-23 bp in length on the both ends.

[0219] External primers HLAMBS (SEQ ID NO: 15) and HLAMBR (SEQ ID NO: 16) have a sequence complementary to the primers HLAMB1 and HLAMB4, respectively, and contain the EcoRI-, HindIII- and BlnI-recognition sequences and the EcoRI-recognition sequence, respectively. In the first PCR reaction, the HLAMB1-HLAMB2 and HLAMB3-HLAMB4 reactions were conducted. After the reactions were completed, both of the resultants were mixed with each other in equivalent quantities, and then assembled in the second PCR reaction. To the resultant reactant, were added the external primers HLAMBS and HLAMBR. This reaction mixture was subjected to the third PCR reaction for amplifying the full length DNA.

[0220] The PCR reactions were conducted using TaKaRa Ex Taq (Takara Shuzo) in accordance with the procedure by the manufacturer. In the first PCR reaction, was used 100  $\mu$ l of either a reaction solution comprising 5 pmoles of HLAMB1, 0.5 pmoles of HLAMB2 and 5U of TaKaRa Ex Taq (Takara Shuzo) or a reaction solution comprising 0.5 pmoles of HLAMB3, 5 pmoles of HLAMB4 and 5U of TaKaRa Ex Taq (Takara Shuzo), over which 50  $\mu$ l of mineral oil was layered, and five cycles of the PCR reaction was conducted using a temperature cycle program of 94°C for 1 min., 60°C for 1 min. and 72°C for 1 min. In the second PCR reaction, was used a mixture of 50  $\mu$ l of each of the reaction solutions, over which 50  $\mu$ l of mineral oil was layered, and three cycles of the PCR reaction was conducted using a temperature cycle program of 94°C for 1 min., 60°C for 1 min. and 72°C for 1 min. In the third PCR reaction, the reaction solution to which 50 pmoles of each of the external primers HLAMBS and HLAMBR were added was used, and thirty cycles of the PCR reaction was conducted using a temperature cycle program of 94°C for 1 min., 60°C for 1 min. and 72°C for 1 min.

[0221] The DNA fragment obtained by the third PCR reaction was subjected to electrophoresis using 3% low melting agarose gel (NuSieve GTG Agarose, FMC), and collected and purified from the gel using GENECLEAN II Kit (BIO101) in accordance with the procedure included in the kit.

[0222] The DNA fragment thus obtained was digested in 20  $\mu$ l of a reaction solution comprising 50 mM Tris-HCl (pH 7.5), 10 mM MgCl<sub>2</sub>, 1 mM DTT, 100 mM NaCl and 8U of EcoRI (Takara Shuzo) at 37°C for 1 hour. The digestion solution was extracted with phenol and chloroform and then precipitated with ethanol to thereby obtain the DNA. The DNA was collected and dissolved in 8  $\mu$ l of a solution comprising 10 mM Tris-HCl (pH 7.4) and 1 mM EDTA.

[0223] 0.8  $\mu$ g of the plasmid pUC19  $\Delta$ HindIII was digested with EcoRI in the same manner as mentioned above. The digestion solution was extracted with phenol and chloroform, followed by ethanol precipitation, obtaining a digested plasmid pUC19  $\Delta$ HindIII. The digested plasmid thus obtained was reacted in 50  $\mu$ l of a reaction solution comprising 50 mM Tris-HCl (pH 9.0), 1 mM MgCl<sub>2</sub> and alkaline phosphatase (*E. coli* C75; Takara Shuzo) at 37°C for 30 min. to dephosphorylate the plasmid (i.e., BAP-treatment). The reaction solution was subjected to phenol and chloroform

extraction and ethanol precipitation to obtain the DNA. The DNA thus obtained was dissolved in 10  $\mu$ l of a solution comprising 10 mM Tris-HCl (pH 7.4) and 1 mM EDTA.

[0224] One  $\mu$ l of the BAP-treated plasmid pUC19  $\Delta$ HindIII thus prepared was mixed with 4  $\mu$ l of the DNA obtained by the above-mentioned PCR reaction to ligate to each other using DNA Ligation Kit Ver.2 (Takara Shuzo). The resultant plasmid was introduced into a competent cell of *E. coli*, JM109, to form a transformant. The transformant was cultured overnight in 2 ml of a 2xYT medium containing 50  $\mu$ g/ml of ampicillin. From the cell, the plasmid was purified using QIAprep Spin Plasmid Kit (QIAGEN).

[0225] With respect to the plasmid described above, the cloned DNA was confirmed on its sequence. For determination the DNA sequence, 373A DNA Sequencer (ABI) and primers "M13 Primer M4" and "M13 Primer RV" (Takara Shuzo) were used. As a result, it was found that the cloned DNA had a deleted portion of 12 bp in length therein. The plasmid containing the DNA was designated "C $\lambda$  $\Delta$ /pUC19". Then, for making up for the portion, primers, HCLMS (SEQ ID NO: 17) and HCLMR (SEQ ID NO: 18), were newly synthesized and a correct DNA was reconstructed by a PCR method.

[0226] The first PCR reaction was conducted, using the plasmid C $\lambda$  $\Delta$ /pUC19 containing the deleted DNA as a template, and the primers HLAMBS and HCLMS or primers HCLMS and HLAMB4. Each of the PCR reaction products was purified respectively. In the second PCR reaction, the PCR products were assembled with each. To the resultant, were added external primers HLAMBS and HLAMB4, followed by the third PCR reaction for amplifying the full length DNA.

[0227] In the first PCR reaction, 100  $\mu$ l of a reaction solutions comprising 0.1  $\mu$ g C $\lambda$  $\Delta$ /pUC19 as a template, either 50 pmoles of each of the primers HLAMBS and HCLMR or 50 pmoles of each of the primers HCLMS and HLAMB4, and 5U of TaKaRa Ex Taq (Takara Shuzo) was used, over which 50  $\mu$ l of mineral oil was layered, and thirty cycles of the PCR reaction was conducted using a temperature cycle of 94°C for 1 min., 60°C for 1 min. and 72°C for 1 min.

[0228] The PCR products, HLAMBS-HCLMR (236 bp) and HCLMS-HLAMB4 (147 bp), were subjected to electrophoresis using 3% low melting agarose gel to isolate the DNA fragment. The DNA fragment was then collected and purified from the gel using GENECLAN II Kit (BIO101). In the second PCR reaction, 20  $\mu$ l of a reaction solution comprising 40 ng of the purified DNA fragments and 1U of TaKaRa Ex Taq (Takara Shuzo) were used, over which 25  $\mu$ l of mineral oil was layered, and five cycles of a temperature cycle of 94°C for 1 min., 60°C for 1 min. and 72°C for 1 min. was executed.

[0229] In the third PCR reaction, 100  $\mu$ l of a reaction solution comprising 2  $\mu$ l of the reaction solution obtained by the second PCR reaction, 50 pmoles of each of external primers HLAMBS and HLAMB4 and 5U of TaKaRa Ex Taq (Takara Shuzo) were used, over which 50  $\mu$ l of mineral oil was layered, and thirty cycles of the PCR reaction was conducted using a temperature cycle of 94°C for 1 min., 60°C for 1 min. and 72°C for 1 min., thereby obtaining a DNA fragment of 357 bp in length (third PCR product). The DNA fragment was subjected to electrophoresis using 3% low melting agarose gel to isolate the DNA fragment. The resultant DNA fragment was collected and purified using GENECLAN Kit (BIO101).

[0230] An amount of 0.1  $\mu$ g of the DNA fragment thus obtained was digested with EcoRI, and then subcloned into a plasmid pUC19  $\Delta$ HindIII which had been treated with BAP. The resultant plasmid was introduced into a competent cell of *E. coli*, JM109, to form a transformant. The transformant thus prepared was cultured overnight in 2 ml of a 2xYT medium containing 50  $\mu$ g/ml of ampicillin. From the cell fraction, the plasmid was purified using QIAprep Spin Plasmid Kit (QIAGEN).

[0231] The DNA sequence of the plasmid thus obtained was confirmed by using M13 Primer M4 and M13 Primer RV (Takara Shuzo) and determined 373A DNA Sequencer (ABI). The plasmid confirmed to have the correct DNA sequence without any deletion was designated "C $\lambda$ /pUC19".

### (iii) Construction of DNA coding for human L chain, $\kappa$ chain C region

[0232] A DNA fragment coding for the L chain  $\kappa$  chain C region was cloned from plasmid HEF-PM1k-gk (WO92/19759) by a PCR method. The forward primer HKAPS (SEQ ID NO: 19) was designed so as to contain the EcoRI- and HindIII and BlnI-recognition sequences and the backward primer HKAPA (SEQ ID NO: 20) was designed so as to contain the EcoRI-recognition sequence, and both of them were synthesized using 394 DNA/RNA Synthesizer (ABI).

[0233] A PCR reaction was conducted using 100  $\mu$ l of a reaction solution comprising 0.1  $\mu$ g of plasmid HEF-PM1k-gk as a template, 50 pmoles of each of primers HKAPS and HKAPA and 5U of TaKaRa Ex Taq (Takara Shuzo), over which 50  $\mu$ l of mineral oil was layered. Thirty cycles of the PCR reaction was conducted using a temperature cycle of 94°C for 1 min., 60°C for 1 min. and 72°C for 1 min., thereby obtaining a DNA fragment of 360 bp in length. The DNA fragment was isolated by electrophoresis using 3% low melting agarose, and then collected and purified using GENECLAN II Kit (BIO101).

[0234] The DNA fragment thus obtained was digested with EcoRI and then cloned into plasmid pUC19  $\Delta$ HindIII which had been treated with BAP. The resultant plasmid was introduced into a competent cell of *E. coli*, JM109, to obtain a

transformant. The transformant thus obtained was cultured overnight in 2 ml of 2xYT medium containing 50 µg/ml of ampicillin. From the cell fraction, the plasmid was purified using QIAprep Spin Plasmid Kit (QIAGEN).

[0235] The purified plasmid DNA was sequenced using M13 Primer M4 and M13 Primer RV (Takara Shuzo) by means of 373A DNA Sequencer (ABI). The plasmid which was confirmed to have a correct base sequence was designated "Cκ/pUC19".

### (3) Construction of chimeric antibody L chain expression vector

[0236] Chimeric #23-57-137-1 antibody L chain expression vector was constructed. The DNA coding for #23-57-137-1 L chain V region was ligated to the HindIII and BlnI sites, present just front of the human antibody C region, of each of the plasmid Cλ/pUC19 and Cκ/pUC19, thereby obtaining pUC19 vectors each containing DNA coding for the chimeric #23-57-137-1 antibody L chain V region and L chain λ or κ chain C region. Each of the resultant vectors was then digested with EcoRI to excise the DNA coding for the chimeric antibody L chain and the DNA was subcloned into HEF expression vector.

[0237] The DNA coding for #23-57-137-1 antibody L chain V region was cloned from plasmid MBC1L24 by a PCR method. The primers were individually synthesized using 394 DNA/RNA Synthesizer (ABI). The backward primer MBCCHL1 used (SEQ ID NO: 21) was designed to contain a HindIII-recognition sequence and a Kozak sequence (Kozak, M. et al., J. Mol. Biol. 196, 947-950, 1987) and the forward primer MBCCHL3 (SEQ ID NO: 22) was designed to contain BglII- and RcoRI-recognition sequences.

[0238] The PCR reaction was conducted using 100 µl of a reaction solution comprising 10 mM Tris-HCl (pH 8.3), 50 mM KCl, 1.5 mM MgCl<sub>2</sub>, 0.2 mM dNTP, 0.1 µg MBC1L24, 50 pmoles of each of primers MBCCHL1 and MBCCHL3 as primers and 1 µl of AmpliTaq (PERKIN ELMER), over which 50 µl of mineral oil was layered. Thirty cycles of the PCR reaction was conducted using a temperature cycle of 94°C for 45 sec., 60°C for 45 sec. and 72°C for 2 min.

[0239] The DNA fragment of 444 bp was electrophoresed using 3% low melting agarose gel, and collected and purified using GENECLAN Kit (BIO101). The purified DNA fragment was dissolved in 20 µl of a solution containing 10 mM Tris-HCl (pH 7.4) and 1 mM EDTA. One µl of the PCR product was digested in 20 µl of a reaction solution comprising 10 mM Tris-HCl (pH 7.5), 10 mM MgCl<sub>2</sub>, 1 mM DTT, 50 mM NaCl, 8U of HindIII (Takara Shuzo) and 8U of EcoRI (Takara Shuzo) at 37°C for 1 hour. The digestion solution was extracted with phenol and chloroform, followed by ethanol precipitation to collect the DNA as precipitates. The DNA thus obtained was dissolved in 8 µl of a solution comprising 10 mM Tris-HCl (pH 7.4) and 1 mM EDTA.

[0240] One µg of plasmid pUC19 was digested with HindIII and EcoRI in the same manner as mentioned above, and then extracted with phenol and chloroform, followed by ethanol precipitation to collect the digested plasmid. The resultant was treated with BAP [i.e., an alkaline phosphatase (E. coli C75; Takara Shuzo)] and then extracted with phenol and chloroform, followed by ethanol precipitation, thereby obtain the DNA. The resultant DNA was dissolved in 10 µl of a solution comprising 10 mM Tris-HCl (pH 7.4) and 1 mM EDTA.

[0241] One µl of the BAP treated plasmid pUC19 was mixed with 4 µl of the above-mentioned PCR product to ligate each other using DNA Ligation Kit Ver. 2 (Takara Shuzo). The resultant plasmid was introduced into a competent cell of E. coli, JM109 (Nippon Gene), in the same manner as described above to form a transformant. The transformant was inoculated overnight on a 2xYT agar medium containing 50 µg/ml of ampicillin at 37°C. The resultant transformant was then cultured overnight in 2 ml of a 2xYT medium containing 50 µg/ml of ampicillin at 37°C. From the cell fraction, the plasmid was purified using QIAprep Spin Plasmid Kit (QIAGEN). After determining the DNA sequence, the plasmid confirming to have a correct DNA sequence was designated "CHL/pUC19".

[0242] One µg of each of plasmids Cλ/pUC19 and Cκ/pUC19 was respectively digested in 20 µl of a reaction solution comprising 20 mM Tris-HCl (pH 8.5), 10 mM MgCl<sub>2</sub>, 1 mM DTT, 100 mM KCl, 8U of HindIII (Takara Shuzo) and 2U of BlnI (Takara Shuzo) at 37°C for 1 hour. The digestion solution was extracted with phenol and chloroform, followed by ethanol precipitation, thereby obtaining a DNA. The DNA was treated with BAP at 37°C for 30 min. and then extracted with phenol and chloroform, followed by ethanol precipitation. The resultant was dissolved in 10 µl of a solution comprising 10 mM Tris-HCl (pH 7.4) and 1 mM EDTA.

[0243] Eight µg of the plasmid CHL/pUC19 which contained a DNA coding for #23-57-137-1 L chain V region was digested with HindIII and BlnI in the same manner as mentioned above. The DNA fragment of 409 bp in length thus obtained was electrophoresed using 3% low melting agarose gel and then collected and purified using GENECLAN II Kit (BIO101) from the gel. The DNA fragment was dissolved in 10 µl of a solution comprising 10 mM Tris-HCl (pH 7.4) and 1 mM EDTA.

[0244] Four µl of the L chain V region DNA was subcloned into 1 µl of each of the BAF-treated plasmids Cλ/pUC19 or Cκ/pUC19, and then introduced into a competent cell of E. coli, JM109, to form a transformant. The transformant was cultured overnight in 3 ml of a 2xYT medium containing 50 µg/ml of ampicillin. From the cell fraction, the plasmid was isolated and purified using QIAprep Spin Plasmid Kit (QIAGEN). The plasmids thus prepared were designated "MBC1L(λ)/pUC19" and "MBC1L(κ)/pUC19", respectively.

[02445] Each of plasmids MBC1L( $\lambda$ )/pUC19 and MBC1L( $\kappa$ )/pUC19 was digested with EcoRI and then subjected to electrophoresis using 3% low melting agarose gel. A DNA fragment of 743 bp in length was isolated and purified from the gel using GENECLANII Kit (BIO101) and dissolved in 10  $\mu$ l of a solution comprising 10 mM Tris-HCl (pH 7.4) and 1 mM EDTA.

[02446] An amount of 2.7  $\mu$ g of expression vector, plasmid HEF-PM1k-gk, was digested with EcoRI and then extracted with phenol and chloroform, followed by ethanol precipitation, thereby obtaining a DNA fragment. The DNA fragment was treated with BAP, and then subjected to electrophoresis using 1% low melting agarose gel. From the gel, a DNA fragment of 6561 bp in length was isolated and purified therefrom using GENECLANII Kit (BIO101). The DNA fragment was dissolved in 10  $\mu$ l of a solution comprising 10 mM Tris-HCl (pH 7.4) and 1 mM EDTA.

[02447] The HEF vector thus prepared was treated with BAP, and 2  $\mu$ l of the BAP-treated HEF vector was mixed with 3  $\mu$ l of the EcoRI fragments of plasmids MBC1L( $\lambda$ )/pUC19 or MBC1L( $\kappa$ )/pUC19, to ligate to each other. The ligation product was introduced into a competent cell of E. coli, JM109, to form a transformant. The transformant was cultured in 2 ml of a 2xYT medium containing 50  $\mu$ g/ml of ampicillin. From the cell fraction, the plasmid was purified using QIAprep Spin Plasmid Kit (QIAGEN).

[02448] The plasmid DNA thus purified was digested in 20  $\mu$ l of a reaction solution comprising 20 mM Tris-HCl (pH 8.5), 10 mM MgCl<sub>2</sub>, 1 mM DTT, 100 mM KCl, 8U of HindIII (Takara Shuzo) and 2 U of PvuI (Takara Shuzo) at 37°C for 1 hour. In this digestion reaction, it was assumed that if the above-mentioned DNA fragment was inserted into the vector in the correct orientation, a digestion fragment of 5104/2195 bp would be obtained, whereas if the above-mentioned DNA fragment was inserted into the vector in the reverse orientation, a digestion fragment of 4387/2926 bp would be obtained. Based on this assumption, the plasmids in which the fragment was inserted in a correct orientation were designated "MBC1L( $\lambda$ )/neo" and "MBC1L( $\kappa$ )/neo", respectively.

#### (4) Transfection of COS-7 cells

[02449] The expression plasmids prepared above were each expressed transiently using COS-7 cells in order to evaluate the chimeric antibody on its binding with and neutralizing activities against antigen.

[0250] The transient expression of the chimeric antibody was conducted using a combination of either plasmids MBC1HcDNA/pCOS1 and MBC1L( $\lambda$ )/neo or plasmids MBC1HcDNA/pCOS1 and MBC1L( $\kappa$ )/neo by means of electroporation using Gene Pulser (Bio Rad) to co-transfect each of these plasmid DNA combinations into COS-7 cells. That is, into 0.8 ml of a cell suspension in which COS-7 cells were suspended in PBS(-) in a concentration of  $1 \times 10^7$  cells/ml, 10  $\mu$ g of each of the plasmid DNAs was added. The resultant solution was applied with pulses at an electrostatic capacity of 1,500V and 2  $\mu$ F to cause electroporation. After 10 min. of recovery period at room temperature, the cells were suspended in a DMEM medium containing 2% Ultra Low IgG fetal calf serum (GIBCO) and then cultured using a 10 cm culture dish in a CO<sub>2</sub> incubator. After culturing for 72 hours, a culture supernatant was collected and centrifuged to remove cell debris and was provided as a sample for the ELISA assay.

[0251] In this procedure, the purification of the chimeric antibodies from the culture supernatant of COS-7 cells was conducted using AffiGel Protein A MAPSII Kit (Bio Rad) in accordance with an instruction included in kit.

#### (5) ELISA assay

##### (i) Determination of antibody concentration

[0252] An ELISA plate for determining antibody concentration was prepared as follows. Each of the wells of a 96-well plate for ELISA (Maxisorp, NUNC) was coated with 100  $\mu$ l of a solution comprising goat anti-human IgG antibody (TAGO) prepared in a coating buffer (0.1 M NaHCO<sub>3</sub>, 0.02% NaN<sub>3</sub>) of a concentration of 1  $\mu$ g/ml and then blocked with 200  $\mu$ l of a dilution buffer [50 mM Tris-HCl, 1 mM MgCl<sub>2</sub>, 0.1 M NaCl, 0.05% Tween20, 0.02% NaN<sub>3</sub>, 1% bovine serum albumin (BSA); pH 7.2]. Into each well was added, a culture supernatant of the COS-7 cells in which the chimeric antibodies had been expressed or the purified chimeric antibodies at stepwise dilution. After incubating at room temperature for 1 hour and washing with PBS-Tween20, each well was added with 100  $\mu$ l of a solution of alkaline phosphatase-conjugated goat anti-human IgG antibodies (TAGO). After incubating at room temperature for 1 hour and washing with PBS-Tween20, each well was added with 1 mg/ml of a substrate solution ("Sigma 104", p-nitrophenylphosphoric acid, SIGMA). The solution was measured for absorbance at 405 nm using Microplate Reader (Bio Rad). As a standard for this determination, Hu IgG1 $\lambda$  Purified (The Binding Site) was used.

##### (ii) Determination of antigen binding ability

[0253] An ELISA plate for the determination of antigen binding ability was prepared as follows. Each of the wells of a 96-well plate for ELISA was coated with 100  $\mu$ l of a solution comprising human PTHrP (1-34) (Peptide Research Insti-

tute) prepared in a coating buffer of a concentration of 1 µg/ml and then blocked with 200 µl of a dilution buffer. Into each well was added, the culture supernatant of the COS-7 cells in which the chimeric antibodies had been expressed or the purified chimeric antibodies at stepwise dilution. After incubating at room temperature and washing with PBS-Tween20, each well was added with 100 µl of a solution of alkaline phosphatase-conjugated goat anti-human IgG antibodies (TAGO). After incubating at room temperature and washing with PBS-Tween20, each well was added with 1 mg/ml of a substrate solution ("Sigma 104", p-nitrophenylphosphoric acid, SIGMA). The solution was measured for absorbance at 405 nm using Microplate Reader (Bio Rad).

[0254] As a result, it was found that the chimeric antibody had a binding ability against human PTHrP (1-34) and also had a correct structure of the cloned mouse antibody V region (FIG. 4). It was also found that there was no difference in the binding ability against PTHrP (1-34) between the chimeric antibody in which the L chain C region has λ chain and those in which the L chain C region has κ chain. Therefore, the L chain C region of the humanized antibody was constructed using the humanized antibody L chain λ chain.

#### (6) Establishment of CHO stable transformed cell line

[0255] For establishing a stable transformant for the chimeric antibody, the above-mentioned expression plasmid was introduced into a CHO cell (DXB11).

[0256] Establishment of a stable transformant for the chimeric antibody was conducted using combinations of expression plasmids for CHO cell, MBC1HcDNA/pCHO1 and MBC1L(λ)/neo or expression plasmids for CHO cell, MBC1HcDNA/pCHO1 and MBC1L(κ)/neo. These combinations of plasmids were individually co-transfected into CHO cells by electroporation using Gene Pulser (Bio Rad). Each of the expression vectors was cleaved with restriction enzyme PvuI to obtain a linear DNA. The resultant DNA was collected by extraction with phenol and chloroform and subsequent precipitation with ethanol. The plasmid DNAs thus prepared were respectively subjected to electroporation. Ten µg of each of the plasmid DNAs was added to 0.8 ml of a cell suspension containing CHO cells in PBS(-) in a concentration of  $1 \times 10^7$  cells/ml. The resultant mixture was applied with pulses at an electrostatic capacity of 1,500V and 25 µF. After 10 min. of recovery period at room temperature, the electroporated cells were suspended in a MEM-α medium (GIBCO) supplemented with 10% fetal calf serum (GIBCO). The resultant suspension was cultured using three 96-well plates (Falcon) in a CO<sub>2</sub> incubator. On the day after starting the cultivation, the medium was replaced by a selective medium [a MEM-α medium supplemented with 10% fetal calf serum (GIBCO) and 500 mg/ml of GENETICIN (G418Sulfate; GIBCO) without ribonucleoside or deoxyribonucleoside]. From the culture medium, cells into which the antibody gene was introduced were selected. After replacing the selective medium by a fresh one, before and after two weeks of cultivation, the cells were observed under a microscope. When a cell growth was observed, the cells were determined for the amount of antibodies produced by the above-mentioned ELISA assay. Among the cells, those which produced a larger amount of antibodies were selectively collected.

[0257] The scale up of the culture of the stable transformant for the established antibodies was conducted in a roller bottle using a MEM medium supplemented with 2% Ultra Low IgG fetal calf serum without ribonucleoside or deoxyribonucleoside. On day 3 and day 4 of the cultivation, the culture supernatant was collected and then filtered using a filter having a pore size of 0.2 µm (Millipore) to remove cell debris therefrom.

[0258] Subsequently, the purification of the chimeric antibodies from the culture supernatant of the CHO cells was conducted using POROS Protein A Column (PerSeptive Biosystems) on ConSep LC100 (Millipore) in accordance with an instruction included within. The purified chimeric antibodies were provided as samples for the determination of neutralizing activity and for the examination of efficacy on hypercalcemic model animals. The concentration and the binding activity of the purified chimeric antibodies against antigen were determined by the same ELISA system.

#### EXAMPLE 3

##### Construction of Humanized Antibody

##### (1) Construction of humanized antibody H chain

##### (i) Construction of humanized H chain V region

[0259] Humanized #23-57-137-1 antibody H chain was prepared by CDR-grafting technique by means of PCR method. For preparing a humanized #23-57-137-1 antibody H chain (version "a") having a FR derived from human antibody S31679 (NMRF-PDB; Cuisinier, A. M. et al., Eur. J. Immunol., 23, 110-118, 1993), the following six types of PCR primers were used: CDR-grafting primers: MBC1HCP1 (SEQ ID NO: 23) and MBC1HGP3 (SEQ ID NO: 24) (both containing a sense DNA sequence) and MBC1HGP2 (SEQ ID NO: 25) and MBC1HGP4 (SEQ ID NO: 26) (both containing an antisense DNA sequence), all of which containing a complementary sequence of 15-21 bp in length on both ends

thereof; and external primers: MBC1HVS1 (SEQ ID NO: 27) and MBC1HVR1 (SEQ ID NO: 28), both having a homology with the CDR-grafting primers MBC1HGP1 and MBC1HGP4, respectively.

[0260] The CDR-grafting primers MBC1HGP1, MBC1HGP2, MBC1HGP3 and MBC1HGP4 were isolated using an urea-denatured polyacrylamide gel (Molecular Cloning: A Laboratory Manual, Sambrook, et al., Cold Spring Harbor Laboratory Press, 1989) and extracted from the gel fraction by a crush-and-soak method (Molecular Cloning: A Laboratory Manual, Sambrook, et al., Cold Spring Harbor Laboratory Press, 1989) in the following manner.

[0261] One nmole of each of the CDR-grafting primers was isolated with 6% denatured polyacrylamide gel to obtain DNA fragments. From the resultant DNA fragments, those having a desired length was identified on a silica gel thin plate by irradiation of UV ray and then collected therefrom by a crush-and-soak method. The resultant was dissolved in 20  $\mu$ l of a solution comprising 10 mM Tris-HCl (pH 7.4) and 1 mM EDTA. The PCR reaction was conducted using TaKaRa Ex Taq (Takara Shuzo). The reaction solution (100  $\mu$ l) used in the PCR reaction comprised 1  $\mu$ l of each of the above-mentioned CDR-grafting primers MBC1HGP1, MBC1HGP2, MBC1HGP3 and MBC1HGP4, 0.25mM dNTP and 2.5U of TaKaRa Ex Taq in the buffer. Five cycles of the PCR reaction was conducted using a temperature cycle of 94°C for 1 min., 55°C for 1 min. and 72°C for 1 min. Into the resultant reaction mixture were added, both of the external primers MBC1HVS1 and MBC1HVR1 each in an amount of 50 pmoles. Using this reaction mixture, additional 30 cycles of the PCR reaction was conducted using the same temperature cycle. The DNA fragment thus amplified was isolated by agarose gel electrophoresis using 4% Nu Sieve GTG agarose (FMC Bio. Products).

[0262] An agarose fragment containing a DNA fragment of 421 bp in length was excised and the DNA fragment was purified therefrom using GENECLANII Kit (BIO101) in accordance with an instruction included in the kit. The DNA fragment thus purified was precipitated with ethanol and then dissolved in 20  $\mu$ l of a solution comprising 10 mM Tris-HCl (pH 7.4) and 1 mM EDTA. The PCR reaction mixture obtained was used for subcloning of the DNA fragment into plasmid pUC19 which had been prepared by digesting the plasmid with BamHI and HindIII; thereafter the base sequence of the resultant plasmid was determined. A plasmid having a correct sequence was designated "hMBCHv/pUC19".

## (ii) Construction of H chain V region for Humanized H chain cDNA

[0263] For the ligation to the cDNA of humanized H chain C region C $\gamma$ 1, the DNA of the humanized H chain V region constructed in the above step was modified by a PCR method. In this method, the backward primer MBC1HVS2 used was designed so as to be hybridizable to the sequence coding for the 5'-end region of the leader sequence of the V region and to carry a Kozak consensus sequence (Kozak et al., J. Mol. Biol. 196, 947-950, 1987) and HindIII- and EcoRI-recognition sequences. The forward primer MBC1HVR2 used for the modification of the DNA for the H chain V region was designed so as to be hybridizable to both the DNA sequence coding for the 3'-end region of the J region and the DNA sequence coding for the 5'-end region of the C region and to carry Apal- and SmaI-recognition sequences.

[0264] The PCR reaction was conducted using TaKaRa Ex Taq (Takara Shuzo) and a buffer was used therewith. The reaction solution used for the PCR reaction comprised 0.4  $\mu$ g of hMBCHv/pUC19 as a DNA template, 50 pmoles of each of MBC1HVS2 and MBC1HVR2 as primers, 2.5U of TaKaRa Ex Taq and 0.25 mM dNTP in the buffer. Thirty cycles of the PCR reaction was conducted using a temperature cycle of 94°C for 1 min., 55°C for 1 min. and 72°C for 1 min. The DNA fragment thus amplified by the PCR method was isolated by agarose gel electrophoresis using 3% Nu Sieve GTG agarose (FMC Bio. Products).

[0265] A DNA fragment of 456 bp in length was excised and the DNA fragment was purified therefrom using GENE-CLEANII Kit (BIO101) in accordance with an instruction included within. The DNA fragment thus purified was precipitated with ethanol and then dissolved in 20  $\mu$ l of a solution comprising 10 mM Tris-HCl (pH 7.4) and 1 mM EDTA. The PCR reaction mixture thus obtained was used for subcloning of the DNA fragment into plasmid pUC19 which had been prepared by digesting the plasmid with EcoRI and SmaI; thereafter the DNA sequence of the resultant plasmid was determined. The plasmid DNA thus prepared which contains a DNA coding for the mouse H chain V region derived from the hybridoma #23-57-137-1 and also contains the EcoRI- and HindIII-recognition sequences and a Kozak sequence on the 5'-end and the Apal- and SmaI-recognition sequences on the 3'-end was designated "hMBC1Hv/pUC19".

## (2) Construction of expression vector for humanized antibody H chain

[0266] Plasmid RVh-PM1f-cDNA containing a cDNA sequence of hPM1 antibody H chain was digested with Apal and BamHI to obtain a DNA fragment containing a base sequence of the H chain C region. The DNA fragment was introduced into plasmid hMBC1Hv/pUC19 which had been prepared by digesting the plasmid with Apal and BamHI. The plasmid thus prepared was designated "hMBC1HcDNA/pUC19". This plasmid was a plasmid containing both a DNA coding for the humanized #23-57-137-1 antibody H chain V region and a DNA coding for the human H chain C region C $\gamma$ 1 and to have EcoRI- and HindIII-recognition sequences on the 5'-end region and a BamHI-recognition sequence on the 3'-end region. The base sequence and the corresponding amino acid sequence of the humanized H chain version



"a" contained in the plasmid hMBC1HcDNA/pUC19 are shown in SEQ ID NO: 58 and SEQ ID NO: 56, respectively.

**[0267]** The plasmid hMBC1HcDNA/pUC19 was digested with EcoRI and BamHI to obtain a DNA fragment containing a base sequence coding for the H chain. The DNA fragment was introduced into expression plasmid pCOS1 which had been prepared by digesting the plasmid with EcoRI and BamHI. The expression plasmid for a humanized antibody thus obtained was designated "hMBC1HcDNA/pCOS1".

**[0268]** To prepare a plasmid for expression in a CHO cell, plasmid hMBC1HcDNA/pUC19 was digested with EcoRI and BamHI to obtain a DNA fragment containing a DNA coding for the H chain. The DNA fragment was introduced into expression vector pCHO1 which had been prepared by digesting the plasmid with EcoRI and BamHI. The expression plasmid for the humanized antibody thus obtained was designated "hMBC1HcDNA/pCHO1".

### (3) Construction of L chain hybrid variable region

#### (i) Preparation of FR1,2/FR3,4 hybrid antibody

**[0269]** A DNA coding for the L chain in which the FR regions were recombined with those from a humanized antibody and a mouse (chimeric) antibody was constructed and evaluated the regions on their suitability for humanization. In this step, a hybrid antibody comprising FR1 and FR2 both derived from a human antibody and FR3 and FR4 both derived from a mouse antibody was prepared by utilizing the AflIII restriction site present in CDR 2.

**[0270]** Ten  $\mu$ g of each of plasmids MBC1L( $\lambda$ )/neo and hMBC1L( $\lambda$ )/neo was digested in 100  $\mu$ l of a reaction solution comprising 10 mM Tris-HCl (pH 7.5), 10 mM MgCl<sub>2</sub>, 1 mM DTT, 50 mM NaCl, 0.01% (w/v) of BSA and 10 U of AflIII (Takara Shuzo) at 37°C for 1 hour. The reaction solution was subjected to electrophoresis using 2% low melting agarose gel, and DNA fragments of 6282 bp in length (referred to as "c1") and 1022 bp in length (referred to as h1) were collected and purified from the gel using GENECLANII Kit (BIO101).

**[0271]** One  $\mu$ g of each of the c1 and h1 fragments obtained was subjected to treatment with BAP. The DNA fragment was extracted with phenol and ethanol, collected by ethanol precipitation, dissolved in 10  $\mu$ l of a solution comprising 10 mM Tris-HCl (pH 7.4) and 1 mM EDTA.

**[0272]** One  $\mu$ l of each of the BAP-treated c1 and h1 DNA fragments were mixed with 4  $\mu$ l of the h2 and c2 DNA fragments, respectively, to ligate to each other (at 4°C overnight). The ligation product was introduced into a competent cell of F. coli, JM109, to form a transformant. The transformant was cultured in 2 ml of a 2xYT medium containing 50  $\mu$ g/ml of ampicillin. From the cell fraction, the plasmid was purified using QIAprep Spin Plasmid Kit (QIAGEN).

**[0273]** The plasmid DNA purified was digested in 20  $\mu$ l of a reaction solution comprising 10 mM Tris-HCl (pH 7.5), 10 mM MgCl<sub>2</sub>, 1 mM DTT, 2U of ApaLI (Takara Shuzo), and 8U of BamHI (Takara Shuzo) or HindIII (Takara Shuzo) at 37°C for 1 hour. In this step, the plasmid was identified based on the expectation that if the c1-h2 fragment was correctly ligated in the plasmid, this ligation would give an ApaLI-digestion fragment of 5560/1246/498 bp or a BamHI/HindIII-digestion fragment of 7134/269 bp.

**[0274]** The expression vector coding for the human FR1,2/mouse FR3,4 hybrid antibody L chain was designated "h/mMBC1L( $\lambda$ )/neo". On the other hand, a clone for the h1-c1 could not be obtained. Therefore, recombination on a pUC vector was conducted, followed by cloning to a HEF vector. Here, used as templates were plasmid hMBC1La $\lambda$ /pUC19, which contained a DNA coding for a humanized antibody L chain V region having no amino acid replacements and plasmid hMBC1Ld $\lambda$ /pUC19, which contained a DNA coding for a humanized antibody L chain V region having an amino acid replacement at the 91-position amino acid in FR3 (i.e., amino acid number 87 according to the definition by Kabat), of tyrosine, by isoleucine.

**[0275]** Ten  $\mu$ l of each of plasmids MBC1L( $\lambda$ )/pUC19, hMBC1La $\lambda$ /pUC19 and hMBC1Ld $\lambda$ /pUC19 was digested in 30  $\mu$ l of a reaction solution comprising 10 mM Tris-HCl (pH 7.5), 10 mM MgCl<sub>2</sub>, 1 mM DTT, 50 mM NaCl, 0.01% (w/v) of BSA, 16U of HindIII and 4U of AflIII at 37°C for 1 hour. The reaction solution was subjected to electrophoresis using 2% low melting agarose gel, and then collected and purified the following DNA fragments using GENECLANII Kit (BIO101): a DNA fragment of 215 bp in length from plasmid MBC1L( $\lambda$ )/pUC19 (referred to as "c2'") or a DNA fragment of 3218bp in length from each of plasmids hMBC1La $\lambda$ /pUC19 and hMBC1Ld $\lambda$ /pUC19MBC (referred to as "hal'" and "hdl'", respectively).

**[0276]** Each of the hal' and hdl' fragments was individually ligated to the c2' fragment and then introduced into a competent cell of E. coli, JM109, to form a transformant. The transformant was cultured in 2 ml of a 2xYT medium containing 50  $\mu$ g/ml of ampicillin. From the cell fraction, the plasmid was purified using QIAprep Spin Plasmid Kit (QIAGEN). The resultant plasmid DNAs containing the hal' fragment and the hdl' fragment were designated "m/hMBC1La $\lambda$ /pUC19" and "m/hMBC1Ld $\lambda$ /pUC19", respectively.

**[0277]** Each of the plasmids m/hMBC1La $\lambda$ /pUC19 and m/hMBC1Ld $\lambda$ /pUC19 was digested with EcoRI. The DNA fragment of 743 bp in length was electrophoresed using 2% low melting agarose gel, and then collected and purified from the gel using GENECLANII Kit (BIO101). The resultant was dissolved in 20  $\mu$ l of a solution comprising 10 mM Tris-HCl (pH 7.4) and 1 mM EDTA.



[0278] Four  $\mu$ l of the DNA fragment obtained was mixed with 1  $\mu$ l of the above-mentioned BAP-treated HEF vector to ligate to each other. The ligation product was introduced into a competent cell of *E. coli*, JM109, to form a transformant. The transformant was cultured in 2 ml of a 2xYT medium supplemented with 50  $\mu$ g/ml of ampicillin. From the cell fraction, the plasmid DNA was purified using QIAprep Spin Plasmid Kit (QIAGEN).

[0279] The plasmid DNA purified was digested in 20  $\mu$ l of a reaction solution comprising 20 mM Tris-HCl (pH 8.5), 10 mM  $MgCl_2$ , 1 mM DTT, 100 mM KCl, 8U of HindIII (Takara Shuzo) and 2U of PvuI (Takara Shuzo) at 37°C for 1 hour. In this step, the plasmid DNA was identified based on the expectation that if the DNA fragment was inserted in the plasmid in a correct orientation, this digestion would give a digestion fragment of 5104/2195 bp, whereas if the DNA fragment is inserted in the plasmid in the reverse orientation, this digestion would give a digestion fragment of 4378/2926 bp. The plasmids thus obtained were expression vectors coding for mouse FR1,2/human FR3,4 hybrid antibody L-chain, which were designated expression vectors "m/hMBC1La $\lambda$ /neo" and "m/hMBC1Ld $\lambda$ /neo", respectively.

#### (ii) Preparation of FR1/FR2 hybrid antibody

[0280] An FR1/FR2 hybrid antibody was prepared in the same manner as mentioned above using a SnaBI restriction site present in CDR1.

[0281] Ten  $\mu$ g of each of the plasmids MBC1L( $\lambda$ )/neo and mMBC1L( $\lambda$ )/neo was digested in 20  $\mu$ l of a reaction solution comprising 10 mM Tris-HCl (pH 7.9), 10 mM  $MgCl_2$ , 1 mM DTT, 50 mM NaCl, 0.01% (w/v) of BSA and 6U of SnaBI (Takara Shuzo) at 37°C for 1 hour. The resultant reaction solution was further digested in 50  $\mu$ l of a reaction solution comprising 20 mM Tris-HCl (pH 8.5), 10 mM  $MgCl_2$ , 1 mM DTT, 100 mM KCl, 0.01% (w/v) of BSA and 6U of PvuI at 37°C for 1 hour.

[0282] The resultant reaction solution was subjected to electrophoresis using 1.5% low melting agarose gel, and then DNA fragments of 4955 bp and 2349 bp in length were collected and purified from the gel using GENECLEANII Kit (BIO101). The DNA fragments obtained from plasmid MBC1L( $\lambda$ )/neo were designated "m1" (4955 bp) and "m2" (2349 bp) and the DNA fragments obtained from plasmid h/mMBC1L( $\lambda$ )/neo were designated "hm1" (4955 bp) and "hm2" (2349 bp). Each of the DNA fragments obtained was dissolved in 40  $\mu$ l of a solution comprising 10 mM Tris-HCl (pH 7.4) and 1 mM EDTA.

[0283] One  $\mu$ l of each of the m1 and hm1 fragments was ligated to 4  $\mu$ l of each of the hm2 and m2 fragments, respectively, and then introduced into a competent cell of *E. coli*, JM109, to form a transformant. The transformant obtained was cultured in 2 ml of a 2xYT medium containing 50  $\mu$ g/ml of ampicillin. From the cell fraction, the plasmid DNA was purified using QIAprep Spin Plasmid Kit (QIAGEN).

[0284] The plasmid DNA purified was digested in 20  $\mu$ l of a reaction solution comprising 10 mM Tris-HCl (pH 7.5), 10 mM  $MgCl_2$ , 1 mM DTT and either 8U of Apal (Takara Shuzo) or 2U of ApaI (Takara Shuzo) at 37°C for 1 hour.

[0285] The plasmids (m1-hm2 and hm1-m2) thus prepared were identified based on the expectation that if each of the DNA fragments is ligated in the plasmid in a correct orientation, the digestion of the plasmid (m1-hm2) with Apal and ApaI would give a fragment of 7304 bp and fragments of 5560/1246/498 bp, respectively, and the digestion of the plasmid (hm1-m2) with Apal and ApaI would give fragments of 6538/766 bp and a fragment of 3535/2025/1246/498 bp, respectively.

[0286] As expression vector coding for a human FR1/mouse FR2,3,4 hybrid antibody L chain was designated "hmmMBC1L( $\lambda$ )/neo" and an expression vector coding for a mouse FR1/human FR2/mouse FR3, 4 hybrid antibody L chain was designated "mhmMBC1L( $\lambda$ )/neo".

#### (4) Construction of humanized antibody L chain

[0287] A humanized #23-57-137-1 antibody L chain was prepared by CDR-grafting technique by means of PCR method. That is, a humanized #23-57-137-1 antibody L chain (version "a") was prepared which contained FR1, FR2 and FR3 derived from human antibody HSU03868 (GEN-BANK, Deftos M. et al., Scand. J. Immunol., 39, 95-103, 1994) and FR4 derived from human antibody S25755 (NBRF-PDB) using the six types of PCR primers:

[0288] CDR-grafting primers, MBC1LGP1 (SEQ ID NO: 29) and MBC1LGP3 (SEQ ID NO: 30), both having a sense DNA sequence, CDR-grafting primers, MBC1LGP2 (SEQ ID NO: 31) and MBC1LGP4 (SEQ ID NO: 32), both having an antisense DNA sequence, all of which CDR-grafting primers having a complementary sequence of 15-21 bp on the both ends thereof; and external primers, MBC1LVS1 (SEQ ID NO: 33) and MBC1LVR1 (SEQ ID NO: 34), both having a homology with the CDR-grafting primers MBC1LGP1 and MBC1LGP4, respectively.

[0289] The CDR-grafting primers MBC1LGP1, MBC1LGP2, MBC1LGP3 and MBC1LGP4 were isolated using a urea-denatured polyacrylamide gel (Molecular Cloning: A Laboratory Manual, Sambrook et al., Cold Spring Harbor Laboratory Press, 1989) and extracted from the gel fraction by a crush-and-soak method (Molecular Cloning: A Laboratory Manual, Sambrook et al., Cold Spring Harbor Laboratory Press, 1989).

[0290] One nmole of each of the CDR-grafting primers was isolated with 6% denatured polyacrylamide gel. From the

resultant, a DNA fragment having a desired length was identified on a silica gel thin plate by irradiation of UV ray and then collected therefrom by a crush-and-soak method. The resultant was dissolved in 20  $\mu$ l of a solution comprising 10 mM Tris-HCl (pH 7.4) and 1 mM EDTA.

**[0291]** The PCR reaction was conducted using TaKaRa Ex Taq (Takara Shuzo) with a buffer. The reaction solution (100  $\mu$ l) used in the PCR reaction comprised 1  $\mu$ l of each of the CDR-grafting primers MBC1LGP1, MBC1LGP2, MBC1LGP3 and MBC1LGP4, 0.25 mM dNTP, 2.5U of TaKaRa Ex Taq in the buffer. Five cycles of the PCR reaction was conducted using a temperature cycle of 94°C for 1 min., 55°C for 1 min. and 72°C for 1 min. Into the resultant reaction mixture were added 50 pmoles of each of the external primers MBC1LVS1 and MBC1LVR1. Using this reaction mixture, additional thirty cycles of the PCR reaction was conducted using the same temperature cycle. The DNA fragment thus amplified was isolated by agarose gel electrophoresis using 3% Nu Sieve GTG agarose (FMC Bio. Products).

**[0292]** An agarose fragment containing a DNA fragment of 421 bp in length was excised and the DNA fragment was purified from the gel using GENECLLEANII Kit (BIO101) in accordance with the instruction included with the kit. The PCR reaction mixture thus prepared was used for subcloning of the DNA fragment into plasmid pUC19 which had been prepared by digesting the plasmid with BamHI and HindIII. The resultant plasmid was determined of its DNA sequence.

The plasmid thus prepared was designated "hMBC1/pUC19". In this plasmid, however, it was found that the 104-position amino acid (amino acid number 96 according to the determining by Kabat) of CDR4 was replaced with arginine. To correct this amino acid to tyrosine, primer MBC1LGP10R (SEQ ID NO: 35) was designed and synthesized. Then the PCR reaction was conducted using TaKaRa Ex Taq (Takara Shuzo) with a buffer. The reaction solution (100  $\mu$ l) used in the PCR reaction comprised 0.6  $\mu$ g of the plasmid hMBC1/pUC19 as a template DNA, 50 pmoles of each of the primers MBC1LVS1 and MBC1LGP10R, 2.5U of TaKaRa Ex Taq (Takara Shuzo) and 0.25 mM dNTP in the buffer, over which mineral oil was layered. Thirty cycles of the PCR reaction was conducted using a temperature cycle of 94°C for 1 min., 55°C for 1 min. and 72°C for 1 min. The DNA fragment thus amplified by PCR method was isolated by agarose gel electrophoresis using 3% Nu Sieve GTG agarose (FMC Bio. Products).

**[0293]** A DNA fragment of 421 bp in length was excised and the DNA fragment was purified therefrom using GENECLLEANII Kit (BIO101) in accordance with an instruction included with the kit. The PCR reaction mixture thus prepared was used for subcloning of the DNA fragment into plasmid pUC19 which had been prepared by digesting the plasmid with BamHI and HindIII.

**[0294]** The plasmid was determined of its DNA sequence using M13 Primer M4 and M13 Primer RV. As a result, it was confirmed that the plasmid had a correct sequence. The plasmid was then digested with HindIII and BlnI and a DNA fragment of 416 bp was isolated therefrom by electrophoresis using 1% agarose gel. The DNA fragment was purified using GENECLLEANII Kit (BIO101) in accordance with an instruction included with the kit and then introduced into plasmid C $\lambda$ /pUC which had been prepared by digesting the plasmid with HindIII and BlnI. The resultant plasmid was designated "hMBC1La $\lambda$ /pUC19". This plasmid was digested with EcoRI to obtain a DNA fragment coding for humanized L chain. The DNA fragment was introduced into plasmid pCOS1 so that the initiation codon for the humanized L chain was located downstream from the EF1 $\alpha$  promoter. The plasmid thus obtained was designated "hMBC1La $\lambda$ /pCOS1". The DNA sequence (including the corresponding amino acid sequence) of the humanized L chain version "a" is shown in SEQ ID NO: 66. The amino acid sequence of the version "a" is shown in SEQ ID NO: 47.

**[0295]** Version "b" was prepared using mutagenic introduction technique by a PCR method. The version "b" was designed so as to replace the 43-position amino acid, glycine, (amino acid number 43 according to the definition by Kabat) with proline and to replace the 49-position amino acid, lysine, (amino acid number 49 according to the definition by Kabat) with aspartic acid. The PCR reaction was conducted using plasmid hMBC1La $\lambda$ /pUC19 as a template with a mutagenic primer MBC1LGP5R (SEQ ID NO: 36) and primer MBC1LVS1. The DNA fragment obtained was digested with BamHI and HindIII, and the digestion fragment was subcloned into the BamHI-HindIII site of pUC19. After sequencing, the plasmid DNA obtained was digested with HindIII and AflIII, and the resultant digestion fragment was ligated to plasmid hMBC1La $\lambda$ /pUC19 which had been prepared by digesting the plasmid with HindIII and AflIII.

**[0296]** The plasmid thus obtained was designated "hMBC1Lb $\lambda$ /pUC19". This plasmid DNA was digested with EcoRI to obtain a DNA fragment containing a DNA coding for the humanized L chain. The DNA fragment was introduced into plasmid pCOS1 so that the initiation codon for the humanized L chain was located downstream from the EF1 $\alpha$  promoter. The plasmid thus obtained was designated "hMBC1Lb $\lambda$ /pCOS1".

**[0297]** Version "c" was prepared using mutagenic introduction technique by a PCR method. The version "c" was designed so as to replace the 84-position amino acid, serine, (amino acid number 80 according to the definition by Kabat) with proline. The PCR reaction was conducted using plasmid hMBC1La $\lambda$ /pUC19 as a template with a mutagenic primer MBC1LGP6S (SEQ ID NO: 37) and primer M13 Primer RV. The DNA fragment obtained was digested with BamHI and HindIII and then subcloned into pUC19 which had been prepared by digesting the plasmid with BamHI and HindIII. After sequencing, the plasmid DNA obtained was digested with BstPI and Aor51HI, and the resultant DNA fragment was ligated to plasmid hMBC1La $\lambda$ /pUC19 which had been prepared by digesting the plasmid with BstPI and Aor51HI. The plasmid thus obtained was designated "hMBC1Lc $\lambda$ /pUC19". This plasmid DNA was digested with EcoRI to obtain a sequence containing a sequence coding for the humanized L chain. The sequence was introduced into the

EcoRI site of plasmid pCOS1 so that the initiation codon for the humanized L chain was located downstream from the EF1 $\alpha$  promoter. The plasmid thus obtained was designated "hMBC1Lc $\lambda$ /pCOS1".

**[0298]** Versions "d", "e" and "f" were also prepared using mutagenic introduction technique by a PCR method. Each of the versions "d", "e" and "f" was designed so as to replace the 91-position amino acid, tyrosine, (amino acid number 87 according to the definition by Kabat) with isoleucine in the versions "a", "b" and "c", respectively. For each of the versions "d", "e" and "f", a PCR reaction was conducted using each of plasmid hMBC1La $\lambda$ /pCOS1 (for version "d"), hMBC1Lb $\lambda$ /pCOS1 (for version "e") and hMBC1Lc $\lambda$ /pCOS1 (for version "f") as a template with a mutagenic primer MBC1LGP11R (SEQ ID NO: 38) and primer M-S1 (SEQ ID NO: 44). The DNA fragment thus obtained was digested with BamHI and HindIII and then subcloned into pUC19 which had been prepared by digesting pUC19 with BamHI and HindIII. After sequencing, the plasmid was digested with HindIII and BlnI, and the resultant digestion fragment was ligated to plasmid C $\lambda$ /pUC19 which had been prepared by digesting the plasmid with HindIII and BlnI.

**[0299]** The plasmids thus obtained were respectively designated "hMBC1Ld $\lambda$ /pUC19", "hMBC1Le $\lambda$ /pUC19" and "hMBC1Lf $\lambda$ /pUC19". Each of these plasmids was digested with EcoRI to obtain a DNA fragment containing a DNA coding for the humanized L chain. The DNA fragment was introduced into the EcoRI site of plasmid pCOS1 so that the initiation codon for the humanized L chain was located downstream from the EF1 $\alpha$  promoter of the plasmid. The plasmids thus obtained were respectively designated "hMBC1Ld $\lambda$ /pCOS1", "hMBC1Le $\lambda$ /pCOS1" and "hMBC1Lf $\lambda$ /pCOS1".

**[0300]** Versions "g" and "h" were also prepared using mutagenic introduction technique by a PCR method. Each of the versions "g" and "h" was designed so as to replace the 36-position amino acid, histidine, (amino acid number 36 according to the definition by Kabat) with tyrosine in the versions "a" and "d", respectively. The PCR reaction was conducted with mutagenic primer MBC1LGP9R (SEQ ID NO: 39) and M13 Primer RV using plasmid hMBC1La $\lambda$ /pUC19 as a template. The PCR product was subjected to an additional PCR reaction using M13 Primer M4 as a primer and plasmid hMBC1La $\lambda$ /pUC19 as a template. The DNA fragment obtained was digested with HindIII and BlnI and then subcloned into plasmid C $\lambda$ /pUC19 which had been prepared by digesting the plasmid with HindIII and BlnI. Using this plasmid as a template, a PCR reaction was conducted using primers MBC1LGP13R (SEQ ID NO: 40) and MBC1LVS1. The PCR fragment obtained was digested with ApaI and HindIII and then introduced into each of plasmids hMBC1La $\lambda$ /pUC19 and hMBC1Ld $\lambda$ /pUC19 which had been prepared by digesting both plasmids with ApaI and HindIII. The plasmids obtained were determined of their DNA sequences. Plasmids which were confirmed to contain a correct sequence were designated "hMBC1Lg $\lambda$ /pUC19" and "hMBC1Lh $\lambda$ /pUC19", respectively. Each of these plasmids was digested with EcoRI to obtain a sequence containing a sequence coding for the humanized L chain. The sequence was introduced into the EcoRI site of plasmid pCOS1 so that the initiation codon for the humanized L chain was located downstream from the EF1 $\alpha$  promoter. The plasmids thus obtained were respectively designated "hMBC1Lg $\lambda$ /pCOS1" and "hMBC1Lh $\lambda$ /pCOS1".

**[0301]** Versions "i", "j", "k", "l", "m", "n" and "o" were also prepared using mutagenic introduction technique by a PCR method. The PCR reaction was conducted using a mutagenic primer MBC1LGP14S (SEQ ID NO: 41) and primer V1RV ( $\lambda$ ) (SEQ ID NO: 43) using plasmid hMBC1La $\lambda$ /pUC19 as a template. The resultant DNA fragment was digested with ApaI and BlnI and then subcloned into plasmid hMBC1Lg $\lambda$ /pUC19 which had been prepared by digesting the plasmid with ApaI and BlnI. The plasmid obtained was determined of its base sequence, and the clone into which the mutation corresponding to each of the versions was introduced, was selected. The plasmid thus obtained was designated "hMBC1Lx $\lambda$ /pUC19 (x=i, j, k, l, m, n or o)". This plasmid was digested with EcoRI to obtain a sequence containing a sequence coding for the humanized L chain. The sequence was introduced into the EcoRI site of plasmid pCOS1 so that the initiation codon for the humanized L chain was located downstream from the EF1 $\alpha$  promoter. The plasmid thus obtained was designated "hMBC1Lx $\lambda$ /pCOS1" (x = i, j, k, l, m, n or o). The DNA sequences (including the corresponding amino acid sequences) of the versions "j", "l", "m" and "o" are shown in SEQ ID NOs: 67, 68, 69 and 70, respectively. The amino acid sequences of these versions are shown in SEQ ID Nos: 48, 49, 50 and 51, respectively.

**[0302]** Versions "p", "q", "r", "s" and "t" are modified form of the versions "i", "j", "m", "l" and "o", respectively, in which the 87-position amino acid, tyrosine, is replaced with isoleucine. These versions were prepared by using the Aor51MI restriction site of FR3 for replacement of the version "h" with the version "i", "j", "m", "l" or "o" in the following manner. From expression plasmid hMBC1Lx $\lambda$ /pCOS1 (x = i, j, m, l or o), an Aor51HI restriction fragment (514 bp) containing CDR3, a portion of FR3 and entire FR4 were deleted. To the deleted portion of the expression plasmid was ligated an Aor51HI restriction fragment (514 bp) containing CDR3 and a portion of FR3 and entire FR4 so that the 91-position amino acid, tyrosine, (the amino acid number 87 according to the definition by Kabat) is replaced with isoleucine. The resultant plasmids were determined of their DNA sequence and the clone of each of the versions "i", "j", "m", "l" and "o" in which 91-position amino acid, tyrosine, (the amino acid number 87 according to the definition by Kabat) was replaced with isoleucine was selected. The versions corresponding to the versions "i", "j", "m", "l" and "o" were designated versions "p", "q", "s", "r", and "t", respectively, and the plasmids for these versions were designated "hMBC1Lx $\lambda$ /pCOS1 (x = p, q, s, r or t)". The DNA sequences (including the corresponding amino acids) of the versions "q", "r", "s" and "t" are shown in SEQ ID Nos: 71, 72, 73 and 74, respectively. The amino acid sequences of these versions are shown in SEQ ID Nos: 52, 53, 54 and 55, respectively.

[0303] Plasmid hMBC1Lqλ/pCOS1 was digested with HindIII and EcoRI and then subcloned into plasmid pUC19 by digesting the plasmid with HindIII and EcoRI. The plasmid thus obtained was designated "hMBC1Lqλ/pUC19".

[0304] The position of the replaced amino acids in each version of the humanized L chain is shown in Table 3 below.

Table 3

| Position of replaced amino acid in sequence lists (amino acid number according to the definition by Kabat) |    |    |    |    |    |    |    |
|--|----|----|----|----|----|----|----|
| Version  | 36 | 43 | 45 | 47 | 49 | 80 | 87 |
| a  |    |    |    |    |    |    |    |
| b  |    | P  |    |    | D  |    |    |
| c  |    |    |    |    |    | P  |    |
| d  |    |    |    |    |    |    | I  |
| e  |    | P  |    |    | D  |    | I  |
| f  |    |    |    |    |    | P  | I  |
| g  | Y  |    |    |    |    |    |    |
| h  | Y  |    |    |    |    | I  |    |
| i  | Y  |    | K  |    |    |    |    |
| j  | Y  |    | K  |    | D  |    |    |
| k  | Y  |    | K  | V  |    |    |    |
| l  | Y  |    | K  | V  | D  |    |    |
| m  | Y  |    |    |    | D  |    |    |
| n  | Y  |    | V  |    |    |    |    |
| o  | Y  |    | V  | D  |    |    |    |
| p  | Y  |    | K  |    |    |    | I  |
| q  | Y  |    | K  |    | D  |    | I  |
| r  | Y  |    |    |    | D  |    | I  |
| s  | Y  |    | K  | V  | D  |    | I  |
| t  | Y  |    |    | V  | D  |    | I  |

[0305] In Table 3 above, capital letters represent the following amino acids: Y: tyrosine; P: proline; K: lysine; V: valine; D: aspartic acid; and I: isoleucine.

[0306] E. coli strain containing plasmid hMBC1HcDNA/pUC19 and E. coli strain containing plasmid hMBC1Lqλ/pUC19 were designated "Escherichia coli JM109 (hMBC1HcDNA/pUC19)" and "Escherichia coli JM109 (hMBC1Lqλ/pUC19)", respectively, which have been deposited under the terms of Budapest Treaty at the National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology, Japan, (1-3, Higashi 1-chome, Tsukuba-shi, Ibaragi-ken, Japan) on August 15, 1996 under the accession No. FERM BP-5629 for Escherichia coli JM109 (hMBC1HcDNA/pUC19) and FERM BP-5630 for Escherichia coli JM109 (hMBC1Lqλ/pUC19).

#### (5) Transfection into COS-7 cell

[0307] For determining the antigen-binding activity and the neutralizing activity of the hybrid antibody and the humanized #23-57-137-1 antibody, the above-mentioned expression plasmids were expressed transiently in COS-7 cells. For the transient expression of the L chain hybrid antibody, each of the following combinations of plasmids was co-transfected into a COS-7 cell by electroporation using Gene Pulser (Bio Rad): hMBC1HcDNA/pCOS1 and h/mMBC1L(λ)/neo; hMBC1HcDNA/pCOS1 and m/hMBC1Laλ/neo; hMBC1HcDNA/pCOS1 and m/hMBC1Ldλ/neo; hMBC1HcDNA/pCOS1 and hmmMBC1L(λ)/neo; and hMBC1HcDNA/pCOS1 and mhmMBC1L(λ)/neo. That is, into 0.8 ml of a cell suspension in which COS-7 cells were suspended in PBS(-) in a concentration of  $1 \times 10^7$  cells/ml, 10 μg of

each of the plasmid DNAs was added. The resultant solution was applied with pulses at an electrostatic capacity of 1,500V and 25  $\mu$ F. After 10 min. of recovery period at room temperature, the cells treated by electroporation were suspended in a DMEM medium supplemented with 2% Ultra Low IgG fetal calf serum (GIBCO) and then cultured using a 10 cm culture dish in a CO<sub>2</sub> incubator. After culturing for 72 hours, a culture supernatant was collected and centrifuged to remove cell debris. The resultant was provided as a sample for the ELISA assay.

[0308] For the transient expression of the humanized #23-57-137-1 antibody, the plasmid combination of either hMBC1HcDNA/pCOS1 or hMBC1L $\lambda$ /pCOS1 ( $x = a - t$ ) was transfected into a COS-7 cell using Gene Pulser (Bio Rad) in the same manner as described for the hybrid antibody above. The culture supernatant obtained was provided as a sample for the ELISA assay.

[0309] Here, the purification of the hybrid antibody or the humanized antibody from the culture supernatant of COS-7 cell was conducted using AffiGel Protein A MAPSII Kit (Bio Rad) in accordance with an instruction included in the kit.

#### (6) ELISA assay

##### (i) Determination of antibody concentration

[0310] An ELISA plate for determining antibody concentration was prepared as follows. Each of the wells of a 96-well plate for ELISA (Maxisorp, NUNC) was coated with 100  $\mu$ l of a coating buffer (0.1 M NaHCO<sub>3</sub>, 0.02% NaN<sub>3</sub>) supplemented with 1  $\mu$ g/ml of goat anti-human IgG antibody (TAGO) and then blocked with 200  $\mu$ l of a dilution buffer [50 mM Tris-HCl, 1 mM MgCl<sub>2</sub>, 0.1 M NaCl, 0.05% Tween20, 0.02% NaN<sub>3</sub>, 1% bovine serum albumin (BSA); pH 7.2]. Into each of the wells was added a culture supernatant of the COS cells in which the hybrid antibody or the humanized antibody was expressed or a solution of the purified hybrid antibody or humanized antibody in stepwise dilution. After incubating at room temperature for 1 hour and washing with PBS-Tween20, 100  $\mu$ l of alkaline phosphatase-conjugated goat anti-human IgG antibody (TAGO) was added to each of the wells. After incubating at room temperature for 1 hour and washing with PBS-Tween20, 1 mg/ml of a substrate solution ("Sigma 104", p-nitrophenylphosphoric acid, SIGMA) was added to each of the wells. The solution was measured for absorbance at 405 nm using Microplate Reader (Bio Rad). As the standard for this determination of antibody concentration, Hu IgG1 $\lambda$  Purified (The Binding Site) was used.

##### (ii) Determination of antigen binding ability

[0311] An ELISA plate for determining antigen binding ability was prepared as follows. Each of the wells of a 96-well plate for ELISA (Maxisorp, NUNC) was coated with 100  $\mu$ l of a coating buffer supplemented with 1  $\mu$ g/ml of human PTHrP (1-34) and then blocked with 200  $\mu$ l of a dilution buffer. Thereafter, into each of the wells, was added a culture supernatant of the COS-7 cells in which the hybrid antibody or humanized antibody was expressed or a solution of the purified hybrid antibody or the purified humanized antibody in stepwise dilution. After incubating at room temperature and washing with PBS-Tween20, 100  $\mu$ l of alkaline phosphatase-conjugated goat anti-human IgG antibody (TAGO) was added to each of the wells. After incubating at room temperature and washing with PBS-Tween20, 1 mg/ml of a substrate solution ("Sigma 104", p-nitrophenylphosphoric acid, SIGMA) was added to each of the wells. The solution was measured for absorbance at 405 nm using Microplate Reader (Bio Rad).

#### (7) Confirmation of activities

##### (i) Evaluation of humanized H chain

[0312] It was found that an antibody comprising the humanized H chain version "a" and the chimeric L chain exhibited the same level of PTHrP-binding activity as that of the chimeric antibody (see FIG. 5). This result suggests that the humanization of the H chain V region is satisfactorily achieved by the version "a". Therefore, the humanized H chain version "a" was provided as a humanized antibody H chain in the following experiments.

##### (ii) Activity of hybrid antibody

##### (ii-a) FR1,2/FR3,4 hybrid antibody

[0313] When the L chain was h/mMBC1Ld( $\lambda$ ), the antibody showed no antigen binding activity. However, when the L chain of the hybrid antibody was either m/hMBC1La $\lambda$  or m/hMBC1Ld $\lambda$ , the antibody showed the same level of antigen binding activity as that of the chimeric #23-57-137-1 antibody (FIG. 6). These results suggest that FR3 and FR4 are suitable for a humanized antibody but there exist amino acid residue(s) that need to be replaced in FR1 and FR2.

## (ii-b) FR1/FR2 hybrid antibody

[0314] When the L chain of the hybrid antibody was mhmMBC1L ( $\lambda$ ), the antibody showed no antigen binding activity. However, when the L chain of the hybrid antibody was hmmMBC1L( $\lambda$ ), the antibody showed the same level of antigen binding activity as that of the chimeric #23-57-137-1 antibody (FIG. 7). These results suggest that FR1 is suitable for a humanized antibody but there exist amino acid residue(s) that need to be replaced in FR2.

## (iii) Activity of humanized antibody

[0315] The humanized antibody in which each of the versions "a" to "t" was used as the L chain was determined of its antigen-binding activity. As a result, it was found that the humanized antibodies having the L chain versions "j", "l", "m", "o", "q", "r", "s" and "t" exhibited the same level of PTHrP-binding activity as that of the chimeric antibody (FIGS. 8 to 11).

## (8) Establishment of CHO stable production cell line

[0316] For establishing a stable transformant for humanized antibody, the above-mentioned expression plasmids were introduced into a CHO cell (DXB11).

[0317] The establishment of a stable transformant of the humanized antibody was conducted using each of the following combinations of plasmid as an expression vector for CHO cells; hMBC1HcDNA/pCHO1 and hMBC1Lm $\lambda$ /pCOS1; hMBC1HcDNA/pCHO1 and hMBC1Lq $\lambda$ /pCOS1; and hMBC1HcDNA/pCHO1 and hMBC1Lr $\lambda$ /pCOS1. The plasmids were co-transfected into a CHO cell by electroporation using Gene Pulser (Bio Rad). Subsequently, each of the expression vectors was cleaved with restriction enzyme PvuI to obtain a linear DNA. The resultant DNA was extracted with phenol and chloroform and then precipitated with ethanol. The DNAs thus prepared were respectively subjected to electroporation as follows. That is, 10  $\mu$ g of each of the plasmid DNAs was added to 0.8 ml of a cell suspension containing CHO cells in PBS(-) in a concentration of  $1 \times 10^7$  cells/ml. The resultant mixture was applied with pulses at an electrostatic capacity of 1,500V and 25  $\mu$ F. After 10 min. of recovery period at room temperature, the cells thus treated were suspended in a MEM- $\alpha$  medium (GIBCO) supplemented with 10% fetal calf serum (GIBCO) and then cultured in a CO<sub>2</sub> incubator using 96-well plates (Falcon). On the day after starting the cultivation, the medium was replaced by a MEM- $\alpha$  selective medium supplemented with 10% fetal calf serum (GIBCO) and 500 mg/ml of GENETICIN (G418Sulfate; GIBCO) but containing no ribonucleoside or deoxyribonucleoside. From the culture medium, cells into which the antibody gene was introduced were selected. After replacing the culture medium by a fresh one, before and after two weeks of cultivation, the cells were observed microscopically. When a satisfactory cell growth was observed, the cells were determined for the amount of antibodies produced by an ELISA assay conventionally used for determining antibody concentration as described above. Among the cells, those which produced a larger amount of antibodies were selectively collected.

[0318] The scale up of the culture of the stable transformant for the antibodies thus established was conducted in a roller bottle using a MEM- $\alpha$  medium supplemented with 2% Ultra Low IgG fetal calf serum without ribonucleoside or deoxyribonucleoside. On each of day 3 and day 4 after the cultivation, the culture supernatant was collected and filtered using a 0.2  $\mu$ m filter having (Millipore) to remove cell debris therefrom. The purification of the humanized antibodies from the culture supernatant of the CHO cells was conducted using POROS Protein A Column (PerSeptive Biosystems) on ConSep LC100 (Millipore) in accordance with an instruction included. The humanized antibodies were provided as a sample for the determination of neutralizing activity and examination of pharmacological efficacy on hypercalcemic model animals. The concentration and the antigen-binding activity of the purified humanized antibodies were determined by the ELISA system as mentioned above.

## EXAMPLE 4

## Determination of Neutralizing activity

[0319] The determination of neutralizing activity of the mouse antibody, the chimeric antibody and the humanized antibody was conducted using rat myeloma cell line ROS17/2.8-5 cells. The ROS17/2.8-5 cells were cultured in Ham's F-12 medium (GIBCO) supplemented with 10% fetal calf serum (GIBCO) using a CO<sub>2</sub> incubator. The ROS17/2.8-5 cells were inoculated in each of the wells of a 96-well plate in a concentration of  $10^4$  cells/100  $\mu$ l/well and cultured for 1 day. The culture medium was replaced with Ham's F-12 medium (GIBCO) supplemented with 4 mM Hydrocortisone and 10% fetal calf serum. After culturing for three to four days, the cultured cells were washed with 260  $\mu$ l of Ham's F-12 medium (GIBCO), and then 80  $\mu$ l of Ham's F-12 medium supplemented with 1 mM isobutyl-1-methyl xanthine (IBMX, SIGMA), 10% fetal calf serum and 10 mM HEPES was added thereto. The resultant mixture was incubated at 37°C for

30 min.

**[0320]** The mouse antibody, the chimeric antibody and the humanized antibody to be tested for neutralizing activity were previously diluted stepwise in the following groups: [10 µg/ml, 3.3 µg/ml, 1.1 µg/ml and 0.37 µg/ml], [10 µg/ml, 2 µg/ml, 0.5 µg/ml and 0.01 µg/ml] and [10 µg/ml, 5 µg/ml, 1.25 µg/ml, 0.63 µg/ml and 0.31 µg/ml]. Each of the diluted antibody sample solution was mixed with an equivalent amount of 4 ng/ml of PTHrP (1-34). Eighty µl of the resultant mixture solution was added into each well. The final concentration of each antibody became a quarter of the concentration of the above-mentioned antibody, and therefore the concentration of PTHrP (1-34) became 1 ng/ml. Ten minutes after the treatment at room temperature, the culture supernatant was removed and the residue was washed with PBS three times. From the resultant, cAMP in the cells was extracted with 10 µl of a 0.3% HCl-95% ethanol and then evaporated with a water jet aspirator to remove the HCl-ethanol. The residue was dissolved in 120 µl of EIA buffer attached to cAMP EIA Kit (CAYMAN CHEMICAL'S) to extract the cAMP therefrom. The cAMP level was determined using cAMP EIA Kit (CAYMAN CHEMICAL'S) in accordance with an instruction included within. As a result, it was found that, among the humanized antibodies having L chain versions showing the same level of antigen-binding activity as that of the chimeric antibody, those having L chain versions "q", "r", "s" and "t" in which the 91-position tyrosine was replaced with isoleucine exhibited the closest neutralizing activity to that of the chimeric antibody, and especially those having a L chain version "q" exhibited the strongest neutralizing activity (FIGs. 12 to 14).

## EXAMPLE 5

### Examination of Pharmacological Efficacy on Hypercalcemic Model Animals (1)

**[0321]** Using a hypercalcemic model animal (a human tumor transplanted nude mouse), a chimeric antibody and humanized antibodies individually having L chain versions "m", "r" and "q" against PTHrP were examined for their therapeutic efficacy on hypercalcemia.

**[0322]** As a hypercalcemic model animal, was used a nude mouse which had been transplanted with human pancreatic cancer PAN-7 [purchased from the Central Institute for Experimental Animals]. It has been known that a nude mouse which has been transplanted with human pancreatic cancer PAN-7 exhibits an increased calcium concentration in blood as increasing the tumor volume and develops hypercalcemia which is associated with, for example, decrease in body weight and spontaneous activity. In this example, therapeutic effect of the chimeric antibody and the humanized antibody of the invention on hypercalcemia induced by the human pancreatic cancer PAN-7 was examined by the measurement of body weight and calcium concentration in blood of the test animal.

**[0323]** The passage of the human pancreatic cancer PAN-7 was conducted using BALB/c-nu/nu nude mice (Nippon Charles River) in vivo. For the evaluation of pharmacological efficacy, 5-weeks-old male BALB/c-nu/nu nude mice (Nippon Charles River) were purchased and then acclimatized them for 1 week, and the mice of 6-weeks-old thus prepared were used for the evaluation. The hypercalcemic model mice were prepared and divided into groups in the following manner. The human pancreatic cancer PAN-7 passed was excised and then finely cut into 3 mm cube of blocks. The resultant tumor blocks were subcutaneously transplanted under the skin flap of the mice at one piece per mouse. Two or three weeks after the transplantation, when it was confirmed that the tumor volume in each of the mice became satisfactorily large, the mice were divided into groups so that tumor volume, calcium concentration in blood and body weights of the mice of the individual groups were averaged, and the mice were used as the hypercalcemic model animals.

**[0324]** The examination of therapeutic efficacy on hypercalcemia was conducted as follows. A single dose of the chimeric antibody or the humanized antibody having a L chain version "m" or "r" against PTHrP was administered to each of the above-mentioned hypercalcemic model mice via tail vein in a dose amount of 10 or 30 µg per mouse. A single dose of the humanized antibody having a L chain version "q" was administered to each of the above-mentioned hypercalcemic model mice via tail vein in a dose amount of 20 or 60 µg per mouse. On day 1, day 4, day 7 and day 11 after the administration, each of the mice was measured for the calcium concentration in blood and measured for the body weight to evaluate the pharmacological efficacy of the antibodies. The tumor volume was determined by measuring the major diameter (a mm) and the minor diameter (b mm) of the tumor and calculating using the both measured values according to Galant's equation  $[ab^2/2]$ . The calcium concentration in blood was determined as ionized calcium concentration in whole blood by drawing blood from each of the mice via the orbit using a hematocrit tube and applying the blood to 643 Automatic  $Ca^{++}$ /pH Analyzer (CIBA-CORNING).

**[0325]** As a result, it was found that the administration of the chimeric antibody and the humanized antibodies each having the L chain versions "m", "r" and "q" leads to a rapid improvement in change of body weight and calcium concentration in blood and a retention of improvement for a prolonged period of time for a subject. This result showed that the chimeric antibody and the humanized antibodies of the present invention are useful for treating malignant tumor-associated hypercalcemia (see FIGs. 15 and 16).



## EXAMPLE 6

## Examination of Pharmacological Efficacy on Hypercalcemia Model Animals (2)

5 [0326] Using a hypercalcemia model animal (a human tumor transplanted nude mouse), a chimeric antibody and a humanized antibody having L chain version "q" against PTHrP were examined for their therapeutic efficacy on hypercalcemia as follows.

[0327] The examination for the therapeutic efficacy on hypercalcemia was conducted as follows. A single dose of the chimeric antibody or the humanized antibody having a L chain version "q" against PTHrP was administered to each of the above-mentioned hypercalcemia model mice via tail vein in a dose amount of 10 or 30  $\mu$ g per mouse. On day 1, day 3, day 7 and day 11 after the administration, each of the mice was determined for the calcium concentration in blood and measured for the body weight to evaluate the pharmacological efficacy of the antibodies. The calcium concentration in blood was determined as ionized calcium concentration in whole blood by drawing blood from each of the mice via the orbit using a hematocrit tube and applying the blood to 643 Automatic  $\text{Ca}^{++}$ /pH Analyzer (CIBA-CORNING).

15 [0328] As a result, in the hypercalcemia model animal carrying human pancreatic cancer PAN-7, the administration of the chimeric antibody and the humanized antibody having the L chain version "q" leads to a rapid improvement with respect to body weight and calcium concentration in blood and to a retention of improvement for a prolonged time period for a subject. This result suggests that the chimeric antibody and the humanized antibody of the present invention are useful agent for treating malignant tumor-associated hypercalcemia (see FIG.17).

## EXAMPLE 7

## Examination of Pharmacological Efficacy on Hypercalcemia Model Animals (3)

25 [0329] Using a hypercalcemia model animal (a human lung cancer LC-6 transplanted nude mouse), a chimeric antibody and a humanized antibody having L chain version "q" against PTHrP were examined for their therapeutic efficacy on hypercalcemia.

[0330] In this experiment, as the hypercalcemia model animal, a nude mouse into which human lung cancer LC-6 (purchased from the Central Institute for Experimental Animals) was transplanted was used. It has been known that a nude mouse into which human lung cancer LC-6 is transplanted tends to show an increased calcium concentration in blood with increased tumor volume and develops hypercalcemia associated with decrease in body weight and spontaneous activity.

[0331] In this example, therapeutic efficacy of the chimeric antibody and the humanized antibody of the invention on hypercalcemia induced by the human lung cancer LC-6 was examined by the measurement of body weight and calcium concentration in blood of the test animal.

[0332] The passage of the human lung cancer strain LC-6 was conducted using BALB/c-nu/nu nude mice (Nippon Charles River) in vivo. For the evaluation of pharmacological efficacy, 5-weeks-old male BALB/c-nu/nu nude mice (Nippon Charles River) were purchased and then acclimatized them for 1 week, and the mice of 6-weeks-old were used.

[0333] The hypercalcemia model mice were prepared and divided into groups in the following manner. The human lung cancer LC-6 passaged was excised and then finely cut into 3 mm cube of blocks. The resultant tumor blocks were subcutaneously transplanted under the skin flap of the mice at one piece per mouse. Two or three weeks after the transplantation, when it was confirmed that the tumor volume in each of the mice had become satisfactorily large, the mice were divided into groups so that tumor volume, calcium concentration in blood and body weight of the mice of the individual groups were averaged, and the mice were used as the hypercalcemia model animals.

45 [0334] The examination of therapeutic efficacy on hypercalcemia was conducted as follows. A single dose of the chimeric antibody or the humanized antibody having a L chain version "q" against PTHrP was administered to each of the above-mentioned hypercalcemia model mice via tail vein in a dose amount of 10 or 30  $\mu$ g per mouse. On day 1, day 3, day 6 and day 10 after the administration, each of the mice was measured for the calcium concentration in blood and measured for the body weight to evaluate the pharmacological efficacy of the antibodies. The calcium concentration in blood was determined as ionized calcium concentration in whole blood by drawing blood from each of the mice via the orbit using a hematocrit tube and applying the blood to 643 Automatic  $\text{Ca}^{++}$ /pH Analyzer (CIBA-CORNING).

50 [0335] As a result, it was found that in the hypercalcemia model animal carrying human lung cancer LC-6, the administration of the chimeric antibody and the humanized antibody having the L chain version "q" leads to a rapid improvement with respect to body weight and calcium concentration in blood and to a retention of improvement for a prolonged time period for a subject. This result suggests that the chimeric antibody and the humanized antibody of the present invention are useful agent for treating malignant tumor-associating hypercalcemia (see FIG.18).



## Example 8

## Kinetic Analysis of Interaction between PTHrP and anti-PTHrP antibody using BIACORE

5 [0336] In this experiment, kinetic analysis of the antigen-antibody interaction using BIACORE was conducted. PTHrP(1-34+Cys) was used as an antigen and adsorbed onto the sensor tip specifically for C-terminals. Purified antibodies of various concentrations were used as an analyte. From the sensorgram obtained, kinetics parameters (binding rate constant "kass" and dissociation rate constant "kdiss") were calculated. With respect to the kinetic analysis, literature "Kinetic analysis of monoclonal antibody-antigen interactions with a new biosensor based analytical system",  
 10 Karlsson, R. et al., (1991), J. Immunol. Methods 145, p.229-240, was used for reference.

(1) Immobilization of PTHrP (1-34+C) onto the sensor tip PTHrP (1-34+C) was adsorbed onto sensor tip CM5 (Pharmacia).

15 [0337] As a running buffer, HBS (10 mM HEPES, pH 7.4; 0.15 M NaCl; 3.4 mM EDTA; 0.005% Surfactant P20) at a flow rate of 5 µl/min. was employed. The carboxyl groups of carboxymethyl dextran on the sensor tip CM5 were activated by an injection of 100 µl of 0.05M N-hydroxysuccinimide (NHS)/0.2M N-ethyl-N'-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC) and an injection of 100 µl of 80 mM 2-(2-pyridyldithio)ethanamine (PDEA)/0.1M borate buffer (pH 8.5), and an additional injection of 10 µl of 5 µg/ml PTHrP (1-34+C)/10mM sodium acetate buffer (pH 5.0) to  
 20 adsorb onto the C-terminals of PTHrP (1-34+C) specifically for Cys residues. Subsequently, an injection of 100 µl of 50mM (L)-cystein/1M NaCl/0.1M sodium formate buffer (pH 4.3) was conducted to block excessively activated groups. Subsequently, an injection of 10 µl of 0.1M glycine-HCl buffer (pH 2.5) and 10 µl of 10mM HCl was conducted to wash the substances having non-covalent bonding. The amount of the PTHrP (1-34+C) thus immunized was 226.4 RU (resonance units) (FIG.19).

25 (2) Interaction between immunized PTHrP (1-34+C) and purified mouse anti-PTHrP antibody

[0338] As a running buffer, HBS at a flow rate of 20 µl/min. was used. The antibody producing hybridomas were injected into the abdominal cavity of a Balb/c mouse and after a couple of weeks, the ascites were collected and applied  
 30 on protein A column to purify antibodies. The purified #23-57-137-1 antibody was designated "MBC" and the purified 3F5 antibody was designated "3F5". These antibodies were diluted with HBS in a series of concentrations of 1.25, 2.5, 5, 10 and 20 µg/ml.

[0339] In the analysis, 40 µl of the antibody solution was injected for 2 min. to give a binding phase, and then HBS was injected for 2 min. to give a dissociation phase. After the dissociation was completed, 10 µl of 10mM HCl was  
 35 injected to recover the sensor tip. The analysis was conducted by using this binding-dissociation-recovering as one cycle and injecting various antibody solutions to obtain a sensorgram.

(3) Interaction between immobilized PTHrP (1-34+C) and purified humanized anti-PTHrP antibody

40 [0340] As a running buffer, HBS at a flow rate of 20 µl/min. was used. The antibody was produced by CHO cells and purified using protein A column. The purified chimeric antibody was designated "chMBC", and the purified humanized antibodies of versions m and q were designated "hMBCm" and "hMBCq", respectively. These antibodies were diluted with HBS in a series of concentrations of 1.25, 2.5, 5, 10 and 20 µg/ml.

[0341] In the analysis, 40 µl of the antibody solution was injected for 2 min. to give a binding phase, and then HBS  
 45 was injected for 2 min. to give a dissociation phase. After the dissociation was completed, 10 µl of 10mM HCl was injected to recover the sensor tip. The analysis was conducted by using a binding-dissociation-recovering as one cycle and by injecting various antibody solutions to obtain a sensorgram.

(4) Kinetic Analysis of the Interaction

50 [0342] The data file of interest was read and a comparison of the reaction patterns was conducted by overlaying the reaction regions of interest (FIGs. 20-24). In each of FIGs. 20-24, lines sequentially indicate from the top the data for the antibody concentrations 1.25, 2.5, 5, 10 and 20 µg/ml. Further, kinetic analysis of the interaction was conducted using an analysis software specifically designed for BIACORE "BIAevaluation 2.1" (Pharmacia) which is capable of  
 55 calculating the kinetics parameters (binding rate constant "kass" and dissociation rate constant "kdiss") by curve cutting (Tables 4 and 5).

Table 4

| Kinetics parameters of MBC and 3F5 |                        |                       |
|------------------------------------|------------------------|-----------------------|
|                                    | MBC                    | 3F5                   |
| Kdiss [l/s]                        | $7.38 \times 10^{-5}$  | $1.22 \times 10^{-2}$ |
| Kass [l/Ms]                        | $7.23 \times 10^5$     | $6.55 \times 10^5$    |
| KD [M]                             | $1.02 \times 10^{-10}$ | $1.86 \times 10^{-8}$ |

Table 5

| Kinetics parameters of chimeric and humanized anti-bodies |         |       |       |
|---|---------|-------|-------|
|   | chH-chλ | hMBCm | hMBCg |
| Kdiss [l/s] ( $\times 10^{-4}$ )                          | 1.66    | 3.16  | 2.32  |
| Kass [l/Ms] ( $\times 10^6$ )                             | 1.24    | 0.883 | 1.03  |
| KD [M] ( $\times 10^{-10}$ )                              | 1.34    | 3.58  | 2.25  |

[0343] In this experiment, for determining the binding rate constant, analysis model type 4 (BIAevaluation 2.1 Software Handbook, A1-A5) was used.

#### Example 9

##### Suppression of Excretion of Phosphorus in a Model of Malignant Tumor-Associated Hypercalcemia

[0344] Malignant tumor-associated hypercalcemia (HHM) is a disease caused by the presence of PTHrP and it has been known that PTHrP accelerates bone resorption and calcium resorption in kidney and riniferous tubule, resulting in the development of hypercalcemia. On the other hand, with respect to phosphorus, PTHrP suppress the resorption of phosphorus in the kidney and riniferous tubule, resulting in the development of eliminant action, and therefore clinical HHM patients often develop hypophosphatemia. Here, the effect of humanized anti-PTHrP antibody on excretion of phosphorus in the kidney was examined using malignant tumor-associated hypercalcemia model rats.

[0345] As a model animal, a nude rat into which human lung cancer LC-6 (purchased from the Central Institute for Experimental Animals) was transplanted was used. It has been known that a nude rat into which human lung cancer LC-6 was subcutaneously transplanted tends to show an increased calcium concentration in blood was the increase of the tumor volume and, as a result, the rat develops hypercalcemia which is associated with, for example, decrease in body weight and spontaneous activity. Using this model animal, the effect of the humanized anti-PTHrP antibody of the invention on phosphate excretion in the kidney was examined by a renal clearance method based on the below-mentioned fractional excretion of phosphate.

[0346] The passage of the human lung cancer LC-6 was conducted using BALB/c-nu/nu nude mice (Nippon Kurea) in vivo. For the evaluation of pharmacological efficacy, 5-weeks-old male F344N/Jcl-rnu nude rats (Nippon Kurea) were purchased and then acclimatized them for 1 week, and the rats of 6-weeks-old were used.

[0347] The malignant tumor-associated hypercalcemic model animals were prepared as follows. The human lung cancer LC-6 tumor passaged was excised and then finely cut into 3 mm cube of blocks. The resultant tumor blocks were subcutaneously transplanted under the skin flap of the rats at one piece per rat. About thirty days after the transplantation, when it was confirmed that the tumor volume in each of the rats became satisfactorily large ( $3000 \text{ mm}^3$ ), the rats to be provided as the malignant tumor-associated hypercalcemia model animals were selected based on calcium concentration in blood and body weight.

[0348] The examination of phosphate excretion by a renal clearance method was conducted in the following manner.

## (1) Renal clearance method

[0349] A malignant tumor-associated hypercalcemia model animal was anesthetized with pentobarbital (Nembutal, Dainippon Pharmaceutical Co., Ltd.), fixed supinely onto a incubation mat maintained at 37°C, and inserted a cannula (a polyethylene tube, PE50, Nippon Beckton Dickinson) to its bladder to collect urine. Subsequently, the model animal was inserted a cannula for infusion (a polyethylene tube, PE10, Nippon Beckton Dickinson) to its femoral vein, and then an infusion solution (0.7% inulin, 5% mannitol, 0.2% pentobarbital and 0.9% sodium chloride) was introduced into the model animal through the cannula at a flow rate of 2 ml/hr using an infusion pump (Terufusion syringe pump; STC-525; TERUMO) to infuse the model animal. After equilibrating for 50 min., urine was collected through the cannula for five times at 20 min. intervals (i.e., from period-1 to period-5) to give urine samples. At the intermediate point of time during each urine collection procedure, approximately 0.25ml of blood samples from the right cervical vein of the model animal were collected using a heparin-treated injection syringe.

## (2) Administration of antibody

[0350] During the above-mentioned clearance test, at the point of time where the collection of urine of period-2 was just started, a humanized anti-PTHrP antibody was administered intravenously to the animal in a dose amount of 1mg/ml/kg.

## (3) Determination of concentration of inulin and phosphorus in urine and blood

[0351] The urine samples obtained at period-1 to period-5 were measured for their volume and then determined for the inulin and phosphorus concentrations thereof. The blood samples also obtained above were subjected to cooling centrifugation to obtain a plasma sample, which was used for determining the inulin and phosphorus concentration. The determination of inulin was conducted by Anthrone-sulfate method (Roe, L. et al., J. Biol. Chem. 178, 839-845, 1949), and the determination of phosphorus was conducted using Hitachi Automatic Analyzer 7170 model with a reagent for inorganic phosphorus determination, Autoseri IP (Daiichi Pure Chemicals) in accordance with a manual (Physke-Sabaroh method).

## (4) Calculation of inulin clearance, phosphorus clearance and fractional excretion of phosphorus.

[0352] Inulin clearance (Cin), phosphorus clearance (Cp) and fractional excretion of phosphorus (FEp) were calculated according to the following equations.

Calculation of inulin clearance (Cin):

$$C_{in} = U_{in} V / P_{in}$$

Wherein Cin represents inulin clearance (ml/kg/min); U<sub>in</sub> represents the concentration of inulin in urine (mg/ml); V represents the amount of urine per unit time (ml/kg/min); and P<sub>in</sub> represents the concentration of inulin in blood (mg/ml).

Calculation of phosphorus clearance (Cp):

$$C_p = U_p V / P_p$$

Wherein Cp represents phosphorus clearance (ml/kg/min); U<sub>p</sub> represents the concentration of phosphorus in urine (mg/ml); V represents the amount of urine per unit time (ml/kg/min); and P<sub>p</sub> represents the concentration of phosphorus in blood (mg/ml).

Calculation of fractional excretion of phosphorus (FEp):

$$FE_p = C_p / C_{in}$$

Wherein FE<sub>p</sub> represents fractional excretion of phosphorus; C<sub>in</sub> represents inulin clearance; and C<sub>p</sub> represents phosphorus clearance. The examination was conducted using four animals. The results were determined as the average value ± standard error.

[0353] The results of fractional excretion of phosphorus and phosphorus concentration in blood are shown in FIGs. 25 and 26.

[0354] FIG. 25 is a graph illustrating the relationship of fractional excretion of phosphorus (= phosphorus clearance/inulin clearance) vs. periods of clearance (1 period = 20 mm.). The humanized anti-PTHrP antibody (1 mg/kg) was administered (i.v.) at the time of the starting of period-2.

[0355] FIG. 26 is a graph illustrating the relationship of phosphorus concentration in plasma vs. periods of clearance (1 period = 20 mm.). The humanized anti-PTHrP antibody (1 mg/kg) was administered (i.v.) at the time of starting of period-2.

[0356] From these results, it was found that the fractional excretion of phosphorus given after administering the antibody (i.e., from period-2 and period-5) was obviously suppressed compared with that given before administering the antibody (i.e., period-1). In other words, it was found that the administration of the neutralizing antibody to a subject developing hypophosphatemia, which causes acceleration of excretion of phosphorus ( $FE_p > 0.2$ ) recovered the phosphorus resorption in the subject to approximately the normal level (fractional resorption of phosphate =  $1 - FE_p > 0.8\%$ ) and, as a result, trend to normalcy of the phosphorus concentration in blood of the subject was observed. These results suggest the usefulness of the antibodies of the present invention as agents treating the accelerated excretion of phosphorus and hypophosphatemia caused by the presence of PTHrP.

[0357] Since PTHrP is a substrate causing malignant tumor-associated hypercalcemia, the possibility of increase in phosphorus excretion and decrease in high energy organic phosphorus in tissue caused by PTHrP is predicted. Accordingly, various diseases associated with hypophosphatemia, such as hypophosphatemic rickets and hypophosphatemic vitamin D-resistant rickets, are considered to be mainly caused by the increase in phosphorus excreted through urine and, therefore, the antibodies of the present invention would also be useful for treating these diseases.

#### Example 10

##### Improvement of Various Clinical Symptoms of Malignant Tumor-associated Hypercalcemia

[0358] It has been known that the malignant tumor-associated hypercalcemia is caused by the presence of PTHrP which is produced by the tumor and that PTHrP accelerates bone resorption and calcium resorption in the kidney and the uriniferous tubule, leading to hypercalcemia. Further, in a patient suffering from hypercalcemia, worsening of clinical symptoms, such as poor performance status, loss of consciousness, systemic malaise, hydrodipsia, nausea and emesis (anorexia) are observed. The effect of the anti-PTHrP antibody on such clinical symptoms was examined using hypercalcemia model animals of human tumor nude mouse transplantation system and human tumor-nude rat transplantation system.

[0359] As the hypercalcemia model animal, nude mice and nude rats into which human lung cancer LC-6 (purchased from the Central Institute for Experimental Animals) had been transplanted were used. Nude mice and nude rats into which human lung cancer LC-6 is transplanted tend to show increased calcium concentration in blood with increase in the tumor volume, leading hypercalcemia associated with decrease in body temperature and body weight.

[0360] The improvement effect of mouse anti-PTHrP antibody on general clinical symptoms of malignant tumor-associated hypercalcemia was examined using a human lung cancer LC-6-nude mouse transplantation system and its result is shown photographically. The effect of the antibody on improvement of decrease in spontaneous activity, body temperature and anorexia was examined using a human lung cancer LC-6-nude mouse transplantation system.

##### 1. Improvement of apparent clinical symptoms associated with hypercalcemia

[0361] The passage of the human lung cancer strain LC-6 was conducted using BALB/c-nu/nu nude mice (Nippon Kurea) in vivo. For the evaluation of pharmacological efficacy, 5-weeks-old male BALB/c-nu/nu nude mice (Nippon Kurea) were purchased and then acclimatized for 1 week, and the mice of 6-weeks-old were used.

[0362] The hypercalcemia model mice were prepared and divided into groups in the following manner. The human lung cancer LC-6 passaged was excised and then finely cut into 3 mm cube of blocks. The resultant tumor blocks were subcutaneously transplanted under the skin flap of the mice at one piece per mouse. Twenty-seven days after the transplantation, when it was confirmed that the tumor volume in each of the mice became satisfactorily large, the mice were divided into groups so that the tumor volume, the calcium concentration in blood and the body weights of the mice of the individual groups were averaged, and the mice were provided as the hypercalcemia model animals.

[0363] The tumor volume was determined by measuring the major diameter (a mm) and the minor diameter (b mm) of the tumor and calculating using the both measured values according to Galant's equation  $[ab^2/2]$ .

[0364] The calcium concentration in blood was determined as ionized calcium concentration in whole blood by drawing blood from each of the mice via the orbit using a hematocrit tube and applying the blood to 643 Automatic  $Ca^{++}/pH$  Analyzer (CIBA-CORNING).

**[0365]** The examination of therapeutic efficacy of the antibody on hypercalcemia was conducted in the following manner. The mouse antibody against PTHrP was administered to each of the above-mentioned hypercalcemia model animal via the tail vein on day 27, 30, 34 and 37 after transplanting the tumor in a dose amount of 100 µg per mouse. For preparation of controls, a phosphate buffered-physiological saline was administered instead of the antibody in the same manner. On 41 days after transplanting the tumor, from each of the antibody-administered group and the control group, a typical mouse was selected and a picture was taken thereof along with a normal mouse.

**[0366]** As a result, in the hypercalcemia model animal transplanted with human lung cancer LC-6, although the antibody-administered mice (shown in center of each of FIGs. 27 and 28) bore the same level of tumor mass as the control mouse (shown in the right of each of FIGs. 27 and 28), they exhibited the same level of appearance as the normal mouse (shown in the left of FIGs. 27 and 28). This result suggest that the administration of the anti-PTHrP antibody exerts an improvement in apparent clinical symptoms (FIGs. 27 and 28).

## 2. Improvement of spontaneous activity decrease associated with hypercalcemia

**[0367]** The passage of the human lung cancer LC-6 was conducted using BALB/c-nu/nu nude mice (Nippon Kurea) in vivo. For the evaluation of pharmacological efficacy, 5-weeks-old male F344/N Jcl-run nude rats (Nippon Kurea) were purchased and then acclimatized for 1 week, and the rats of 6-weeks-old were used.

**[0368]** The hypercalcemia model animals were prepared in the following manner. The human lung cancer LC-6 passaged was excised and then finely cut into 3 mm cube of blocks. The resultant tumor blocks were subcutaneously transplanted under the skin flap of the mice at one piece per mouse. About thirty days after the transplantation, when it was confirmed that the tumor volume in each of the mice had become satisfactorily large, the mice were divided into groups so that the tumor volume, the calcium concentration in blood and the body weights of the mice of the individual groups were averaged, and the mice were provided as the hypercalcemia model animals.

**[0369]** The calcium concentration in blood was determined as ionized calcium concentration in whole blood by drawing blood from each of the mice via the orbit using a hematocrit tube and applying the blood to 643 Automatic Ca<sup>++</sup>/pH Analyzer (CIBA-CORNING).

### (1) Method for determination of spontaneous activity

**[0370]** The determination of spontaneous activity was conducted using ANIMEX activity meter type SE (FARAD, Electronics, Sweden), which was placed in predetermined position in the polyethylene cage in which each of the model animals was individually nurtured (watering and feeding). This apparatus was designed to measure the amount of movement of each rat. Using this apparatus, the amount of movement was recorded as the count per a definite time of period. The measurement was conducted for 13 hours (from 7:00 p.m. of a certain day to 8:00 a.m. of next day) and the results were given as count per hour.

### (2) Administration of antibody

**[0371]** The humanized anti-PTHrP antibody was administered each of the above-prepared rats which developed hypercalcemia via its tail vein as a control in a dose amount of 5 mg/0.5 ml/kg. Saline was administered to another group of the rats in the same manner. The measurement was conducted with alternation of an antibody-administrated rat and a control rat.

**[0372]** The measurement was conducted on day 0 (i.e., the day before administration), 2, 4, 7 and 14 for the antibody-administered rats and on day 1, 3, 5, 8 and 15 for the control rats.

**[0373]** As a result, the control rats showed no change or a decrease in spontaneous activity during the test period, whereas the antibody-administered rats showed an increase in spontaneous activity on and after day 4 of the administration (FIG.29).

## 3. Improvement in body temperature decrease associated with hypercalcemia

**[0374]** The passage of human lung cancer LC-6 and the preparation of the malignant tumor-associated hypercalcemia model animals were conducted in the same manner as in step 2 above.

### (1) Method for measuring body temperature

**[0375]** The measurement of body temperature was conducted using a digital thermometer by anesthetizing the animal with pentobarbital (Nembutal, Dainippon Pharmaceutical Co., Ltd.) and inserting a temperature sensor into the rectum thereof.

## (2) Administration of antibody

[0376] The humanized anti-PTHrP antibody was administered to each of the above-mentioned hypercalcemia model rats via the tail vein in a dose amount of 1mg/ml/kg. For a control, saline was administered to another model rat via the tail vein. Further, a normal rat to which no antibody was administered was also measured for its body temperature. The measurement of body temperature of the rats was conducted on day 0 (i.e., the day of the administration), 1, 2 and 3 after the administration with respect to all of the antibody-administered rats, the control rat and the normal rat.

[0377] As a result, the normal rat showed no change in body temperature (34.2 - 34.4°C) throughout the test period, whereas the malignant tumor-associated hypercalcemia model rats showed a decrease in body temperature by about 2°C compared with the normal rats. When the humanized anti-PTHrP antibody was administered to the model rats, it was confirmed that the malignant tumor-associated hypercalcemia model rats recover their decreased body temperatures to the same level as that of the normal rats three days after administration. These results suggests that the humanized anti-PTHrP antibody of the present invention is effective for improving the body temperature decrease of the malignant tumor-associated hypercalcemia model animal (FIG.30).

## 4. Improvement in food intake decrease induced

[0378] The passage of the human lung cancer LC-6 and the preparation of the hypercalcemia model animals were conducted in the same manner as described in above section 2. The model animals prepared were divided into groups so that the calcium concentration in blood and the body weights of the mice of the individual groups were averaged, and the mice were used in the experiments below.

## (1) Measurement of amount of feed intake

[0379] During the test period, the rats were individually placed into a metabolic cage and nurtured with water and feed. With respect to each of the rats, the amount ingested was determined as the amount (g) per 24 hours (starting from 9:00 a.m. of a certain day to 9:00 a.m. of the next day). The determination was conducted by measuring the total weight of the feedstock container both at 9:00 a.m. of the day (i.e., tare) and at 9:00 a.m. of the next day and calculating the weight difference therebetween.

## (2) Administration of antibody

[0380] The humanized anti-PTHrP antibody was administered to each of the hypercalcemia model rats (HHM rats) described above via its tail vein in a dose amount of 5 mg/0.5 ml/kg. Saline was administered to each of control group via its tail vein in the same manner. Saline was also administered to each of normal rats via tail vein in the same manner. With respect to all of the antibody-administered rats, the control rats and the normal rats, the determination of the amount of food intake was conducted on day 0 (i.e., previous day of the administration to the day of the administration), day 1 (i.e., period from the day of the administration to the next day), day 3 (i.e., period from three days after the administration to the next day) and day 5 (i.e., period from five days after the administration to the next day).

[0381] As a result, before administering the antibody, the amount ingested by the hypercalcemia model rats (5-9 rats) was 8.11 g in average, whereas that of the normal rats was 12.06 g in average, which demonstrates an obvious decrease in the amount of ingestion by hypercalcemia model rats. When the humanized ante-PTHrP antibody was administered to the model rats, on and after the day after administering the antibody, although almost no change was observed in the amount of ingestion by the control rats, the amount of ingested by the antibody-administered rats recovered to the same level of that in the normal rats. These results suggest that the humanized anti-PTHrP antibody of the present invention is effective in improving the decrease in the amount ingested for the malignant tumor-associated hypercalcemia model (Table 6).

Table 6

| Effect on ingestion |                |                     |                                 |       |       |       |
|---------------------|----------------|---------------------|---------------------------------|-------|-------|-------|
| Animal              | Individual No. | Administration*     | Eating amount of individual (g) |       |       |       |
|                     |                |                     | day 0                           | day 1 | day 3 | day 5 |
| Normal rat          | 1              | Saline              | 13.7                            | 16.7  | 18.63 | 18.71 |
|                     | 2              | Saline              | 14.27                           | 15.3  | 19.55 | 19.39 |
|                     | 3              | Saline              | 9.83                            | 15.5  | 20.72 | 19.88 |
|                     | 4              | Saline              | 10.42                           | 15.04 | 20.28 | 22.03 |
| HHM rat             | 5              | Saline              | 10.77                           | 14.24 | 12.66 | 11.82 |
|                     | 6              | Saline              | 6.99                            | 8.92  | 2.59  | 14.8  |
| HHM rat             | 7              | Anti-PTHrP antibody | 7.46                            | 17.65 | 22.52 | 17.99 |
|                     | 8              | Anti-PTHrP antibody | 12                              | 12.38 | 20.94 | 23.1  |
|                     | 9              | Anti-PTHrP antibody | 3.35                            | 16.65 | 20.36 | 21.89 |

\*

Administration of saline (Saline) : 0.5 ml/kg, via tail vein;  
and  
Administration of antibody: 5 mg/0.5 ml/kg, via tail vein.

**[0382]** From the above-mentioned results, it was demonstrated that the chimeric antibodies and the humanized antibodies of the present invention are useful as agents for improving the various clinical symptoms of malignant tumor-associated hypercalcemia.

#### 5. Improvement of decrease in blood pH induced by hypercalcemia

**[0383]** The passage of human lung cancer LC-6 and the preparation of the malignant tumor-associated hypercalcemia model animals were conducted in the same manner as in step 2 above. The model animals were divided into groups so that the calcium concentration in blood and the body weight of the mice of the individual groups were averaged.

##### (1) Determination of blood pH

**[0384]** Blood was collected from each test animal using a heparin-treated injection syringe by cardiac blood drawing technique and then applying the resultant blood sample to 643 Automatic  $\text{Ca}^{++}$ /pH Analyzer (CIBA-CORNING) to determine pH of the blood sample.

##### (2) Administration of antibody

**[0385]** The humanized anti-PTHrP antibody was administered to each of the above-mentioned hypercalcemia model rats (HHM rats) via its tail vein in a dose amount of 5 mg/0.5 ml/kg (n=3). Saline was administered to each of control group via its tail vein in the same manner (n=2). With respect to any of the antibody-administered rats and the control rats, the determination of blood pH was conducted on day 0 (i.e., the day of administration), day 1 and day 7. The results are given as average of the pH values obtained.

**[0386]** As a result, before administering the antibody, the pH of the blood obtained from the hypercalcemic model rats was about 7.49 (whereas that from the normal rats was  $7.40 \pm 0.02$ ), which means that the model rats obviously had developed metabolic alkalosis. When the humanized anti-PTHrP antibody of the present invention was administered to the model rats, although the control rats showed almost no change in blood pH, the antibody-administered rats showed such an improvement in pH values that the pH values recovered to near the pH value of the normal rats seven days after administering the antibody. As one of the clinical symptoms of malignant tumor-associated hypercalcemia (HHM), metabolic alkalosis has been reported which is known to be induced by the inhibition of excretion of bicarbonate ion ( $\text{HCO}_3^-$ ) in kidney. Since the administration of the humanized anti-PTHrP antibody of the present invention normalized

the blood pH in the hypercalcemia model animals, it is suggested that the antibody can improve the metabolic alkalosis found in HHM (FIG. 31).

[0387] From the results mentioned above, it was demonstrated that the chimeric antibodies and the humanized antibodies of the present invention are useful as agents for improving the clinical symptoms of malignant tumor-associated hypercalcemia.

#### INDUSTRIAL APPLICABILITY

[0388] According to the present invention, a chimeric antibody and a humanized antibody against PTHrP are provided. These antibodies have a low antigenicity against human and therefore are useful as agents for treating hypercalcemia, hypophosphatemia and the like.



Sequence Listing

5

(2) INFORMATION FOR SEQ ID NO: 1:

10

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20 base pairs

(B) TYPE: nucleic acid

15

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

20

(ii) MOLECULE TYPE: other nucleic acid

(A) DESCRIPTION: /desc = "synthetic DNA"

25

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

AAATAGCCCT TGACCAGGCA

30

20

35

(2) INFORMATION FOR SEQ ID NO: 2:

(i) SEQUENCE CHARACTERISTICS:

40

(A) LENGTH: 38 base pairs

(B) TYPE: nucleic acid

45

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

50

(ii) MOLECULE TYPE: other nucleic acid

(A) DESCRIPTION: /desc = "synthetic DNA"

55

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

5

CTGGTTCGGC CCACCTCTGA AGTTCCAGA ATCGATAG

38

10

(2) INFORMATION FOR SEQ ID NO: 3:

15

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 28 base pairs

(B) TYPE: nucleic acid

20

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

25

(ii) MOLECULE TYPE: other nucleic acid

(A) DESCRIPTION: /desc = "synthetic DNA"

30

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:

GGATCCCGGG CCAGTGGATA GACAGATG

28

35

(2) INFORMATION FOR SEQ ID NO: 4:

40

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 29 base pairs

45

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

50

(ii) MOLECULE TYPE: other nucleic acid

55

(A) DESCRIPTION: /desc = "synthetic DNA"

5

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:

GGATCCCGGG TCAGRGAAG GTGGRAACA

29

10

(2) INFORMATION FOR SEQ ID NO: 5:

15

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 17 base pairs

20

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

25

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

30

(A) DESCRIPTION: /desc = "synthetic DNA"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:

35

GTTTCCAG TCACGAC

17

40

(2) INFORMATION FOR SEQ ID NO: 6:

45

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 17 base pairs

50

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

55

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(A) DESCRIPTION: /desc = "synthetic DNA"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6:

CAGGAAACAG CTATGAC

(2) INFORMATION FOR SEQ ID NO: 7:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 31 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(A) DESCRIPTION: /desc = "synthetic DNA"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:

GTCTAAGCTT CCACCATGAA ACTTCGGGCT C

(2) INFORMATION FOR SEQ ID NO: 8:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 30 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

5

(ii) MOLECULE TYPE: other nucleic acid

10

(A) DESCRIPTION: /desc = "synthetic DNA"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8:

15

TGTTGGATCC CTGCAGAGAC AGTGACCAGA

30

20

(2) INFORMATION FOR SEQ ID NO: 9:

(i) SEQUENCE CHARACTERISTICS:

25

(A) LENGTH: 36 base pairs

(B) TYPE: nucleic acid

30

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

35

(ii) MOLECULE TYPE: other nucleic acid

(A) DESCRIPTION: /desc = "synthetic DNA"

40

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9:

GTCTGAATTC AAGCTTCCAC CATGGGGTTT GGGCTG

36

45

(2) INFORMATION FOR SEQ ID NO: 10:

50

(i) SEQUENCE CHARACTERISTICS:

55

(A) LENGTH: 41 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(A) DESCRIPTION: /desc = "synthetic DNA"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10:

TTTCCCGGGC CCTTGGTGA GGCTGAGGAG ACGGTGACCA G

41

(2) INFORMATION FOR SEQ ID NO: 11:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 109 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(A) DESCRIPTION: /desc = "synthetic DNA"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11:

GTCTGAATTC AAGCTTAGTA CTGCGCCAGC CCAAGGCCAA CCCCACGGTC ACCCTGTTCC

60

CGCCCTCCTC TGAGGAGCTC CAAGCCAACA AGGCCACACT AGTGTGTCT

109

(2) INFORMATION FOR SEQ ID NO: 12:

5

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 110 base pairs

10

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

15

(ii) MOLECULE TYPE: other nucleic acid

(A) DESCRIPTION: /desc = "synthetic DNA"

20

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12:

25

GGTTTGGTGG TCTCCACTCC CGCCTTGACG GGGCTGCCAT CTGCCTTCCA GGCCACTGTC 60

ACAGCTCCCG GGTAGAAGTC ACTGATCAGA CACACTAGTG TGGCCTTGTT 110

30

(2) INFORMATION FOR SEQ ID NO: 13:

35

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 98 base pairs

40

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

45

(ii) MOLECULE TYPE: other nucleic acid

(A) DESCRIPTION: /desc = "synthetic DNA"

50

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 13:

55

GGAGTGGAGA CCACCAAACC CTCCAAACAG AGCAACAACA AGTACGCGGC CAGCAGCTAC 60  
 CTGAGCCTGA CGCCCGAGCA GTGGAAGTCC CACAGAAG 98

5

10

(2) INFORMATION FOR SEQ ID NO: 14:

15

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 106 base pairs

(B) TYPE: nucleic acid

20

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

25

(ii) MOLECULE TYPE: other nucleic acid

(A) DESCRIPTION: /desc = "synthetic DNA"

30

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 14:

TGTTGAATTC TTACTATGAA CATTCTGTAG GGGCCACTGT CTTCTCCACG GTGCTCCCTT 60  
 CATGCGTGAC CTGGCAGCTG TAGCTTCTGT GGGACTTCCA CTGCTC 106

35

40

(2) INFORMATION FOR SEQ ID NO: 15:

45

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 43 base pairs

(B) TYPE: nucleic acid

50

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

55



(ii) MOLECULE TYPE: other nucleic acid

(A) DESCRIPTION: /desc = "synthetic DNA"

5

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 15:

10

GTCTGAATTC AAGCTTAGTA CTTGGCCAGC CCAAGGCCAA CCC

43

15

(2) INFORMATION FOR SEQ ID NO: 16:

(i) SEQUENCE CHARACTERISTICS:

20

(A) LENGTH: 20 base pairs

(B) TYPE: nucleic acid

25

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

30

(ii) MOLECULE TYPE: other nucleic acid

(A) DESCRIPTION: /desc = "synthetic DNA"

35

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 16:

TGTTGAATTC TTACTATGAA

20

40

(2) INFORMATION FOR SEQ ID NO: 17:

45

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 39 base pairs

50

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

55

(D) TOPOLOGY: linear

5

(ii) MOLECULE TYPE: other nucleic acid

(A) DESCRIPTION: /desc = "synthetic DNA"

10

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 17:

CAACAAGTAC GCGGCCAGCA GCTACCTGAG CCTGACGCC

39

15

(2) INFORMATION FOR SEQ ID NO: 18:

20

(i) SEQUENCE CHARACTERISTICS:

25

(A) LENGTH: 39 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

30

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

35

(A) DESCRIPTION: /desc = "synthetic DNA"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 18:

40

GTAGCTGCTG GCCGCGTACT TGTGTGTGCT CTGTTTGA

39

45

(2) INFORMATION FOR SEQ ID NO: 19:

50

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 46 base pairs

55

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(A) DESCRIPTION: /desc = "synthetic DNA"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 19:

GTCTGAATTC AAGCTTAGTC CTAGGTCGAA CTGTGGCTGC ACCATC

46

(2) INFORMATION FOR SEQ ID NO: 20:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 34 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(A) DESCRIPTION: /desc = "synthetic DNA"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 20:

TGTTGAATTC TTACTAACAC TCTCCCTGT TGAA

34

(2) INFORMATION FOR SEQ ID NO: 21:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 35 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(A) DESCRIPTION: /desc = "synthetic DNA"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 21:

GTCTAAGCTT CCACCATGGC CTGGACTCCT CTCTT

35

(2) INFORMATION FOR SEQ ID NO: 22:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 48 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(A) DESCRIPTION: /desc = "synthetic DNA"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 22:

TGTTGAATTC AGATCTAACT ACTTACCTAG GACAGTGACC TTGGTCCC

48

(2) INFORMATION FOR SEQ ID NO: 23:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 128 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(A) DESCRIPTION: /desc = "synthetic DNA"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 23:

GTCTAAGCTT CCACCATGGG GTTTGGGCTG AGCTGGGTTT TCCTCGTTGC TCTTTTAAGA 60  
GGTGTCCAGT GTCAGGTGCA GCTGGTGGAG TCTGGGGGAG GCGTGGTCCA GCCTGGGAGG 120  
TCCCTGAG 128

(2) INFORMATION FOR SEQ ID NO: 24:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 125 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(A) DESCRIPTION: /desc = "synthetic DNA"

## EP 0 962 467 A1

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 24:

5 ACCATTAGTA GTGGTGGTAG TTACACCTAC TATCCAGACA GTGTGAAGGG GCGATTCACC 60  
ATCTCCAGAG ACAATTCCAA GAACACGCTG TATCTGCAA TGAACAGCCT GAGAGCTGAG 120  
GACAC 125

10

(2) INFORMATION FOR SEQ ID NO: 25:

15

(i) SEQUENCE CHARACTERISTICS:

20 (A) LENGTH: 132 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
25 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

30 (A) DESCRIPTION: /desc = "synthetic DNA"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 25:

35 CTACCACCAC TACTAATGGT TGCCACCAC TCCAGCCCCT TGCCTGGAGC CTGGCGGACC 60  
CAAGACATGC CATAGCTACT GAAGGTGAAT CCAGAGGCTG CACAGGAGAG TCTCAGGGAC 120  
40 CTCCCAGGCT GG 132

40

45 (2) INFORMATION FOR SEQ ID NO: 26:

(i) SEQUENCE CHARACTERISTICS:

50 (A) LENGTH: 110 base pairs  
(B) TYPE: nucleic acid

55

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(A) DESCRIPTION: /desc = "synthetic DNA"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 26:

TGTTGGATCC CTGAGGAGAC GGTGACCAGG GTTCCCTGGC CCCAGTAAGC AAAGTAAGTC 60  
 ATAGTAGTCT GTCTCGCACA GTAATACACA GCCGTGTCCT CAGCTCTCAG 110

(2) INFORMATION FOR SEQ ID NO: 27:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 30 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(A) DESCRIPTION: /desc = "synthetic DNA"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 27:

GTCTAAGCTT CCACCATGGG GTTTGGGCTG 30

(2) INFORMATION FOR SEQ ID NO: 28:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 30 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(A) DESCRIPTION: /desc = "synthetic DNA"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 28:

TGTTGGATCC CTGAGGAGAC GGTGACCAGG

30

(2) INFORMATION FOR SEQ ID NO: 29:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 133 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(A) DESCRIPTION: /desc = "synthetic DNA"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 29:

ACAAAGCTTC CACCATGGCC TGGACTCCTC TCTTCTTCTT CTTTGTCTT CATGCTCAG 60

GTTCCTTCTC CCAGCTTGTG CTGACTCAAT CGCCCTCTGC CTCTGCCTCC CTGGGAGCCT 120

CGGTCAAGCT CAC 133



(2) INFORMATION FOR SEQ ID NO: 30:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 118 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(A) DESCRIPTION: /desc = "synthetic DNA"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 30:

AGCAAGATGG AAGCCACAGC ACAGGTGATG GGATTCCTGA TCGCTTCTCA GGCTCCAGCT 60  
CTGGGGCTGA GCGCTACCTC ACCATCTCCA GCCTCCAGTC TGAGGATGAG GCTGACTA 118

(2) INFORMATION FOR SEQ ID NO: 31:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 128 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(A) DESCRIPTION: /desc = "synthetic DNA"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 31:

5 CTGTGGCTTC CATCTTGCTT AAGTTTCATC AAGTACCGAG GGCCCTTCTC TGGCTGCTGC 60  
 TGATGCCATT CAATGGTGTA CGTACTGTGC TGACTACTCA AGGTGCAGGT GAGCTTGACC 120  
 GAGGCTCC 128  
 10

(2) INFORMATION FOR SEQ ID NO: 32:

15

(i) SEQUENCE CHARACTERISTICS:

20

(A) LENGTH: 114 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

25

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

30

(A) DESCRIPTION: /desc = "synthetic DNA"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 32:

35

CTTGATCOG GGCTGACCTA GGACGGTCAG TTTGGTCCCT CCGCCGAACA CCCTCACAAA 60  
 TTGTTCCCTTA ATTGTATCAC CCACACCACA GTAATAGTCA GCCTCATCCT CAGA 114  
 40

(2) INFORMATION FOR SEQ ID NO: 33:

45

(i) SEQUENCE CHARACTERISTICS:

50

(A) LENGTH: 17 base pairs

(B) TYPE: nucleic acid

55

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

5

(ii) MOLECULE TYPE: other nucleic acid

10

(A) DESCRIPTION: /desc = "synthetic DNA"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 33:

15

ACAAAGCTTC CACCATG

17

20

(2) INFORMATION FOR SEQ ID NO: 34:

(i) SEQUENCE CHARACTERISTICS:

25

(A) LENGTH: 19 base pairs

(B) TYPE: nucleic acid

30

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

35

(ii) MOLECULE TYPE: other nucleic acid

(A) DESCRIPTION: /desc = "synthetic DNA"

40

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 34:

CTTGGATCCG GGCTGACCT

19

45

(2) INFORMATION FOR SEQ ID NO: 35:

50

(i) SEQUENCE CHARACTERISTICS:

55

(A) LENGTH: 75 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(A) DESCRIPTION: /desc = "synthetic DNA"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 35:

CTTGATCCG GGCTGACCTA GGACGGTCAG TTGGTCCCT CCGCCGAACA CGTACACAAA 60  
TTGTTCCTTA ATTGT 75

(2) INFORMATION FOR SEQ ID NO: 36:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 43 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(A) DESCRIPTION: /desc = "synthetic DNA"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 36:

AAAGGATCCT TAAGATCCAT CAAGTACCGA GGGGGCTTCT CTG 43

(2) INFORMATION FOR SEQ ID NO: 37:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 46 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(A) DESCRIPTION: /desc = "synthetic DNA"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 37:

ACAAAGCTTA GCGCTACCTC ACCATCTCCA GCCTCCAGCC TGAGGA

46

(2) INFORMATION FOR SEQ ID NO: 38:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 111 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(A) DESCRIPTION: /desc = "synthetic DNA"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 38:

CTTGATCCG GGCTGACCTA GGACGGTCAG TTTGGTCCCT CCGCCGAACA CGTACACAAA

60

TTGTTCTTA ATTGTATCAC CCACACCACA GATATAGTCA GCCTCATCCT C

111

5

(2) INFORMATION FOR SEQ ID NO: 39:

10

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 42 base pairs

15

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

20

(ii) MOLECULE TYPE: other nucleic acid

25

(A) DESCRIPTION: /desc = "synthetic DNA"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 39:

30

CTTCTCTGGC TGCTGCTGAT ACCATTCAAT GGTGTACGTA CT

42

35

(2) INFORMATION FOR SEQ ID NO: 40:

40

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 26 base pairs

(B) TYPE: nucleic acid

45

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

50

(ii) MOLECULE TYPE: other nucleic acid

(A) DESCRIPTION: /desc = "synthetic DNA"

55

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 40:

5 CGAGGGCCCT TCTCTGGCTG CTGCTG

26

10 (2) INFORMATION FOR SEQ ID NO: 41:

15 (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 35 base pairs

(B) TYPE: nucleic acid

20 (C) STRANDEDNESS: single

(D) TOPOLOGY: linear

25 (ii) MOLECULE TYPE: other nucleic acid

(A) DESCRIPTION: /desc = "synthetic DNA"

30

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 41:

35 GAGAAGGGCC CTARGTACST GATGRAWCTT AAGCA

35

40 (2) INFORMATION FOR SEQ ID NO: 42:

45 (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 35 base pairs

(B) TYPE: nucleic acid

50 (C) STRANDEDNESS: single

(D) TOPOLOGY: linear

55

(ii) MOLECULE TYPE: other nucleic acid

(A) DESCRIPTION: /desc = "synthetic DNA"

5

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 42:

10

CACGAATTCA CTATCGATTG TGGAACTTC AGAGG

35

15

(2) INFORMATION FOR SEQ ID NO: 43:

(i) SEQUENCE CHARACTERISTICS:

20

(A) LENGTH: 18 base pairs

(B) TYPE: nucleic acid

25

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

30

(ii) MOLECULE TYPE: other nucleic acid

(A) DESCRIPTION: /desc = "synthetic DNA"

35

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 43:

GGCTTGGAGC TCCTCAGA

18

40

(2) INFORMATION FOR SEQ ID NO: 44:

45

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20 base pairs

50

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

55



(D) TOPOLOGY: linear

5

(ii) MOLECULE TYPE: other nucleic acid

(A) DESCRIPTION: /desc = "synthetic DNA"

10

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 44:

GACAGTGGTT CAAAGTTTTT

20

15

(2) INFORMATION FOR SEQ ID NO: 45:

20

(i) SEQUENCE CHARACTERISTICS:

25

(A) LENGTH: 118 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

30

(ii) MOLECULE TYPE: protein

35

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 45:

Gln Leu Val Leu Thr Gln Ser Ser Ser Ala Ser Phe Ser Leu Gly

40

1 5 10 15

Ala Ser Ala Lys Leu Thr Cys Thr Leu Ser Ser Gln His Ser Thr

20 25 30

45

Tyr Thr Ile Glu Trp Tyr Gln Gln Gln Pro Leu Lys Pro Pro Lys

35 40 45

Tyr Val Met Asp Leu Lys Gln Asp Gly Ser His Ser Thr Gly Asp

50

50 55 60

Gly Ile Pro Asp Arg Phe Ser Gly Ser Ser Ser Gly Ala Asp Arg

55

# EP 0 962 467 A1

5  
10  
15  
20  
25  
30  
35  
40  
45  
50  
55

65 70 75  
Tyr Leu Ser Ile Ser Asn Ile Gln Pro Glu Asp Glu Ala Met Tyr  
80 85 90  
Ile Cys Gly Val Gly Asp Thr Ile Lys Glu Gln Phe Val Tyr Val  
95 100 105  
Phe Gly Gly Gly Thr Lys Val Thr Val Leu Gly Gln Pro  
110 115

(2) INFORMATION FOR SEQ ID NO: 46:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 118 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 46:

Glu Val Gln Leu Val Glu Ser Gly Gly Asp Leu Val Lys Pro Gly  
1 5 10 15  
Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser  
20 25 30  
Ser Tyr Gly Met Ser Trp Ile Arg Gln Thr Pro Asp Lys Arg Leu  
35 40 45  
Glu Trp Val Ala Thr Ile Ser Ser Gly Gly Ser Tyr Thr Tyr Tyr  
50 55 60  
Pro Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala

**EP 0 962 467 A1**

5

(2) INFORMATION FOR SEQ ID NO: 47:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 116 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 47:

Gln Leu Val Leu Thr Gln Ser Pro Ser Ala Ser Ala Ser Leu Gly

1                      5                      10                      15

Ala Ser Val Lys Leu Thr Cys Thr Leu Ser Ser Gln His Ser Thr

20                      25                      30

Tyr Thr Ile Glu Trp His Gln Gln Gln Pro Glu Lys Gly Pro Arg

35                      40                      45

Tyr Leu Met Lys Leu Lys Gln Asp Gly Ser His Ser Thr Gly Asp

50                      55                      60

Gly Ile Pro Asp Arg Phe Ser Gly Ser Ser Ser Gly Ala Glu Arg

75

# EP 0 962 467 A1

5 Tyr Leu Thr Ile Ser Ser Leu Gln Ser Glu Asp Glu Ala Asp Tyr  
 80 85 90  
 Tyr Cys Gly Val Gly Asp Thr Ile Lys Glu Gln Phe Val Tyr Val  
 10 95 100 105  
 Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly  
 110 115

15

(2) INFORMATION FOR SEQ ID NO: 48:

20

(i) SEQUENCE CHARACTERISTICS:

25

(A) LENGTH: 118 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

30

(ii) MOLECULE TYPE: protein

35

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 48:

Gln Leu Val Leu Thr Gln Ser Pro Ser Ala Ser Ala Ser Leu Gly  
 1 5 10 15  
 Ala Ser Val Lys Leu Thr Cys Thr Leu Ser Ser Gln His Ser Thr  
 20 25 30  
 Tyr Thr Ile Glu Trp Tyr Gln Gln Gln Pro Glu Lys Gly Pro Lys  
 35 40 45  
 Tyr Leu Met Asp Leu Lys Gln Asp Gly Ser His Ser Thr Gly Asp  
 50 55 60  
 Gly Ile Pro Asp Arg Phe Ser Gly Ser Ser Ser Gly Ala Glu Arg

55

# EP 0 962 467 A1

5  
10  
15

65 70 75  
Tyr Leu Thr Ile Ser Ser Leu Gln Ser Glu Asp Glu Ala Asp Tyr  
80 85 90  
Tyr Cys Gly Val Gly Asp Thr Ile Lys Glu Gln Phe Val Tyr Val  
95 100 105  
Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gln Pro  
110 115

(2) INFORMATION FOR SEQ ID NO: 49:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 118 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 49:

40  
45  
50  
55

Gln Leu Val Leu Thr Gln Ser Pro Ser Ala Ser Ala Ser Leu Gly  
1 5 10 15  
Ala Ser Val Lys Leu Thr Cys Thr Leu Ser Ser Gln His Ser Thr  
20 25 30  
Tyr Thr Ile Glu Trp Tyr Gln Gln Gln Pro Glu Lys Gly Pro Lys  
35 40 45  
Tyr Val Met Asp Leu Lys Gln Asp Gly Ser His Ser Thr Gly Asp  
50 55 60  
Gly Ile Pro Asp Arg Phe Ser Gly Ser Ser Ser Gly Ala Glu Arg

# EP 0 962 467 A1

5 Tyr Leu Thr Ile Ser Ser Leu Gln Ser Glu Asp Glu Ala Asp Tyr  
 80 85 90  
 Tyr Cys Gly Val Gly Asp Thr Ile Lys Glu Gln Phe Val Tyr Val  
 10 95 100 105  
 Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gln Pro  
 110 115

15

(2) INFORMATION FOR SEQ ID NO: 50:

20

(i) SEQUENCE CHARACTERISTICS:

25

(A) LENGTH: 118 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

30

(ii) MOLECULE TYPE: protein

35

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 50:

40

Gln Leu Val Leu Thr Gln Ser Pro Ser Ala Ser Ala Ser Leu Gly

1 5 10 15

Ala Ser Val Lys Leu Thr Cys Thr Leu Ser Ser Gln His Ser Thr

20 25 30

45

Tyr Thr Ile Glu Trp Tyr Gln Gln Gln Pro Glu Lys Gly Pro Arg

35 40 45

Tyr Leu Met Asp Leu Lys Gln Asp Gly Ser His Ser Thr Gly Asp

50

50 55 60

Gly Ile Pro Asp Arg Phe Ser Gly Ser Ser Ser Gly Ala Glu Arg

55

# EP 0 962 467 A1

5 Tyr Leu Thr Ile Ser Ser Leu Gln Ser Glu Asp Glu Ala Asp Tyr  
 80 85 90  
 Tyr Cys Gly Val Gly Asp Thr Ile Lys Glu Gln Phe Val Tyr Val  
 10 95 100 105  
 Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gln Pro  
 110 115  
 15

(2) INFORMATION FOR SEQ ID NO: 51:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 118 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 51:

Gln Leu Val Leu Thr Gln Ser Pro Ser Ala Ser Ala Ser Leu Gly  
 1 5 10 15  
 Ala Ser Val Lys Leu Thr Cys Thr Leu Ser Ser Gln His Ser Thr  
 20 25 30  
 Tyr Thr Ile Glu Trp Tyr Gln Gln Gln Pro Glu Lys Gly Pro Arg  
 35 40 45  
 Tyr Val Met Asp Leu Lys Gln Asp Gly Ser His Ser Thr Gly Asp  
 50 55 60  
 Gly Ile Pro Asp Arg Phe Ser Gly Ser Ser Ser Gly Ala Glu Arg

# EP 0 962 467 A1

5  
10  
15  
20  
25  
30  
35  
40  
45  
50  
55

65 70 75  
Tyr Leu Thr Ile Ser Ser Leu Gln Ser Glu Asp Glu Ala Asp Tyr  
80 85 90  
Tyr Cys Gly Val Gly Asp Thr Ile Lys Glu Gln Phe Val Tyr Val  
95 100 105  
Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gln Pro  
110 115

(2) INFORMATION FOR SEQ ID NO: 52:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 118 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 52:

Gln Leu Val Leu Thr Gln Ser Pro Ser Ala Ser Ala Ser Leu Gly  
1 5 10 15  
Ala Ser Val Lys Leu Thr Cys Thr Leu Ser Ser Gln His Ser Thr  
20 25 30  
Tyr Thr Ile Glu Trp Tyr Gln Gln Gln Pro Glu Lys Gly Pro Lys  
35 40 45  
Tyr Leu Met Asp Leu Lys Gln Asp Gly Ser His Ser Thr Gly Asp  
50 55 60  
Gly Ile Pro Asp Arg Phe Ser Gly Ser Ser Ser Gly Ala Glu Arg



**EP 0 962 467 A1**

5

74

20

25

25

30

35

40

40

45

43

43

50

50

55

# EP 0 962 467 A1

5 Tyr Leu Thr Ile Ser Ser Leu Gln Ser Glu Asp Glu Ala Asp Tyr  
 80 85 90  
 10 Ile Cys Gly Val Gly Asp Thr Ile Lys Glu Gln Phe Val Tyr Val  
 95 100 105  
 Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gln Pro  
 110 115

15

(2) INFORMATION FOR SEQ ID NO: 54:

20

(i) SEQUENCE CHARACTERISTICS:

25

(A) LENGTH: 118 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

30

(ii) MOLECULE TYPE: protein

35

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 54:

40

Gln Leu Val Leu Thr Gln Ser Pro Ser Ala Ser Ala Ser Leu Gly

1 5 10 15

Ala Ser Val Lys Leu Thr Cys Thr Leu Ser Ser Gln His Ser Thr

20 25 30

45

Tyr Thr Ile Glu Trp Tyr Gln Gln Gln Pro Glu Lys Gly Pro Lys

35 40 45

Tyr Val Met Asp Leu Lys Gln Asp Gly Ser His Ser Thr Gly Asp

50

50 55 60

Gly Ile Pro Asp Arg Phe Ser Gly Ser Ser Ser Gly Ala Glu Arg

55

# EP 0 962 467 A1

5 Tyr Leu Thr Ile Ser Ser Leu Gln Ser Glu Asp Glu Ala Asp Tyr  
 80 85 90  
 10 Ile Cys Gly Val Gly Asp Thr Ile Lys Glu Gln Phe Val Tyr Val  
 95 100 105  
 Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gln Pro  
 110 115  
 15

(2) INFORMATION FOR SEQ ID NO: 55:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 118 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 55:

Gln Leu Val Leu Thr Gln Ser Pro Ser Ala Ser Ala Ser Leu Gly  
 1 5 10 15  
 40 Ala Ser Val Lys Leu Thr Cys Thr Leu Ser Ser Gln His Ser Thr  
 20 25 30  
 45 Tyr Thr Ile Glu Trp Tyr Gln Gln Gln Pro Glu Lys Gly Pro Arg  
 35 40 45  
 Tyr Val Met Asp Leu Lys Gln Asp Gly Ser His Ser Thr Gly Asp  
 50 55 60  
 Gly Ile Pro Asp Arg Phe Ser Gly Ser Ser Ser Gly Ala Glu Arg

# EP 0 962 467 A1

65 70 75  
 Tyr Leu Thr Ile Ser Ser Leu Gln Ser Glu Asp Glu Ala Asp Tyr  
 5  
 80 85 90  
 Ile Cys Gly Val Gly Asp Thr Ile Lys Glu Gln Phe Val Tyr Val  
 10  
 95 100 105  
 Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gln Pro  
 110 115

15

(2) INFORMATION FOR SEQ ID NO: 56:

20

(i) SEQUENCE CHARACTERISTICS:

25

(A) LENGTH: 118 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

30

(ii) MOLECULE TYPE: protein

35

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 56:

40

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly

1 5 10 15

Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser

20 25 30

45

Ser Tyr Gly Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu

35 40 45

Glu Trp Val Ala Thr Ile Ser Ser Gly Gly Ser Tyr Thr Tyr Tyr

50

50 55 60

Pro Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser

55

# EP 0 962 467 A1

65 70 75  
 Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp  
 5 80 85 90  
 Thr Ala Val Tyr Tyr Cys Ala Arg Gln Thr Thr Met Thr Tyr Phe  
 10 95 100 105  
 Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser  
 110 115

15

(2) INFORMATION FOR SEQ ID NO: 57:

20

(i) SEQUENCE CHARACTERISTICS:

25

(A) LENGTH: 411 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

30

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA to mRNA

35

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 57:

40

ATG AAC TTC GGG CTC AGC TTG ATT TTC CTT GCC CTC ATT TTA AAA 45

Met Asn Phe Gly Leu Ser Leu Ile Phe Leu Ala Leu Ile Leu Lys

-15 -10 -5

45

GGT GTC CAG TGT GAG GTG CAA CTG GTG GAG TCT GGG GGA GAC TTA 90

Gly Val Gln Cys Glu Val Gln Leu Val Glu Ser Gly Gly Asp Leu

1 5 10

50

GTG AAG CCT GGA GGG TCC CTG AAA CTC TCC TGT GCA GCC TCT GGA 135

Val Lys Pro Gly Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly

55

# EP 0 962 467 A1

15                      20                      25  
 5                      TTC ACT TTC AGT AGC TAT GGC ATG TCT TGG ATT CGC CAG ACT CCA 180  
                     Phe Thr Phe Ser Ser Tyr Gly Met Ser Trp Ile Arg Gln Thr Pro  
                     30                      35                      40  
 10                      GAC AAG AGG CTG GAG TGG GTC GCA ACC ATT AGT AGT GGT GGT AGT 225  
                     Asp Lys Arg Leu Glu Trp Val Ala Thr Ile Ser Ser Gly Gly Ser  
                     45                      50                      55  
 15                      TAC ACC TAC TAT CCA GAC AGT GTG AAG GGG CGA TTC ACC ATC TCC 270  
                     Tyr Thr Tyr Tyr Pro Asp Ser Val Lys Gly Arg Phe Thr Ile Ser  
                     60                      65                      70  
 20                      AGA GAC AAT GCC AAG AAC ACC CTA TAC CTG CAA ATG AGC AGT CTG 315  
                     Arg Asp Asn Ala Lys Asn Thr Leu Tyr Leu Gln Met Ser Ser Leu  
                     75                      80                      85  
 25                      AAG TCT GAG GAC ACA GCC ATG TTT TAC TGT GCA AGA CAG ACT ACT 360  
                     Lys Ser Glu Asp Thr Ala Met Phe Tyr Cys Ala Arg Gln Thr Thr  
                     90                      95                      100  
 30                      ATG ACT TAC TTT GCT TAC TGG GGC CAA GGG ACT CTG GTC ACT GTC 405  
                     Met Thr Tyr Phe Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val  
                     105                      110                      115  
 35                      TCT GCA 411  
                     Ser Ala  
 40

(2) INFORMATION FOR SEQ ID NO: 58:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 411 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

5

(ii) MOLECULE TYPE: cDNA to mRNA

10

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 58:

15

ATG GGG TTT GGG CTG AGC TGG GTT TTC CTC GTT GCT CTT TTA AGA 45

Met Gly Phe Gly Leu Ser Trp Val Phe Leu Val Ala Leu Leu Arg

-15 -10 -5

20

GGT GTC CAG TGT CAG GTG CAG CTG GTG GAG TCT GGG GGA GGC GTG 90

Gly Val Gln Cys Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val

1 5 10

25

GTC CAG CCT GGG AGG TCC CTG AGA CTC TCC TGT GCA GCC TCT GGA 135

Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly

15 20 25

30

TTC ACC TTC AGT AGC TAT GGC ATG TCT TGG GTC CGC CAG GCT CCA 180

Phe Thr Phe Ser Ser Tyr Gly Met Ser Trp Val Arg Gln Ala Pro

30 35 40

35

GGC AAG GGG CTG GAG TGG GTG GCA ACC ATT AGT AGT GGT GGT AGT 225

Gly Lys Gly Leu Glu Trp Val Ala Thr Ile Ser Ser Gly Gly Ser

45 50 55

40

TAC ACC TAC TAT CCA GAC AGT GTG AAG GGG CGA TTC ACC ATC TCC 270

Tyr Thr Tyr Tyr Pro Asp Ser Val Lys Gly Arg Phe Thr Ile Ser

60 65 70

45

AGA GAC AAT TCC AAG AAC ACG CTG TAT CTG CAA ATG AAC AGC CTG 315

Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu

75 80 85

50

AGA GCT GAG GAC ACG GCT GTG TAT TAC TGT GCG AGA CAG ACT ACT 360

Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gln Thr Thr

55

# EP 0 962 467 A1

90 95 100  
 5 ATG ACT TAC TTT GCT TAC TGG GGC CAG GGA ACC CTG GTC ACC GTC 405  
 Met Thr Tyr Phe Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val  
 105 110 115  
 10 TCC TCA 411  
 Ser Ser

15  
 (2) INFORMATION FOR SEQ ID NO: 59:

20 (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 11 amino acids  
 25 (B) TYPE: amino acid  
 (D) TOPOLOGY: linear

30 (ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 59:  
 35 Lys Ala Ser Gln Asp Val Asn Thr Ala Val Ala  
 1 5 10

40  
 (2) INFORMATION FOR SEQ ID NO: 60:

45 (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 7 amino acids  
 50 (B) TYPE: amino acid  
 (D) TOPOLOGY: linear

55



(ii) MOLECULE TYPE: peptide

5

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 60:

Ser Ala Ser Asn Arg Tyr Thr

10

1 5

15

(2) INFORMATION FOR SEQ ID NO: 61:

20

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 9 amino acids

(B) TYPE: amino acid

25

(D) TOPOLOGY: linear

30

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 61:

35

Gln Gln His Tyr Ser Thr Pro Phe Thr

1 5

40

(2) INFORMATION FOR SEQ ID NO: 62:

45

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 5 amino acids

50

(B) TYPE: amino acid

(D) TOPOLOGY: linear

55

(ii) MOLECULE TYPE: peptide

5

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 62:

Pro Tyr Trp Met Gln

10

1 5

15

(2) INFORMATION FOR SEQ ID NO: 63:

20

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 16 amino acids

(B) TYPE: amino acid

25

(D) TOPOLOGY: linear

30

(ii) MOLECULE TYPE: peptide

35

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 63:

Ser Ile Phe Gly Asp Gly Asp Thr Arg Tyr Ser Gln Lys Phe Lys Gly

1 5 10 15

40

(2) INFORMATION FOR SEQ ID NO: 64:

45

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 11 amino acids

50

(B) TYPE: amino acid

(D) TOPOLOGY: linear

55

(ii) MOLECULE TYPE: peptide

5

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 64:

Gly Leu Arg Arg Gly Gly Tyr Tyr Phe Asp Tyr

10

1 5 10

15

(2) INFORMATION FOR SEQ ID NO: 65:

20

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 411 base pairs

(B) TYPE: nucleic acid

25

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

30

(ii) MOLECULE TYPE: cDNA to mRNA

35

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 65:

ATG GCC TGG ACT CCT CTC TTC TTC TTT GTT CTT CAT TGC TCA 45

40

Met Ala Trp Thr Pro Leu Phe Phe Phe Phe Val Leu His Cys Ser

-15 -10 -5

GGT TCT TTC TCC CAA CTT GTG CTC ACT CAG TCA TCT TCA GCC TCT 90

45

Gly Ser Phe Ser Gln Leu Val Leu Thr Gln Ser Ser Ser Ala Ser

1 5 10

TTC TCC CTG GGA GCC TCA GCA AAA CTC ACG TGC ACC TTG AGT AGT 135

50

Phe Ser Leu Gly Ala Ser Ala Lys Leu Thr Cys Thr Leu Ser Ser

15 20 25

55

# EP 0 962 467 A1

5 CAG CAC AGT ACG TAC ACC ATT GAA TGG TAT CAG CAA CAG CCA CTC 180  
Gln His Ser Thr Tyr Thr Ile Glu Trp Tyr Gln Gln Gln Pro Leu  
30 35 40

10 AAG CCT CCT AAG TAT GTG ATG GAT CTT AAG CAA GAT GGA AGC CAC 225  
Lys Pro Pro Lys Tyr Val Met Asp Leu Lys Gln Asp Gly Ser His  
45 50 55

15 AGC ACA GGT GAT GGG ATT CCT GAT CGC TTC TCT GGA TCC AGC TCT 270  
Ser Thr Gly Asp Gly Ile Pro Asp Arg Phe Ser Gly Ser Ser Ser  
60 65 70

20 GGT GCT GAT CGC TAC CTT AGC ATT TCC AAC ATC CAG CCA GAA GAT 315  
Gly Ala Asp Arg Tyr Leu Ser Ile Ser Asn Ile Gln Pro Glu Asp  
75 80 85

25 GAA GCA ATG TAC ATC TGT GGT GTG GGT GAT ACA ATT AAG GAA CAA 360  
Glu Ala Met Tyr Ile Cys Gly Val Gly Asp Thr Ile Lys Glu Gln  
90 95 100

30 TTT GTG TAT GTT TTC GGC GGT GGG ACC AAG GTC ACT GTC CTA GGT 405  
Phe Val Tyr Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu Gly  
105 110 115

35 CAG CCC 411  
Gln Pro

(2) INFORMATION FOR SEQ ID NO: 66:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 405 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

5

(ii) MOLECULE TYPE: cDNA to mRNA

10

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 66:

15

ATG GCC TGG ACT CCT CTC TTC TTC TTC TTT GTT CTT CAT TGC TCA 45

Met Ala Trp Thr Pro Leu Phe Phe Phe Phe Val Leu His Cys Ser

-15 -10 -5

20

GGT TCT TTC TCC CAG CTT GTG CTG ACT CAA TCG CCC TCT GCC TCT 90

Gly Ser Phe Ser Gln Leu Val Leu Thr Gln Ser Pro Ser Ala Ser

1 5 10

25

GCC TCC CTG GGA GCC TCG GTC AAG CTC ACC TGC ACC TTG AGT AGT 135

Ala Ser Leu Gly Ala Ser Val Lys Leu Thr Cys Thr Leu Ser Ser

15 20 25

30

CAG CAC AGT ACG TAC ACC ATT GAA TGG CAT CAG CAG CAG CCA GAG 180

Gln His Ser Thr Tyr Thr Ile Glu Trp His Gln Gln Gln Pro Glu

30 35 40

35

AAG GGC CCT CGG TAC TTG ATG AAA CTT AAG CAA GAT GGA AGC CAC 225

Lys Gly Pro Arg Tyr Leu Met Lys Leu Lys Gln Asp Gly Ser His

45 50 55

40

AGC ACA GGT GAT GGG ATT CCT GAT CGC TTC TCA GGC TCC AGC TCT 270

Ser Thr Gly Asp Gly Ile Pro Asp Arg Phe Ser Gly Ser Ser Ser

60 65 70

45

GGG GCT GAG CGC TAC CTC ACC ATC TCC AGC CTC CAG TCT GAG GAT 315

Gly Ala Glu Arg Tyr Leu Thr Ile Ser Ser Leu Gln Ser Glu Asp

75 80 85

50

GAG GCT GAC TAT TAC TGT GGT GTG GGT GAT ACA ATT AAG GAA CAA 360

Glu Ala Asp Tyr Tyr Cys Gly Val Gly Asp Thr Ile Lys Glu Gln

55

# EP 0 962 467 A1

90 95 100  
 TTT GTG TAC GTG TTC GGC GGA GGG ACC AAA CTG ACC GTC CTA GGT 405  
 Phe Val Tyr Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly

105 110 115

(2) INFORMATION FOR SEQ ID NO: 67:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 411 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA to mRNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 67:

ATG GCC TGG ACT CCT CTC TTC TTC TTT GTT CTT CAT TGC TCA 45  
 Met Ala Trp Thr Pro Leu Phe Phe Phe Phe Val Leu His Cys Ser

-15 -10 -5

GGT TCT TTC TCC CAG CTT GTG CTG ACT CAA TCG CCC TCT GCC TCT 90  
 Gly Ser Phe Ser Gln Leu Val Leu Thr Gln Ser Pro Ser Ala Ser

1 5 10

GCC TCC CTG GGA GCC TCG GTC AAG CTC ACC TGC ACC TTG AGT AGT 135  
 Ala Ser Leu Gly Ala Ser Val Lys Leu Thr Cys Thr Leu Ser Ser

15 20 25

CAG CAC AGT ACG TAC ACC ATT GAA TGG TAT CAG CAG CAG CCA GAG 180  
 Gln His Ser Thr Tyr Thr Ile Glu Trp Tyr Gln Gln Gln Pro Glu

# EP 0 962 467 A1

5  
 30 35 40  
 AAG GGC CCT AAG TAC CTG ATG GAT CTT AAG CAA GAT GGA AGC CAC 225  
 Lys Gly Pro Lys Tyr Leu Met Asp Leu Lys Gln Asp Gly Ser His  
 45 50 55  
 10  
 AGC ACA GGT GAT GGG ATT CCT GAT CGC TTC TCA GGC TCC AGC TCT 270  
 Ser Thr Gly Asp Gly Ile Pro Asp Arg Phe Ser Gly Ser Ser Ser  
 60 65 70  
 15  
 GGG GCT GAG CGC TAC CTC ACC ATC TCC AGC CTC CAG TCT GAG GAT 315  
 Gly Ala Glu Arg Tyr Leu Thr Ile Ser Ser Leu Gln Ser Glu Asp  
 75 80 85  
 20  
 GAG GCT GAC TAT TAC TGT GGT GTG GGT GAT ACA ATT AAG GAA CAA 360  
 Glu Ala Asp Tyr Tyr Cys Gly Val Gly Asp Thr Ile Lys Glu Gln  
 90 95 100  
 25  
 TTT GTG TAC GTG TTC GGC GGA GGG ACC AAA CTG ACC GTC CTA GGC 405  
 Phe Val Tyr Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly  
 105 110 115  
 30  
 CAG CCC 411  
 35  
 Gln Pro

40 (2) INFORMATION FOR SEQ ID NO: 68:

- 45 (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 411 base pairs
  - (B) TYPE: nucleic acid
  - 50 (C) STRANDEDNESS: double
  - (D) TOPOLOGY: linear
- 55

# EP 0 962 467 A1

(ii) MOLECULE TYPE: cDNA to mRNA

5

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 68:

10

ATG GCC TGG ACT CCT CTC TTC TTC TTC TTT GTT CTT CAT TGC TCA 45

Met Ala Trp Thr Pro Leu Phe Phe Phe Phe Val Leu His Cys Ser

-15 -10 -5

15

GGT TCT TTC TCC CAG CTT GTG CTG ACT CAA TCG CCC TCT GCC TCT 90

Gly Ser Phe Ser Gln Leu Val Leu Thr Gln Ser Pro Ser Ala Ser

1 5 10

20

GCC TCC CTG GGA GCC TCG GTC AAG CTC ACC TGC ACC TTG AGT AGT 135

Ala Ser Leu Gly Ala Ser Val Lys Leu Thr Cys Thr Leu Ser Ser

15 20 25

25

CAG CAC AGT ACG TAC ACC ATT GAA TGG TAT CAG CAG CAG CCA GAG 180

Gln His Ser Thr Tyr Thr Ile Glu Trp Tyr Gln Gln Gln Pro Glu

30 35 40

30

AAG GGC CCT AAG TAC GTG ATG GAT CTT AAG CAA GAT GGA AGC CAC 225

Lys Gly Pro Lys Tyr Val Met Asp Leu Lys Gln Asp Gly Ser His

45 50 55

35

AGC ACA GGT GAT GGG ATT CCT GAT GGC TTC TCA GGC TCC AGC TCT 270

Ser Thr Gly Asp Gly Ile Pro Asp Arg Phe Ser Gly Ser Ser Ser

60 65 70

40

GGG GCT GAG GGC TAC CTC ACC ATC TCC AGC CTC CAG TCT GAG GAT 315

Gly Ala Glu Arg Tyr Leu Thr Ile Ser Ser Leu Gln Ser Glu Asp

75 80 85

45

GAG GCT GAC TAT TAC TGT GGT GTG GGT GAT ACA ATT AAG GAA CAA 360

Glu Ala Asp Tyr Tyr Cys Gly Val Gly Asp Thr Ile Lys Glu Gln

90 95 100

50

TTT GTG TAC GTG TTC GGC GGA GGG ACC AAA CTG ACC GTC CTA GGC 405

55



Phe Val Tyr Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly

5 105 110 115

CAG CCC 411

Gln Pro

10

(2) INFORMATION FOR SEQ ID NO: 69:

15

(i) SEQUENCE CHARACTERISTICS:

20

(A) LENGTH: 411 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

25

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA to mRNA

30

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 69:

35

ATG GCC TGG ACT CCT CTC TTC TTC TTT GTT CTT CAT TGC TCA 45

Met Ala Trp Thr Pro Leu Phe Phe Phe Phe Val Leu His Cys Ser

-15 -10 -5

40

GGT TCT TTC TCC CAG CTT GTG CTG ACT CAA TCG CCC TCT GCC TCT 90

Gly Ser Phe Ser Gln Leu Val Leu Thr Gln Ser Pro Ser Ala Ser

1 5 10

45

GCC TCC CTG GGA GCC TCG GTC AAG CTC ACC TGC ACC TTG AGT AGT 135

Ala Ser Leu Gly Ala Ser Val Lys Leu Thr Cys Thr Leu Ser Ser

15 20 25

50

CAG CAC AGT ACG TAC ACC ATT GAA TGG TAT CAG CAG CAG CCA GAG 180

Gln His Ser Thr Tyr Thr Ile Glu Trp Tyr Gln Gln Gln Pro Glu

55

EP 0 962 467 A1

5  
 30 35 40  
 AAG GGC CCT AGG TAC CTG ATG GAT CTT AAG CAA GAT GGA AGC CAC 225  
 Lys Gly Pro Arg Tyr Leu Met Asp Leu Lys Gln Asp Gly Ser His  
 45 50 55  
 10 AGC ACA GGT GAT GGG ATT CCT GAT CGC TTC TCA GGC TCC AGC TCT 270  
 Ser Thr Gly Asp Gly Ile Pro Asp Arg Phe Ser Gly Ser Ser Ser  
 60 65 70  
 15 GGG GCT GAG CGC TAC CTC ACC ATC TCC AGC CTC CAG TCT GAG GAT 315  
 Gly Ala Glu Arg Tyr Leu Thr Ile Ser Ser Leu Gln Ser Glu Asp  
 75 80 85  
 20 GAG GCT GAC TAT TAC TGT GGT GTG GGT GAT ACA ATT AAG GAA CAA 360  
 Glu Ala Asp Tyr Tyr Cys Gly Val Gly Asp Thr Ile Lys Glu Gln  
 90 95 100  
 25 TTT GTG TAC GTG TTC GGC GGA GGG ACC AAA CTG ACC GTC CTA GGC 405  
 Phe Val Tyr Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly  
 105 110 115  
 30 CAG CCC 411  
 35 Gln Pro

(2) INFORMATION FOR SEQ ID NO: 70:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 411 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA to mRNA

5

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 70:

10

ATG GCC TGG ACT CCT CTC TTC TTC TTT GTT CTT CAT TGC TCA 45

Met Ala Trp Thr Pro Leu Phe Phe Phe Phe Val Leu His Cys Ser

-15 -10 -5

15

GGT TCT TTC TCC CAG CTT GTG CTG ACT CAA TCG CCC TCT GCC TCT 90

Gly Ser Phe Ser Gln Leu Val Leu Thr Gln Ser Pro Ser Ala Ser

1 5 10

20

GCC TCC CTG GGA GCC TCG GTC AAG CTC ACC TGC ACC TTG AGT AGT 135

Ala Ser Leu Gly Ala Ser Val Lys Leu Thr Cys Thr Leu Ser Ser

15 20 25

25

CAG CAC AGT ACG TAC ACC ATT GAA TGG TAT CAG CAG CAG CCA GAG 180

Gln His Ser Thr Tyr Thr Ile Glu Trp Tyr Gln Gln Gln Pro Glu

30 35 40

30

AAG GGC CCT AGG TAC GTG ATG GAT CTT AAG CAA GAT GGA AGC CAC 225

Lys Gly Pro Arg Tyr Val Met Asp Leu Lys Gln Asp Gly Ser His

45 50 55

35

AGC ACA GGT GAT GGG ATT CCT GAT CGC TTC TCA GGC TCC AGC TCT 270

Ser Thr Gly Asp Gly Ile Pro Asp Arg Phe Ser Gly Ser Ser Ser

60 65 70

40

GGG GCT GAG CGC TAC CTC ACC ATC TCC AGC CTC CAG TCT GAG GAT 315

Gly Ala Glu Arg Tyr Leu Thr Ile Ser Ser Leu Gln Ser Glu Asp

75 80 85

45

GAG GCT GAC TAT TAC TGT GGT GTG GGT GAT ACA ATT AAG GAA CAA 360

Glu Ala Asp Tyr Tyr Cys Gly Val Gly Asp Thr Ile Lys Glu Gln

90 95 100

50

TTT GTG TAC GTG TTC GGC GGA GGG ACC AAA CTG ACC GTC CTA GGC 405

55

# EP 0 962 467 A1

Phe Val Tyr Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly

105

110

115

CAG CCC 411

Gln Pro

(2) INFORMATION FOR SEQ ID NO: 71:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 411 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA to mRNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 71:

ATG GCC TGG ACT CCT CTC TTC TTC TTC TTT GTT CTT CAT TGC TCA 45

Met Ala Trp Thr Pro Leu Phe Phe Phe Phe Val Leu His Cys Ser

-15

-10

-5

GGT TCT TTC TCC CAG CTT GTG CTG ACT CAA TCG CCC TCT GCC TCT 90

Gly Ser Phe Ser Gln Leu Val Leu Thr Gln Ser Pro Ser Ala Ser

1

5

10

GCC TCC CTG GGA GCC TCG GTC AAG CTC ACC TGC ACC TTG AGT AGT 135

Ala Ser Leu Gly Ala Ser Val Lys Leu Thr Cys Thr Leu Ser Ser

15

20

25

CAG CAC AGT ACG TAC ACC ATT GAA TGG TAT CAG CAG CAG CCA GAG 180

Gln His Ser Thr Tyr Thr Ile Glu Trp Tyr Gln Gln Gln Pro Glu

# EP 0 962 467 A1

5  
 10  
 15  
 20  
 25  
 30  
 35

30 35 40  
 AAG GGC CCT AAG TAC CTG ATG GAT CTT AAG CAA GAT GGA AGC CAC 225  
 Lys Gly Pro Lys Tyr Leu Met Asp Leu Lys Gln Asp Gly Ser His  
 45 50 55  
 AGC ACA GGT GAT GGG ATT CCT GAT CGC TTC TCA GGC TCC AGC TCT 270  
 Ser Thr Gly Asp Gly Ile Pro Asp Arg Phe Ser Gly Ser Ser Ser  
 60 65 70  
 GGG GCT GAG CGC TAC CTC ACC ATC TCC AGC CTC CAG TCT GAG GAT 315  
 Gly Ala Glu Arg Tyr Leu Thr Ile Ser Ser Leu Gln Ser Glu Asp  
 75 80 85  
 GAG GCT GAC TAT ATC TGT GGT GTG GGT GAT ACA ATT AAG GAA CAA 360  
 Glu Ala Asp Tyr Ile Cys Gly Val Gly Asp Thr Ile Lys Glu Gln  
 90 95 100  
 TTT GTG TAC GTG TTC GGC GGA GGG ACC AAA CTG ACC GTC CTA GGC 405  
 Phe Val Tyr Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly  
 105 110 115  
 CAG CCC 411  
 Gln Pro

40 (2) INFORMATION FOR SEQ ID NO: 72:

45 (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 411 base pairs  
 (B) TYPE: nucleic acid  
 50 (C) STRANDEDNESS: double  
 (D) TOPOLOGY: linear  
 55

# EP 0 962 467 A1

(ii) MOLECULE TYPE: cDNA to mRNA

5

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 72:

10

ATG GCC TGG ACT CCT CTC TTC TTC TTT GTT CTT CAT TGC TCA 45

Met Ala Trp Thr Pro Leu Phe Phe Phe Phe Val Leu His Cys Ser

-15 -10 -5

15

GGT TCT TTC TCC CAG CTT GTG CTG ACT CAA TCG CCC TCT GCC TCT 90

Gly Ser Phe Ser Gln Leu Val Leu Thr Gln Ser Pro Ser Ala Ser

1 5 10

20

GCC TCC CTG GGA GCC TCG GTC AAG CTC ACC TGC ACC TTG AGT AGT 135

Ala Ser Leu Gly Ala Ser Val Lys Leu Thr Cys Thr Leu Ser Ser

15 20 25

25

CAG CAC AGT ACG TAC ACC ATT GAA TGG TAT CAG CAG CAG CCA GAG 180

Gln His Ser Thr Tyr Thr Ile Glu Trp Tyr Gln Gln Gln Pro Glu

30 35 40

30

AAG GGC CCT AGG TAC CTG ATG GAT CTT AAG CAA GAT GGA AGC CAC 225

Lys Gly Pro Arg Tyr Leu Met Asp Leu Lys Gln Asp Gly Ser His

45 50 55

35

AGC ACA GGT GAT GGG ATT CCT GAT CGC TTC TCA GGC TCC AGC TCT 270

Ser Thr Gly Asp Gly Ile Pro Asp Arg Phe Ser Gly Ser Ser Ser

60 65 70

40

GGG GCT GAG CGC TAC CTC ACC ATC TCC AGC CTC CAG TCT GAG GAT 315

Gly Ala Glu Arg Tyr Leu Thr Ile Ser Ser Leu Gln Ser Glu Asp

75 80 85

45

GAG GCT GAC TAT ATC TGT GGT GTG GGT GAT ACA ATT AAG GAA CAA 360

Glu Ala Asp Tyr Ile Cys Gly Val Gly Asp Thr Ile Lys Glu Gln

90 95 100

50

TTT GTG TAC GTG TTC GGC GGA GGG ACC AAA CTG ACC GTC CTA GGC 405

55

Phe Val Tyr Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly

105 110 115

CAG CCC 411

Gln Pro

(2) INFORMATION FOR SEQ ID NO: 73:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 411 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA to mRNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 73:

ATG GCC TGG ACT CCT CTC TTC TTC TTC TTT GTT CTT CAT TGC TCA 45

Met Ala Trp Thr Pro Leu Phe Phe Phe Phe Val Leu His Cys Ser

-15 -10 -5

GGT TCT TTC TCC CAG CTT GTG CTG ACT CAA TCG CCC TCT GCC TCT 90

Gly Ser Phe Ser Gln Leu Val Leu Thr Gln Ser Pro Ser Ala Ser

1 5 10

GCC TCC CTG GGA GCC TCG GTC AAG CTC ACC TGC ACC TTG AGT AGT 135

Ala Ser Leu Gly Ala Ser Val Lys Leu Thr Cys Thr Leu Ser Ser

15 20 25

CAG CAC AGT ACG TAC ACC ATT GAA TGG TAT CAG CAG CAG CCA GAG 180

Gln His Ser Thr Tyr Thr Ile Glu Trp Tyr Gln Gln Gln Pro Glu

# EP 0 962 467 A1

5  
 30 35 40  
 AAG GGC CCT AAG TAC GTG ATG GAT CTT AAG CAA GAT GGA AGC CAC 225  
 Lys Gly Pro Lys Tyr Val Met Asp Leu Lys Gln Asp Gly Ser His  
 45 50 55  
 10  
 AGC ACA GGT GAT GGG ATT CCT GAT CGC TTC TCA GGC TCC AGC TCT 270  
 Ser Thr Gly Asp Gly Ile Pro Asp Arg Phe Ser Gly Ser Ser Ser  
 60 65 70  
 15  
 GGG GCT GAG CGC TAC CTC ACC ATC TCC AGC CTC CAG TCT GAG GAT 315  
 Gly Ala Glu Arg Tyr Leu Thr Ile Ser Ser Leu Gln Ser Glu Asp  
 75 80 85  
 20  
 GAG GCT GAC TAT ATC TGT GGT GTG GGT GAT ACA ATT AAG GAA CAA 360  
 Glu Ala Asp Tyr Ile Cys Gly Val Gly Asp Thr Ile Lys Glu Gln  
 90 95 100  
 25  
 TTT GTG TAC GTG TTC GGC GGA GGG ACC AAA CTG ACC GTC CTA GGC 405  
 Phe Val Tyr Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly  
 105 110 115  
 30  
 CAG CCC 411  
 35  
 Gln Pro

40 (2) INFORMATION FOR SEQ ID NO: 74:

- 45 (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 411 base pairs
  - (B) TYPE: nucleic acid
  - 50 (C) STRANDEDNESS: double
  - (D) TOPOLOGY: linear
- 55



(ii) MOLECULE TYPE: cDNA to mRNA

5

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 74:

10

ATG GCC TGG ACT CCT CTC TTC TTC TTC TTT GTT CTT CAT TGC TCA 45

Met Ala Trp Thr Pro Leu Phe Phe Phe Phe Val Leu His Cys Ser

-15 -10 -5

15

GGT TCT TTC TCC CAG CTT GTG CTG ACT CAA TCG CCC TCT GCC TCT 90

Gly Ser Phe Ser Gln Leu Val Leu Thr Gln Ser Pro Ser Ala Ser

1 5 10

20

GCC TCC CTG GGA GCC TCG GTC AAG CTC ACC TGC ACC TTG AGT AGT 135

Ala Ser Leu Gly Ala Ser Val Lys Leu Thr Cys Thr Leu Ser Ser

15 20 25

25

CAG CAC AGT ACG TAC ACC ATT GAA TGG TAT CAG CAG CAG CCA GAG 180

Gln His Ser Thr Tyr Thr Ile Glu Trp Tyr Gln Gln Gln Pro Glu

30 35 40

30

AAG GGC CCT AGG TAC GTG ATG GAT CTT AAG CAA GAT GGA AGC CAC 225

Lys Gly Pro Arg Tyr Val Met Asp Leu Lys Gln Asp Gly Ser His

45 50 55

35

AGC ACA GGT GAT GGG ATT CCT GAT CGC TTC TCA GGC TCC AGC TCT 270

Ser Thr Gly Asp Gly Ile Pro Asp Arg Phe Ser Gly Ser Ser Ser

60 65 70

40

GGG GCT GAG CGC TAC CTC ACC ATC TCC AGC CTC CAG TCT GAG GAT 315

Gly Ala Glu Arg Tyr Leu Thr Ile Ser Ser Leu Gln Ser Glu Asp

75 80 85

45

GAG GCT GAC TAT ATC TGT GGT GTG GGT GAT ACA ATT AAG GAA CAA 360

Glu Ala Asp Tyr Ile Cys Gly Val Gly Asp Thr Ile Lys Glu Gln

90 95 100

50

TTT GTG TAC GTG TTC GGC GGA GGG ACC AAA CTG ACC GTC CTA GGC 405

55

Phe Val Tyr Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly

5 105 110 115

CAG CCC 411

Gln Pro

10

(2) INFORMATION FOR SEQ ID NO: 75:

15

(i) SEQUENCE CHARACTERISTICS:

20

(A) LENGTH: 34 amino acids

(B) TYPE: amino acid

25

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

30

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 75:

35

Ala Val Ser Glu His Gln Leu Leu His Asp Lys Gly Lys Ser Ile

1 5 10 15

40

Gln Asp Leu Arg Arg Arg Phe Phe Leu His His Leu Ile Ala Glu

20 25 30

Ile His Thr Ala

45

50

## Claims

1. A chimeric L chain comprising a L chain C region of a human antibody and an L chain V region of a mouse monoclonal antibody against a human parathyroid hormone related protein.
2. The chimeric L chain according to claim 1, wherein the L chain V region comprises the amino acid sequence as shown in SEQ ID NO:45.

55

3. The chimeric L chain according to claim 1, wherein the C region is a C $\lambda$  chain.
4. A chimeric H chain comprising an H chain C region of a human antibody and an H chain V region of a mouse monoclonal antibody against a human parathyroid hormone related protein.
5. The chimeric H chain according to claim 4, wherein the H chain V region comprises the amino acid sequence as shown in SEQ ID NO:46.
6. The chimeric H chain according to claim 4, wherein the C region is a C $\lambda$ 1 chain.
7. A chimeric monoclonal antibody against a human parathyroid hormone related protein, comprising a chimeric L chain according to any one of claims 1 to 3 and a chimeric H chain according to any one of claims 4 to 6.
8. A polypeptide comprising an L chain V region of a humanized antibody, comprising framework regions 1 to 4 of an L chain V region of a human antibody and complementarity determining regions 1 to 3 of an L chain V region of a mouse monoclonal antibody against a human parathyroid hormone related protein.
9. The polypeptide according to claim 8, wherein the complementarity determining regions 1 to 3 comprise the amino acid sequences as shown in SEQ ID NOs:59-61, respectively.
10. The polypeptide according to claim 8, wherein said framework regions 1 to 3 are derived from the framework regions 1 to 3 of human antibody HSU03868, respectively, and said framework region 4 is from the framework region 4 of human antibody S25755.
11. The polypeptide according to claim 8, wherein said framework regions 1 to 3 are substantially identical with the framework regions 1 to 3 of human antibody HSU03868, respectively, and said framework region 4 is substantially identical with the framework region 4 of human antibody S25755.
12. The polypeptide according to claim 8, wherein in the framework regions the 36th and 49th amino acids in accordance with Kabat's definition are tyrosine and aspartic acid, respectively.
13. The polypeptide according to claim 12, comprising the amino acid sequence as shown in any one of SEQ ID NOs:48-51.
14. The polypeptide according to claim 8, wherein in the framework regions the 45th and 87th amino acids in accordance with Kabat's definition are lysine and isoleucine, respectively.
15. The polypeptide according to claim 14, comprising the amino acid sequence as shown in any one of SEQ ID NOs:52-55.
16. A polypeptide comprising an H chain V region of a humanized antibody, comprising framework regions 1 to 4 of an H chain V region of a human antibody and complementarity determining regions 1 to 3 of an H chain V region of a mouse monoclonal antibody against a human parathyroid hormone related protein.
17. The polypeptide according to claim 16, wherein the complementarity determining regions 1 to 3 comprise the amino acid sequences as shown in SEQ ID NOs:62-64, respectively.
18. The polypeptide according to claim 16, wherein said framework regions 1 to 4 are derived from the framework regions 1 to 4 of a human antibody of human subgroup III.
19. The polypeptide according to claim 16, wherein said framework regions 1 to 4 are derived from the framework regions 1 to 4 of human antibody S31679, respectively.
20. The polypeptide according to claim 16, wherein said framework regions 1 to 4 are substantially identical with the framework regions 1 to 4 of human antibody S31679, respectively.
21. A polypeptide comprising an H chain V region of a humanized antibody, comprising the amino acid sequence as shown in SEQ ID NO:56.

22. An L chain of a humanized antibody against a human parathyroid hormone related protein, comprising a polypeptide comprising an L chain C region of a human antibody and a polypeptide according to any one of claims 8 to 15.
23. The L chain of a humanized antibody according to claim 22, wherein the C region is a C $\lambda$  chain, said framework regions 1 to 3 are substantially identical with the framework regions 1 to 3 of human antibody HSU03868, respectively, and said framework region 4 is substantially identical with the framework region 4 of human antibody S25755, and the complementarity determining regions 1 to 3 comprise the amino acid sequences as shown in SEQ ID NOs:59-61, respectively.
24. An H chain of a humanized antibody against a human parathyroid hormone related protein, comprising a polypeptide comprising an H chain C region of a human antibody and a polypeptide according to any one of claims 16 to 21.
25. The H chain of a humanized antibody according to claim 24, wherein the C region is a C $\lambda$ 1 chain, said framework regions 1 to 4 are derived from the framework regions 1 to 4 of human antibody HSGIII, respectively, and the complementarity determining regions 1 to 3 comprise the amino acid sequences as shown in SEQ ID NOs:62-64, respectively.
26. A humanized antibody against a human parathyroid hormone related protein comprising an L chain of a humanized antibody according to claim 22 or 23 and an H chain of a humanized antibody according to claim 24 or 25.
27. An antibody against a human parathyroid hormone related protein having a dissociation constant of  $1.86 \times 10^{-7}$  [M] or less.
28. An antibody against a human parathyroid hormone related protein having a dissociation rate constant of  $1.22 \times 10^{-1}$  [I/Sec] or less.
29. An antibody against a human parathyroid hormone related protein having an association rate constant of  $6.55 \times 10^4$  [I/M.Sec] or more.
30. An antibody against a human parathyroid hormone related protein having a dissociation rate constant of  $1.22 \times 10^{-1}$  [I/Sec] or less and an association rate constant of  $6.55 \times 10^4$  [I/M.Sec] or more.
31. The antibody according to claim 27, wherein the dissociation constant is measured by a surface plasmon resonance sensor.
32. The antibody according to claim 28 or 30, wherein the dissociation rate constant is measured by a surface plasmon resonance sensor.
33. The antibody according to claim 29 or 30, wherein the association rate constant is measured by a surface plasmon resonance sensor.
34. The antibody according to claim 27, wherein the dissociation constant is  $1.02 \times 10^{-11}$  to  $1.86 \times 10^{-7}$  [M].
35. The antibody according to claim 27, wherein the dissociation constant is  $1.02 \times 10^{-10}$  to  $1.86 \times 10^{-8}$  [M].
36. The antibody according to claim 27, wherein the dissociation constant is  $1.34 \times 10^{-10}$  to  $3.58 \times 10^{-10}$  [M].
37. The antibody according to claim 28, wherein the dissociation rate constant is  $7.38 \times 10^{-6}$  to  $1.22 \times 10^{-1}$  [I/Sec].
38. The antibody according to claim 28, wherein the dissociation rate constant is  $7.38 \times 10^{-5}$  to  $1.22 \times 10^{-2}$  [I/Sec].
39. The antibody according to claim 28, wherein the dissociation rate constant is  $1.66 \times 10^{-4}$  to  $3.16 \times 10^{-4}$  [I/Sec].
40. The antibody according to claim 28, wherein the dissociation rate constant is  $2.32 \times 10^{-4}$  [I/Sec].
41. The antibody according to claim 29, wherein the association rate constant is  $6.55 \times 10^4$  to  $1.24 \times 10^7$  [I/M.Sec].

42. The antibody according to claim 29, wherein the association rate constant is  $6.55 \times 10^5$  to  $1.24 \times 10^6$  [l/M.Sec].
43. The antibody according to claim 29, wherein the association rate constant is  $7.23 \times 10^5$  to  $1.03 \times 10^6$  [l/M.Sec].
- 5 44. The antibody according to claim 29, wherein the association rate constant is  $1.03 \times 10^6$  [l/M.Sec].
45. An antibody against a human parathyroid hormone related protein having a dissociation rate constant of  $2.32 \times 10^{-4}$  to  $3.16 \times 10^{-4}$  [l/Sec] and an association rate constant of  $0.883 \times 10^6$  to  $1.03 \times 10^6$  [l/M.Sec].
- 10 46. The antibody according to any one of claims 27 to 45 wherein the antibody is a human, humanized, chimeric or primatized antibody.
47. A DNA comprising a base sequence coding for an L chain V region of a mouse monoclonal antibody against a human parathyroid hormone related protein.
- 15 48. The DNA according to claim 47, wherein the L chain V region comprises the amino acid sequence as shown in SEQ ID NO:45.
49. The DNA according to claim 47, wherein the base sequence coding for the L chain V region is shown in SEQ ID NO:65.
- 20 50. A DNA comprising a base sequence coding for an H chain V region of a mouse monoclonal antibody against a human parathyroid hormone related protein.
- 25 51. The DNA according to claim 50, wherein the H chain V region comprises the amino acid sequence as shown in SEQ ID NO:46.
52. The DNA according to claim 50, wherein the base sequence coding for the H chain V region is shown in SEQ ID NO:57.
- 30 53. A DNA coding for a chimeric L chain according to any one of claims 1 to 3.
54. The DNA according to claim 53, wherein the DNA coding for the chimeric L chain comprises the base sequence as shown in SEQ ID NO:65.
- 35 55. A DNA coding for a chimeric H chain according to any one of claims 4 to 6.
56. The DNA according to claim 55, wherein the DNA coding for the chimeric H chain comprises the base sequence as shown in SEQ ID NO:57.
- 40 57. A DNA comprising a base sequence coding for a polypeptide according to any one of claims 8 to 15.
58. The DNA according to claim 57, comprising the base sequence as shown in any one of SEQ ID NOs:66-74.
- 45 59. A DNA comprising a base sequence coding for a polypeptide according to any one of claims 16 to 21.
60. The DNA according to claim 59, comprising the base sequence as shown in SEQ ID NO:58.
61. A DNA coding for an L chain of a humanized antibody according to claim 22 or 23.
- 50 62. A DNA for an L chain of a humanized antibody, comprising a base sequence coding for the amino acid sequence as shown in any one of SEQ ID NOs:47-55.
63. The DNA according to claim 62, wherein the DNA for an L chain of a humanized antibody comprises the base sequence as shown in any one of SEQ ID NOs:66-74.
- 55 64. A DNA coding for an H chain of a humanized antibody according to claim 24 or 25.

65. A DNA for an H chain of a humanized antibody, comprising a base sequence coding for the amino acid sequence as shown in SEQ ID NO:56.
- 5 66. The DNA according to claim 65, wherein the DNA for an H chain of a humanized antibody comprises the base sequence as shown in SEQ ID NO:58.
67. A recombinant vector comprising a DNA according to any one of claims 47 to 66.
68. A transformant transformed with a recombinant vector according to claim 67.
- 10 69. A process for preparing a chimeric antibody against a human parathyroid hormone related protein comprising cultivating a transformant transformed with an expression vector comprising a DNA according to any one of claims 47 to 49, 53 and 54 and an expression vector comprising a DNA according to any one of claims 50 to 52, 55 and 56 and collecting a chimeric antibody against a human parathyroid hormone related protein from the resulting culture.
- 15 70. A process for preparing a humanized antibody against a human parathyroid hormone related protein comprising cultivating a transformant transformed with an expression vector comprising a DNA according to any one of claims 57, 58 and 61 to 63 and an expression vector comprising a DNA according to any one of claims 59, 60 and 64 to 65 and collecting a humanized antibody against a human parathyroid hormone related protein from the resulting culture.
- 20 71. A pharmaceutical composition comprising a humanized antibody against a human parathyroid hormone related protein as an effective ingredient.
- 25 72. An agent for suppressing hypercalcemia comprising a humanized antibody against a human parathyroid hormone related protein as an effective ingredient.
73. An agent for suppressing hypercalcemia associated with malignant tumor, comprising a humanized antibody against a human parathyroid hormone related protein as an effective ingredient.
- 30 74. The agent for suppressing hypercalcemia according to claim 73, wherein the malignant tumor is at least one selected from the group consisting of cancer of the pancreas, lung cancer, cancer of the pharynx, cancer of the larynx, cancer of the tongue, cancer of the gingiva, cancer of the esophagus, cancer of the stomach, cancer of the biliary duct, cancer of the breast, cancer of the kidney, cancer of the urinary bladder, cancer of the uterus and prostate cancer, and malignant lymphoma.
- 35 75. A pharmaceutical composition comprising an antibody according to any one of claims 27 to 46 as an effective ingredient.
- 40 76. An agent for suppressing hypercalcemia comprising an antibody according to any one of claims 27 to 46 as an effective ingredient.
77. An agent for suppressing hypercalcemia associated with malignant tumor, comprising an antibody according to any one of claims 27 to 46 as an effective ingredient.
- 45 78. The agent for suppressing hypercalcemia according to claim 77, wherein the malignant tumor is at least one selected from the group consisting of cancer of the pancreas, lung cancer, pharynx, cancer of the larynx, cancer of the tongue, cancer of the gingiva, cancer of the esophagus, cancer of the stomach, cancer of the biliary duct, cancer of the breast, cancer of the kidney, cancer of the urinary bladder, cancer of the uterus and prostate cancer, and malignant lymphoma.
- 50 79. An agent for improving hypophosphatemia comprising a humanized antibody against a human parathyroid hormone related protein as an effective ingredient.
- 55 80. The agent for improving hypophosphatemia according to claim 79, wherein the hypophosphatemia is hypophosphatemic rickets.
81. The agent for improving hypophosphatemia according to claim 79, wherein the hypophosphatemia is hypophos-

phatemic vitamin D-resistant rickets.

82. An agent for improving hypophosphatemia comprising an antibody according to any one of claims 27 to 46 as an effective ingredient.

5

83. The agent for improving hypophosphatemia according to claim 82, wherein the hypophosphatemia is hypophosphatemic rickets.

84. The agent for improving hypophosphatemia according to claim 82, wherein the hypophosphatemia is hypophosphatemic vitamin D-resistant rickets.

10

15

20

25

30

35

40

45

50

55

FIG. 1






FIG.2




FIG.3

| v region |      |     |      | Plasmid               | Activity |
|----------|------|-----|------|-----------------------|----------|
| FR1      | CDR1 | FR2 | CDR2 |                       |          |
| H        |      | H   |      | h/mMBC1L( $\lambda$ ) | —        |
| m        |      | m   |      | m/hMBC1L( $\lambda$ ) | +        |
| H        |      | m   |      | hmmMBC1L( $\lambda$ ) | +        |
| m        |      | H   |      | mhmMBC1L( $\lambda$ ) | —        |

H : FR of Human Antibody  
m : FR of Mouse Antibody

FIG.4




FIG.5

Determination of Antigen-Binding Activity




FIG.6

Determination of Antigen-Binding Activity




FIG.7

Determination of Antigen-Binding Activity




FIG.8

Determination of Antigen-Binding Activity




FIG.9

Determination of Antigen-Binding Activity






FIG.10

Determination of Antigen-Binding Activity




FIG.1 1

Determination of Antigen-Binding Activity




FIG. 12

Neutralizing Activity of  
Humanized anti-PTHrP (1-34) Antibody




FIG.13

Neutralizing Activity of  
Humanized anti-PTHrP (1-34) Antibody




FIG. 14

Neutralizing Activity of  
Humanized anti-PTHrP (1-34) Antibody





FIG. 15

Effect of Chimeric Antibody and Humanized Antibody on Hypercalcemic Model Animal (Nude Mouse Carrying Human Pancreatic Cancer PAN-7)



Days after Tumor Transplantation (Day)

FIG.16

Effect of Chimeric Antibody and Humanized Antibody on Hypercalcemic Model Animal (Nude Mouse Carrying Human Pancreatic Cancer PAN-7)




FIG.17

Effect of Chimeric Antibody and Humanized Antibody on Hypercalcemic Model Animal (Nude Mouse Carrying Human Pancreatic Cancer PAN-7)








FIG.18


Effect of Chimeric Antibody and Humanized Antibody on Hypercalcemic Model Animal (Nude Mouse Carrying Human Lung Cancer LC-6-JCK)






| Fc | Time  | Window | AbsResp | SD   | Slope | Baseline | RelResp | Id                        |
|----|-------|--------|---------|------|-------|----------|---------|---------------------------|
| 2  | 368.5 | 5.0    | 11784.0 | 0.17 | 0.07  | Yes      | 0       | pre-NHS+EDC               |
| 2  | 1622  | 5.0    | 12157.3 | 2.29 | -1.22 | Yes      | 373.2   | NHS+EDC-100ul             |
| 2  | 2966  | 5.0    | 12604.9 | 1.36 | -0.71 | No       | 447.6   | PDEA-100ul                |
| 2  | 3530  | 5.0    | 14058.6 | 8.34 | -4.45 | No       | 1901.3  | (1-34+C)5ug/ml-10ul-pH5.0 |
| 2  | 5546  | 5.0    | 12423.6 | 2.08 | -1.10 | No       | 266.3   | Gys/NaCl-100ul            |
| 2  | 5804  | 5.0    | 12396.6 | 0.28 | -0.13 | No       | 239.3   | Gly/HCl-10ul              |
| 2  | 6063  | 5.0    | 12383.6 | 0.13 | 0.00  | No       | 226.4   | 10mM-HCl-10ul             |


Sensorgram of Mobilization of PTHrP (1-34+C) onto Sensor Tip




Overlaying of MBC Sensorgram




Overlaying of 3F5 Sensorgram



Overlaying of chMBC Sensorgram



Overlaying of hMBCm Sensorgram



Overlaying of hMBCq Sensorgram

FIG.25

Effect on Fractional Excretion of Phosphate


(1 period: 20 min., Average Value  $\pm$  Standard Error)



FIG.26




FIG.27



FIG.28




FIG.29

Effect on Spontaneous Movement




FIG.30

Effect on Body Temperature





FIG.31

Effect on Blood pH



## INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP97/03382

| <b>A. CLASSIFICATION OF SUBJECT MATTER</b> Int. Cl <sup>6</sup> C07K16/18, C07K16/46, C12N15/13, C12N15/62, C12N5/16, C12P21/02, C12P21/08, A61K39/395// (C12P21/02, C12R1:91), (C12P21/08, C12R1:91)<br>According to International Patent Classification (IPC) or to both national classification and IPC  |  |  |
|---|--|--|
| <b>B. FIELDS SEARCHED</b><br>Minimum documentation searched (classification system followed by classification symbols)<br>Int. Cl <sup>6</sup> C07K16/00-16/46, C12N15/00-15/90, C12N5/00-5/28, C12P21/00-21/08, A61K39/395-39/44<br>Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched<br>Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)<br>BIOSIS (DIALOG), WPI (DIALOG), GenBank (Genetyx), EMBL (Genetyx)  |  |  |
| <b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>   |  |  |
| Category*   | Citation of document, with indication, where appropriate, of the relevant passages   | Relevant to claim No.  |
| X   | JP, 4-228089, A (Kaneka Corp.), August 18, 1992 (18. 08. 92) (Family: none)  | 1-7, 27-56, 67-69, 75-78   |
| Y   |  | 8-26, 57-66, 70-74, 79-84  |
| Y   | JP, 4-502408, A (Protein Design Labs, Inc.), May 7, 1992 (07. 05. 92)<br>& WO, 90/07861, A & EP, 451216, A & CA, 2006865, A & AU, 9051532, A & PT, 92758, A & ZA, 8909956, A & CN, 1043875, A & FI, 9102436, A & NO, 9102385, A & DK, 9101191, A | 8-26, 57-66, 70-74, 79-84  |
| Y   | WO, 93/13133, A (Yamanouchi Pharmaceutical Co., Ltd.), July 8, 1993 (08. 07. 93)<br>& AU, 9230958, A & EP, 619324, A   | 8-26, 57-66, 70-74, 79-84  |
| <input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.  |  |  |
| * Special categories of cited documents:<br>"A" document defining the general state of the art which is not considered to be of particular relevance<br>"E" earlier document but published on or after the international filing date<br>"I" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)<br>"O" document referring to an oral disclosure, use, exhibition or other means<br>"P" document published prior to the international filing date but later than the priority date claimed<br>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention<br>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone<br>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art<br>"&" document member of the same patent family |  |  |
| Date of the actual completion of the international search<br>December 9, 1997 (09. 12. 97)  |  | Date of mailing of the international search report<br>December 24, 1997 (24. 12. 97) |
| Name and mailing address of the ISA/<br>Japanese Patent Office<br>Facsimile No.   |  | Authorized officer<br>Telephone No.  |

Form PCT/ISA/210 (second sheet) (July 1992)

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP97/03382

| C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT |   |                           |
|---|---|---------------------------|
| Category*   | Citation of document, with indication, where appropriate, of the relevant passages  | Relevant to claim No.     |
| Y   | QUEEN, C. et al. "A humanized antibody that binds to the interleukin 2 receptor", Proc. Natl. Acad. Sci. USA (1989) Vol. 86, p. 10029-10033 | 8-26, 57-66, 70-74, 79-84 |

Form PCT/ISA/210 (continuation of second sheet) (July 1992)